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Abstract
The work in this thesis explores the dynamic nature of Escherichia coli lineages
co-existing in the human intestinal tract. The work is supported via full genome
sequencing of co-existing E. coli strains isolated from infants enrolled in the AL-
LERGYFLORA study. Both sets of isolates examined here were selected due to an
observed change in their antibiotic susceptibility proﬁle. Via full genome sequencing,
we identiﬁed that in both cases a conjugative plasmid harboring antibiotic resistance
genes was transferred between co-existing E. coli lineages and is responsible for the
change in antibiotic susceptibility. In one case, the transfer occurred in the absence
of antibiotic treatment and the transconjugant remained amongst the gut microbiota
for months, providing evidence to the hypothesis that resistance genes are stably
maintained once acquired. To our knowledge, this is the ﬁrst documented case where
transfer of resistance genes was observed in situ of a non-perturbed gut in the absence
of antibiotic treatment. Additionally, cases of genomic deletions, phage infections and
curing, and plasmid loss were observed, highlighting that strains in the gut are highly
dynamic. The detection of these micro-evolutionary events was facilitated through
the isolation of strains, yielding a high-resolution view into the strain heterogeneity
of the human gut.
Also included in this thesis is work highlighting that a large proportion of the gut
microbiota can indeed be cultivated using carefully designed conditions. Antibiotic
tolerance phenotypes were determined, and this mapping was used to carefully tailor
antibiotic combinations to speciﬁcally select for previously uncultivated bacteria. Us-
ing this method, four previously uncultivated species were successfully cultured and
genome sequenced, and two of which had 16S rRNA identities of less than 95% to
previously cultured bacteria. We assessed the genomic coverage and abundance of
these sequenced isolates in the gut using publicly available metagenomes.
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Dansk Resume
Formålet med denne afhandling er at afdække de dynamiske egenskaber mellem ﬂere
stammer af Escherichia coli ved deres sameksistens i den menneskelige tarmkanal.
Arbejdet er baseret på genomisk sekventering af sameksisterende E. coli stammer isol-
eret fra nyfødte, der undergik ”ALLERGYFLORA” undersøgelsen. De to set prøver
blev udvalgt på baggrund af en observeret forandring i deres modtagelighed over for
antibiotika. Via genomisk sekventering identiﬁcerede vi i begge tilfælde et plasmid
med antibiotisk resistente gener, var blevet overført mellem forskellige stammer af E.
coli, og derved medføre en ændring i stammernes modtagelighed for antibiotika. I
et tilfælde foregik overførelsen af gener i fravær af antibiotika, hvorefter modtageren
af generne forblev i fordøjelses systemet i månedsvis. Derved underbygger det tesen
om, at gener kan regnes for stabile, når de først er tilegnede. Det er til vores viden
første gang overførslen af resistente gener er observerede naturligt i tarmsystemet, i
fravær af antibiotika. Ydermere har vi også observeret, genomiske deletioner, virus
infektioner og tabet af plasmider. Dette underbygger vores tese om, at tarmsystemet
er et meget dynamisk sted, på bakteriernes genomiske stamme niveau.
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This PhD thesis was prepared at the Centre for Systems Microbiology, in the Depart-
ment of Systems Biology at the Technical University of Denmark in fulﬁllment of the
requirements for the PhD degree.
Kongens Lyngby, October 15, 2014
Heidi Kira Gumpert
vi
Acknowledgements
I would ﬁrst like to thank everyone who has been a part of the Sommer lab during
my time there. It has been both a pleasure to work with you, and to get to know you
all. Thanks for all the discussions, and thanks for all the coﬀees and cake.
My profound gratitude to everyone who has provided me with guidance in the
lab and other help along the way. Thank you ﬁrst to Morten, for your supervision,
guidance and motivation throughout my time in your group. From Mari helping me
out at the very beginning (and throughout), and for keeping the lab in good working
order. To Christian, my main partner in crime, I thank you for all the work and
discussion of the projects we’ve done together. And thanks to my other fellow PhDs,
Dionisio and Rachel, as well. Thank you to my favourite phage girl, Lejla, for both
your discussions and advice, and your keen wit. Elizabeth, I have really appreciated
sharing my fondness over gut microbes with you, and you have been perhaps the only
one whom I could discuss working with our type of sample matter with. Thank you
to Andreas for being a super helpful and knowledgeable lab bench neighbour - best
of luck to you now starting your PhD.
A special thanks to all my oﬃce mates over the years, from my most recent
’homeboys’ Marius and Mostafa, and to Thomas, and the full house of Marie, Kira,
Hans and Mads. You guys had the honour of being closest to my particular brand of
wonderment - thanks for that. And thanks for adding to a healthy oﬃce milieu.
I would also like to thank Nahid Karami, Agnes Wold and Ingegerd Alderberth
from the Sahlgrenska Academy, our collaborators on the E. coli colonization in
Swedish infants project. Thanks for working with Morten and I, and thank you
for the discussions we’ve had and your input on the project.
And of course warmest thanks to all the dear friends and family in my life.
viii
Abbreviations
ABU asymptomatic bacteriuria
AIEC adhesive invasive E. coli
Amp ampicillin
bp base pairs
CF cystic ﬁbrosis
CFU colony forming unit
DGGE denaturing gradient gel electrophoresis
DM25 Davis medium with 25mg/mL glucose
EIEC enteroinvasive E. coli
ESBL extended spectrum beta-lactamase
FISH ﬂuorescent in situ hybridization
HGT horizontal gene transfer
HMP Human microbiome project
HUS hemolytic-uremic syndrome
INDEL insertion and/or deletion
IS insertion sequence
kb kilobases
MDR multi-drug resistant
MHBII Mueller Hinton broth II, cation-adjusted
MIC minimum inhibitory concentration
MLST multi locus sequence typing
MRSA methicillin resistant Staphylococcus aureus
NMEC neotal meningitis E. coli
OD optical density
ORF open reading frame
PCR polymerase chain reaction
PE paired-end (reads)
PFGE pulsed-ﬁeld gel electrophoresis
Pip piperacillin
RAPD random ampliﬁed polymorphic DNA
RFLP restriction fragment length polymorphism
x Abbreviations
Abbreviations, continued.
SD standard deviation
SE single-end (reads)
Sfx sulfamethoxazole
SNP single nucleotide polymorphism
Str streptomycin
TB tuberculosis
TGGE temperature gel gradient electrophoresis
T-RFLP terminal restriction fragment length polymorphism
UPEC uropathogenic E. coli
UTI urinary tract infection
VRE vancomycin resistant Enterococcus
Contents
Abstract i
Dansk Resume iii
Preface v
Acknowledgements vii
Abbreviations ix
Contents xi
1 Outline of Thesis 1
2 List of Publications 3
3 Introduction 5
3.1 Antibiotic Resistance Mechanisms . . . . . . . . . . . . . . . . . . . . 5
3.2 Routes to Antibiotic Resistance . . . . . . . . . . . . . . . . . . . . . . 6
3.3 Horizontal Gene Transfer Mechanisms . . . . . . . . . . . . . . . . . . 7
3.4 Mutational vs. Horizontally Acquired Antibiotic Resistance . . . . . . 9
3.5 Origins of Antibiotic Resistance . . . . . . . . . . . . . . . . . . . . . . 11
3.6 The Resistome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3.7 Horizontal Gene Transfer in the Environment . . . . . . . . . . . . . . 13
3.8 Human Gut Microbiota . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.9 Maturation of the Human Gut Microbiota . . . . . . . . . . . . . . . . 17
3.10 Studying the Human Gut Microbiota . . . . . . . . . . . . . . . . . . . 18
3.11 Lineage Dynamics in the Human Gut Microbiotia . . . . . . . . . . . . 21
3.12 Horizontal Gene Exchange within the Human Gut Microbiota . . . . . 22
3.13 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4 Transfer of multiple antibiotic resistance genes in situ of the infant gut
without antibiotic perturbation 47
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
xii Contents
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.5 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.6 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.7 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.8 Supplementary Information . . . . . . . . . . . . . . . . . . . . . . . . 76
5 Pathogenic and commensal Escherichia coli lineage dynamics in
situ of the gut during antibiotic treatment 93
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
5.5 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
5.6 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.7 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.8 Supplementary Information . . . . . . . . . . . . . . . . . . . . . . . . 115
6 Cultivation-basedmultiplex phenotyping of the humangutmicrobiota
allows targeted recovery of previously uncultured bacteria 127
6.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
6.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
6.5 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
6.6 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6.7 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6.8 Supplementary Discussion . . . . . . . . . . . . . . . . . . . . . . . . . 155
6.9 Supplementary References . . . . . . . . . . . . . . . . . . . . . . . . . 158
6.10 Supplementary Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 160
6.11 Supplementary Information . . . . . . . . . . . . . . . . . . . . . . . . 166
7 Conclusion and Perspectives 177
7.1 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
CHAPTER 1
Outline of Thesis
This thesis has been organised into a total of six chapters. This ﬁrst chapter outlines
the rest of the subsequent chapters. Chapter two includes a list of publications that
the author contributed to, highlighting which publications are included in this thesis.
Chapter three provides an introduction to the subject areas of antibiotic resistance,
horizontal gene transfer and reservoirs of antibiotic resistance genes, and the human
gut microbiota. Relevant work is also reviewed here, including how the human gut
microbiota is studied, dynamics of the lineages of the human gut microbiota and
horizontal gene exchange within the human gut.
Chapters four and ﬁve of this thesis discuss two cases of horizontal transfer of
antibiotic resistance genes between co-existing E. coli lineages in the gut. The ﬁrst
case occurs in the absence of antibiotic treatment, and the transconjugant is even
maintained in the gut microbiota for months after the transconjugant was detected.
The second case occurs during antibiotic treatment, and the transconjugant is not
detected at a later time point. The analysis of these sets of isolates showed that these
strains existing in the gut are highly dynamic, and multiple cases of phage infections
and clearance, plasmid acquisition and loss, and large genomic deletions are reported.
The ﬁnal chapter of this thesis discusses how selecting carefully designed culture
conditions a large proportion of the gut microbiota can indeed be cultivated as op-
posed to current belief. Speciﬁcally, antibiotic tolerance phenotypes were determined,
and this mapping was used to carefully tailor antibiotic combinations to speciﬁcally
select for previously uncultivated bacteria. Using this method, four previously uncul-
tivated species were successfully cultured and genome sequenced.
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CHAPTER 3
Introduction
Antibiotic resistance is an ever-growing public health concern. Antibiotic resistance,
where bacteria are able to resist the eﬀects of an antibiotic they were once suscepti-
ble to, results in reduced eﬃcacy of the antibiotic and may cause treatment failure,
leading to prolonged illness and increased mortality [1]. The search for new antibi-
otics to treat infections that are no longer susceptible to previously used antibiotics
is ongoing. However, with a long innovation gap and other diﬃculties, there have
been very few new antibiotic drugs brought to market [2]. The World Health Orga-
nization has recently reported that the threat of the post antibiotic era, where the
current antibiotics are no longer able to treat common infections, may indeed be a
real possibility for the 21st century [1]. While one part of the solution to the current
antibiotic resistance problem includes the discovery of new antibiotics, much focus is
directed on solutions to curb the increase of antibiotic resistant bacteria.
3.1 Antibiotic Resistance Mechanisms
Antibiotic resistance is achieved by a variety of tactics (Fig. 3.1). Resistance may
be achieved through reduced uptake or through active elimination of the drug, both
resulting in a reduced and insuﬃcient drug concentration inside the bacterium to be
eﬀective. Reduced drug uptake via low permeability can be due to intrinsic drug
resistance, where the bacterium is not susceptible to the drug due to its physiology,
but it can also be due to a change or loss of uptake proteins such as porins [3]. Eﬄux
pumps, which actively export compounds, are widespread amongst bacteria and have
been found to export a broad range of antibiotics and other biocides [4]. Resistance
can also be achieved via an alteration of the drug target no longer allowing the drug to
interact with the target in an eﬀective way. For example, resistance to the quinolone
drug, nalidixic acid, can be achieved in Escherichia coli via mutation altering the
interaction between DNA gyrase and nalidixic acid, such that it can no longer bind
in an eﬃcient manner [5, 6]. Alternatively the drug target can also be modiﬁed post-
6 3 Introduction
Antibiotics
Reduced 
drug uptake
Altered
drug targetDrug inactivation
Increased
efflux
Pathway 
circumvention
Figure 3.1 | Mechanisms of antibiotic resistance. Figure courtesy of Christian
Munck.
transcription, as in the case of macrolide resistance involving post-transcriptional
methylation of the 23S ribosome [7]. Resistance can also arise via the ability to break
down the drug, rendering it inactive. Beta-lactamase enzymes illustrate a classic
example of resistance achieved through degradation of the drug. These enzymes are
able to cleave the beta-lactam ring of the drug, resulting in inactivation [8]. Other
mechanisms also exist such as bypassing the antibiotic inhibited reaction, sequestering
the antibiotic via protein binding, or titration of the antibiotic by increasing the
number of drug target [8]. Additionally, it is not uncommon that more than one of
these mechanisms can confer resistance to a single antibiotic, and for one mechanism
to confer resistance to multiple antibiotics.
3.2 Routes to Antibiotic Resistance
A bacterium can become resistant to an antibiotic via two routes. It can be achieved
vertically through inheritance or horizontally via acquisition of foreign genetic ma-
terial that confers resistance [9]. Vertical transfer of antibiotic resistance involves
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propagation of a particular resistant strain [10]. Vertical inheritance of antibiotic
resistance determinants includes both resistances that have come about through mu-
tation as well as through the acquisition of foreign genetic material. Horizontal gene
transfer (HGT) of antibiotic resistance genes can occur through a variety of mecha-
nisms, including phage transduction, conjugation or uptake of foreign DNA by natu-
rally competent bacteria [9]. The origin of the genes conferring resistance need not
be from a related species. Many plasmids have been found to have a wide host range,
and even conjugative transfer between gram-positive and gram-negative bacteria have
been reported [11].
3.3 Horizontal Gene Transfer Mechanisms
There are a variety of mechanisms for horizontal gene transfer. As previously men-
tioned, these mechanisms include phage transduction, conjugation or uptake of foreign
DNA.
Phage transduction is the process by which a bacterial virus, a bacteriophage, in-
cludes a portion of its infected host’s DNA into the virion and transfers that genetic
information to another bacterium [12]. Once a phage has successfully entered the
host bacterium, it will either undergo multiplication of the phage and subsequent
lysis or it will incorporate its genetic material into the host’s chromosome [13]. These
options are called the lytic and lysogenic pathways, respectively. A phage entering
the lysogenic state results in the host bacterium gaining additional genetic informa-
tion. The phage may contain additional genes, such as antibiotic resistance genes,
in addition to the phage-speciﬁc genes. A lysogenic phage may enter the lytic state,
thereby being released to infect other bacteria. During this process, the phage may
excise itself from the host’s genome restoring the region to its uninfected state, or it
may be excised with genomic material from the host. Phage transduction can either
be specialized, where only DNA adjacent to the insertion site is accidentally packaged
into the phage, or it can be generalized, where any DNA can be packaged into the
phage [12].
Another method of horizontal gene transfer is via conjugation. In conjugation,
bacteria are temporarily united in order to transfer genetic information. DNA is
believed to be transferred via the hollow conjugation pilus, yet there is some debate
whether the pili may play a role in the stabilization of the cells and that DNA may
be transferred through a pore [14]. However, conjugation has been directly observed
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between single E. coli cells and at considerable distances [15], and DNA has been
detected within the pilus [16]. Single-stranded DNA is transferred to the receiver by
separating the two DNA strands before it is passed through the conjugation pilus
[17]. Conjugation is conservative for plasmids, as this splitting process leaves both
the donor and a receiver with a template of the plasmid.
Conjugative systems exist both on plasmids and in conjugative transposons to
facilitate mobilization of their genetic information. Generally, the vector encoding
the conjugation machinery is transferred. However, other genetic elements that do
not encode their own conjugation machinery can be transferred instead. For example,
mobilizable plasmids carry only the genetic information for the processing of conjuga-
tive DNA, and rely on another element in the cell to provide the system to form a
mating channel [18].
Lastly, bacteria that are naturally competent may take up naked DNA. This pro-
cess is called transformation. Many naturally competent bacteria become competent
in response to an environmental cue, such as cell density, nutrient access or limita-
tion [19]. In contrast to the other two mechanisms of horizontal gene transfer, this
mechanism is only dependent on the receiver taking up the external DNA and not on
mobilization elements [20]. However, natural transformation still relies on exposure
to extracellular DNA, which is continually released into the environment from dete-
riorated cells and viral particles, and from actively excreting cells [19]. Interestingly,
many genera of bacteria have been found to actively excrete DNA [19]. The DNA
that is transformed is typically short in length, approximately one to three genes, and
is therefore less likely to be subjected to restriction enzyme digestion in the host [21].
Importantly, in all of these methods of horizontal gene transfer, either autonomous
replication or integration into the host chromosome is necessary for continued prop-
agation of the genetic information. Plasmids normally ensure their replication and
correct segregation into daughter cells during cell division. If the plasmid relies on pro-
teins to initiate replication, the replication proteins must be compatible with the host
bacterium in order for successful replication of the plasmid [19]. Additionally, other
plasmids using the same replication and partitioning systems are unable to co-exist
in the same host [21]. For this reason, plasmids are often classiﬁed into ’incompatibil-
ity’ groups based on possible co-existence. Furthermore, autonomous plasmids must
ensure segregational stability, which is often achieved through a relatively high copy
number of the plasmid and relying on segregation by chance, or through low copy
number and active partitioning mechanisms [19]. Similar to transposons, phages, and
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exogenous DNA, parts of plasmids may also be integrated into the chromosome [22].
Integration has diﬀerent host demands. Integration can occur through homologous
recombination, therefore being dependent on homology to the host [21]. Integration
may occur through insertion sequence (IS) elements, requiring their presence on the
chromosome, but independent of sequence homology [21].
3.4 Mutational vs. Horizontally Acquired Antibiotic
Resistance
While the exact clinical contributions of either mutational- or horizontally-acquired
antibiotic resistances are unclear, examples highlighting the signiﬁcance of both ex-
ist [23]. Antibiotic resistance that arises through mutation is of signiﬁcant clinical
importance during long-term treatment regimes [24, 25]. One of the ﬁrst infections
to be treated via antibiotic chemotherapy was tuberculosis (TB) caused by Mycobac-
terium tuberculosis. Initially, streptomycin monotherapy treatment took a total of
24 months. This long exposure to antibiotics during treatment was met with emerg-
ing drug resistances. The role mutational resistances played were recognized, and
drug-combination therapy was introduced. Although treatment time was reduced to
6 months, failures in adherence of treatment plans had unfortunately resulted in the
development and global spread of multi-drug resistance M. tuberculosis [26, 27]. The
signiﬁcance of antibiotic resistance via mutation in TB is also due to the compartmen-
tal nature of the infection [24, 9]. This compartmentalization leaves M. tuberculosis
little opportunity to interact with other strains and potentially acquiring resistance
genes horizontally [24].
Pseudomonas aeruginosa is an opportunistic pathogen, and is of particular con-
cern for cystic ﬁbrosis (CF) patients. It causes a chronic airway infection in most
CF patients, and ultimately most patients succumb to respiratory failure caused in
conjunction with chronic bacterial infection and accompanying airway failure [28].
Patients often undergo long-term antibiotic treatment in an attempt to reduce the
severity and improve long-term prognosis of the patients [29], but this long-term
treatment is associated with the development of resistance [9]. Analysis of clinical
P. aeruginosa isolates collected over a 35-year time period from CF patients have re-
vealed that antibiotic resistance via the acquisition of genetic material does not play
a role in resistance of P. aeruginosa for CF patients, and that it is rather acheived
via mutation [30, 25, 31]. Speciﬁc examples of resistances found in P. aeruginosa iso-
10 3 Introduction
lates from the lungs of CF patients include gyrA mutations conferring ﬂuoroquinolone
resistance [25], and de-repressed beta-lactamase production conferring beta-lactam re-
sistance [32]. Therefore, for some bacterial infections, resistance via mutation plays
a signiﬁcant role due to the nature of the infection or the treatment regime.
For many human pathogens, horizontal gene transfer is signiﬁcant in the develop-
ment of multidrug resistant human pathogens [33].
The increase in multi-drug-resistant (MDR) Acinetobacter baumannii isolates from
clinics around the world is a worrisome development, especially as some strains have
been reported to be resistant to all known antibiotics [34, 35]. Acinetobacter spp.
are among a unique class of gram-negative bacteria that are ”naturally competent”,
and some strains have been shown to readily undergo recombination [34]. A genome
sequencing study of an A. baumannii isolate identiﬁed that 17% of all open reading
frames were contained in as many as 28 alien genomic islands, 8 of which contained
antibiotic resistance genes, indicating that the genome has acquired a large amount of
foreign DNA [36]. Genome analysis of a MDR A. baumannii epidemic strain revealed
an 86kb resistance island with 45 identiﬁed resistance genes [35]. Furthermore, with
82 out of the 88 open reading frames predicted to have originated from other gram-
negative organisms, such as Pseudomonas sp., Salmonella sp., and E. coli [35]. While
resistance genes on conjugative plasmids have been the determinants of resistance for
some Acinetobacter spp., it is currently transposons that have been found to play a
signiﬁcant role in the dissemination of antibiotic resistance determinants, particularly
in the MDR phenotype [34].
In gram-negative Enterobacteriaceae, conjugative plasmids play a key role in the
evolution and dissemination of beta-lactamase resistance genes in both nosocomial
and community acquired infections [9]. A particularly striking example of this is the
dissemination of the CTX-M genes, which are now globally dispersed and are the
dominant type of extended spectrum beta-lactamases (ESBL) in Europe [33].
Amongst gram-positive bacteria, it is the commensal bacterium Staphylococcus
aureus that now in its methicillin resistant form (MRSA) is arguably considered one
of the most serious super bugs. Resistance to methicillin is most frequently obtained
through the staphylococcal cassette chromosome (scc) containing the mecA penicillin
binding protein gene [37]. This cassette is a large mobile genetic fragment that has
even been determined to have been imported into a single MRSA clone on at least
23 occasions [37].
Vancomycin, which is primarily used to treat infections caused by gram-positive
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bacteria that are unresponsive to other less toxic antibiotics [38], was ﬁrst met with
resistance in treating enterococci infections the late 1980s in Europe [39, 40]. A few
years later, similar vanA vancomycin resistant enterococci (VRE) were detected in the
Eastern United States, followed by cases world wide [41, 42]. The VanA-type of high-
level resistance to vancomycin was the ﬁrst to be described and is the most common
[43]. Sequence analysis has determined that the van gene cluster is associated with a
Tn1546 transposon and is responsible for the dissemination to clinical Enterococcus
faecium isolates [44]. The VanA-type of resistance has also been found in S. aureus
isolates, even in MRSA isolates, where the resistance genes were also located on a
plasmid-borne Tn1546 [43].
3.5 Origins of Antibiotic Resistance
One hypothesis for the origin of antibiotic resistance genes is termed the ”producer
hypothesis”. This hypothesis postulates that the natural producers of antibiotics
also have a gene countering the eﬀect of the antibiotics they produce [45]. Indeed,
most of the successful, early antibiotics were isolated from strains in soil samples
belonging to the genera Streptomyces [46], and many of the antibiotics used in the
clinic today are structurally based on these compounds [47]. Consequently, these
antibiotic-producing strains require immunity proteins in order for themselves to not
be aﬀected. One proposed role of these antibiotics is to help compete in soil for both
space and food [46]. However, as only very few of the low molecular weight compounds
secreted by microbes in the environment have identiﬁed antibiotic activity or even
reach the concentrations required to act as an antibiotic, it is also speculated that
these antibiotics are part of a larger class of signaling molecules [48]. In fact, some
common clinically used antibiotics at sub-inhibitory concentrations even trigger the
expression of virulence factors in the opportunistic pathogen P. aeruginosa [49]. In the
antibiotics as warfare argument, other strains in close spatial contact with antibiotic
producers would have a selective advantage over similar strains if they harbour the
genes to counter-act the eﬀects of these antibiotics. An advantage would exist whether
their own antibiotic resistance genes evolved, or whether antibiotic resistance genes
were acquired from the producer via horizontal gene transfer.
Antibiotic resistance also comes about through mutation, as mentioned earlier.
On long evolutionary time-scales, this could include re-appropriation of a gene. How-
ever, during shorter courses of antibiotic treatment, this is primarily only relevant for
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resistances that only require a small amount of mutations in a gene. It is horizontal
gene transfer that gives prokaryotic genomes high plasticity, providing a faster route
to antibiotic resistance [50, 51].
Interestingly, it is evident that antibiotic resistance is in fact an ancient phe-
nomenon and predates our widespread use of antibiotics [52]. In a study by D’Costa
and colleagues, two permafrost sediment cores taken from the Beringian forest in the
Yukon territory of Canada, and estimated to be approximated 30,000 years old. DNA
was extracted from this sample and interrogated for resistance genes via polymerase
chain reaction (PCR). Resistance genes for several major classes of antibiotics were
identiﬁed, and conﬁrmed that ancient forms of the VanA vancomycin resistance pro-
tein had similar enzymatic function and structure as the modern form. The work
highlights that antibiotic resistance is a naturally occurring phenomenon.
3.6 The Resistome
The collection of all genes conferring antibiotic resistance is called the ”resistome” [53].
This includes all antibiotic resistance genes from pathogenic and commensal bacteria,
from antibiotic producing bacteria, and cryptic genes that might not necessarily be
expressed [53]. It additionally includes all precursor genes that could evolve from
moderate into eﬀective antibiotic resistance genes [53].
One of the ﬁrst sampling of an environment’s resistome was by D’Costa and col-
leagues of the soil resistome [54]. In this study they isolated spore-forming bacteria
from the soil and screened this library against 21 diﬀerent antibiotics, encompassing
eight drug classes, including both natural and semisynthetic compounds. They found
that every strain was in fact resistant to more than one antibiotic, and they observed
resistances to every class of drugs tested.
In an alternative approach, Sommer and colleagues investigated the reservoir of
antibiotic resistance genes in the human microbiota [55]. In addition to assessing the
antibiotic resistance proﬁles of isolates cultured aerobically from the gut, they also em-
ployed a culture-independent strategy. Here, they isolated DNA from the human mi-
crobiota from saliva and fecal samples of healthy individuals. They sheared DNA into
one- to three-kilobase (kb) fragments, cloned the DNA into an expression vector, and
transformed the vector into an E. coli host strain. The resulting functional metage-
nomic libraries were screened via plating onto 13 diﬀerent antibiotic-supplemented
plates for metagenomic DNA fragments conferring antibiotic resistance. This culture-
3.7 Horizontal Gene Transfer in the Environment 13
independent approach led them to identify many resistance genes that had not been
previously identiﬁed via sequencing.
Studies investigating the resistome have played a signiﬁcant part in showing that
a large pool of resistance genes exists. When sampling diﬀerent environments, resis-
tances can be found to antibiotics that they would never have been exposed to [54].
Given the possibility of mobilizing these genes via horizontal gene transfer, this is a
worrying matter. In fact, this pool of resistance genes is consistent with the emergence
of antibiotic resistances in clinical isolates occurring shortly after the introduction of
an antibiotic [52].
Related the concept of the resistome, is the ”subsistome”. This termed was coined
by J. Davies to describe the collection of genes that Dantas and colleagues identiﬁed
which allow bacteria to degrade and subsist on antibiotics as their only carbon source
[56, 9]. The ability for a human pathogen to subsist on antibiotics has been shown
for a collection of Salmonella isolates [57]. Interestingly in many of the cases of
subsistence, the identiﬁed gene was not related to a functional resistance gene.
3.7 Horizontal Gene Transfer in the Environment
Horizontal gene transfer is an ancient phenomenon, with transfer even occurring be-
tween the domains of life [58]. Much of bacterial innovation has been credited to
horizontal gene transfer, whereas in eukaryotes, modiﬁcation of existing genetic in-
formation plays a large role [50]. The ﬁrst indication that horizontal gene transfer is
signiﬁcant for bacterial evolution was recognized in the mid 1950s, when genetically
transferable antibiotic resistances were unexpectedly observed [9]. Yet prior to enter-
ing the full genomic sequencing age, early evolutionary biologist were still wary to cite
horizontal gene transfer as the cause for inconsistencies in phylogenetic analyses [59].
Nevertheless, the signiﬁcance of horizontal gene transfer was established as bacterial
genome sequencing eﬀorts intensiﬁed, yielding many indications of transfer [59].
Detecting horizontal gene transfer in the environment has been done in various
ways. Studies have either been retrospective, based on identifying previous transfer
events that have occurred, or prospective, based on direct observation of transfer
events. Furthermore, various types of evidence exist, but are generally either sequence
or phenotypic based. A short survey highlighting studies detecting horizontal gene
transfer, or methods to detect horizontal gene transfer follows.
Shoemaker and colleagues conducted a retrospective study examining a collection
14 3 Introduction
of Bacteroides isolates isolated over a period of more than 40 years to determine
the extent of horizontal gene transfer within both clinical and community isolates
[60]. First, they probed their isolates via DNA hybridization for tetracycline and
erythromycin resistance genes. Apart from ﬁnding an increase in carriage of resis-
tance genes over time, they found a high proportion of the resistant isolates carried
only a small subset of the resistance genes they probed for. Next, they sequenced
the identiﬁed resistance genes, which showed they had high sequence similarity. As
the Bacteroides strains were only distantly related to each other, the high sequence
similarity indicates that horizontal gene transfer was probable.
Other examples of retrospective studies include the work to determine the origin
of the extended spectrum beta-lactamase CTX-M genes and their mobilization. Se-
quence analysis of the CTX-M gene clusters showed that the environmental source
was from chromosomal beta-lactamases in the genus Kluyvera [61, 62, 63, 64, 65]. In
silico analyses have shown that for some gene clusters they were even mobilized from
their respective Kluyvera progenitors more than once [66]. The mobilization of these
genes is largely attributed to IS elements, but also to a lesser extent to bacteriophages
[66].
Studying horizontal gene transfer in a retrospective manner provides information
on the interactions and evolutionary history of the genes, mobilizable elements and
strains studied. With respect to studying the dissemination of antibiotic resistance, it
highlights potential reservoirs of antibiotic resistance and illustrates possible dissem-
ination routes to pathogens. However, challenges exist to certainly state the exact
routes of dissemination retrospectively. Additionally, it is only possible to uncover
successful events that have been conserved [67].
Perspective studies of horizontal gene transfer aim to observe transfer events.
However, observing transfer events in natural settings can be diﬃcult for various
practical reasons. Observation not only requires that an event occurs, which can be
infrequent, but it also requires proper sampling of the environment before and after
transfer, amongst other factors. While controlled in vitro experiments have resulted
in knowledge regarding rates of transfer and factors regarding transfer, the results
may unfortunately not be transferable to natural environments, as the experimental
conditions may not adequately reﬂect natural conditions. This has led to the devel-
opment of artiﬁcial microcosms to study transfer, as well as seeding an environment
with a particular donor strain and/or receiver strain.
When using a microcosm or adding speciﬁc donor bacteria to an environment,
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there have traditionally been three approaches used for the detection of transfer:
cultivation-based, ﬂuorescence-based and molecular-based [67, 68]. A cultivation-
based approach requires that the recipient bacteria are able to be cultivated, which
is non-trivial in many environments. Furthermore, there must be a discernable phe-
notype associated with the mobilized element and the phenotype must be expressed
in the recipient bacteria in order to detect the transfer [67]. Fluorescence-based
approaches genetically modify mobilization elements to include expression of a ﬂuo-
rescent protein. This approach allows for spatial-temporal observation of transfer and
has been used to identify transfer ’hot-spots’ [67]. The last approach, a molecular-
based approach, relies on quantitative PCR of distinct sequences to monitor an in-
crease in mobilization element relative to the level of the donor bacterium [68].
Horizontal gene transfer has been observed in settings that did not use an artiﬁ-
cial set-up with donor bacteria. Of the three previously mentioned approaches, it is
primarily the culture-based approach that is amenable to studies where an environ-
ment is not seeded with a speciﬁc donor bacterium. Yet to observe a transfer event,
thorough screening and characterization of the selected strains from the environment
is required.
A new approach based on metagenomic data developed in the Banﬁeld research
group could avoid the issues and diﬃculties associated with perspective studies. This
research group developed a method to assemble complete or near-complete genomes
from a complex bacterial community [69]. Furthermore, using time-series sequencing
data they were able to reliably assign mobilization elements to a particular species,
but also to monitor their relative levels within the population. For example, they
witnessed free phages in the gut environment, as well as phage integration and phage
clearance. This method could provide an easier means to studying horizontal gene
transfer in natural environment settings in the future.
3.8 Human Gut Microbiota
The human gut is home to one of the densest microbial ecosystems, namely the gut
microbiota. In fact, most of the microbes belonging to the human microbiota are lo-
cated within the intestinal tract, and they even out-number our own cells [70]. While
the vast majority of microbes inhabiting the gut are from the bacterial domain, both
Archaea and Eukarya are present as well [71]. Most studies give estimates of the
bacterial species present in the human gut between 300 to 1000 species [71, 72, 73],
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with some estimates of the total collective diversity assessed between 15,000 to 36,000
species [74]. The anaerobic environment of the gut is dominated by the Bacteroidetes
and Firmicutes phyla, with the latter primarily containing members of the Clostridia
class [72]. Also present, but found in much lower abundances are bacteria belong-
ing to the Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia phyla
[72]. Facultative anaerobes, species that can perform both aerobic and anaerobic
metabolism, constitute approximately 0.1% of the bacteria, consequently few Pro-
teobacteria (including E. coli) would be expected [72].
Studies have sought to determine whether a core gut microbiota, a set of microbial
species shared in common, exists. Qin et al. have indicated that some bacterial species
are shared, but a subsequent study by the Human Microbiome Project were unable
to identify a core [73, 75, 76]. However, the concept of a core microbiome, where
genes are common in the gut microbiota, has proved to be more resilient, with genes
encoding for similar metabolic functions shared across microbiomes [77, 76].
The gut microbiota has been envisioned as a microbial organ within a host or-
gan, with many important functions for human health [78]. For example, the gut
microbiota plays a role in the maturation of the adaptive immune system, protects
the host against pathogens, synthesizes essential amino acids and vitamins, provides
access to nutrients that are otherwise non-digestible, and inﬂuences energy storage
[79, 71, 80, 78].
The role of the human gut microbiota has also been implicated in certain diseases.
A study by Ley and colleagues focusing on obesity have found that there is a compo-
sitional diﬀerence of the major bacterial divisions, the Bacteriodetes and Firmicutes,
with obese individuals having fewer Bacteriodetes and more Firmicutes than the lean
control individuals [81]. Through diet intervention, the relative proportions of Bac-
teriodetes increased compared to the Firmicutes. In a diﬀerent study by Turnbaugh
and colleagues, they found that the obesity-associate gut microbiome has an increased
potential for energy harvest, highlighting that the gut microbiome is an important
component to consider, much like genetic factors and life-style [82].
Study of the gut microbiota has also been applied to bowel diseases, such as
Crohn’s disease and ulcerative colitis inﬂammatory bowel diseases. Frank and col-
leagues found that a subset of patients had a depletion of the normal commensal gut
bacteria, particularly the Bacteroidetes and Firmicutes [74]. Gevers and colleagues
sought to detect a possible disease signal within the microbiota in new-onset Crohn’s
disease, where the microbiota has not yet been perturbed due to treatment, and found
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analysis of rectal-mucosal microbiota oﬀers a potential early diagnosis [83].
The role the gut microbiota plays in the development of allergy has also been
investigated. Studies have found that reduced diversity during the initial colonization
of the gut after birth has been linked to the development of allergy later on [84, 85, 86].
3.9 Maturation of the Human Gut Microbiota
The infant intestinal tract is believed to be a bacteria-free environment before birth.
The colonization process of the infant gut starts upon delivery, during its ﬁrst expo-
sures to bacteria, and converges towards a mature gut microbiota by age three [87].
Diﬀerences in the colonization and composition of the gut microbiota during this time
has been linked to the mode of delivery [88, 89, 90], and to whether the infant was
initially given breast milk or was formula fed [91, 88, 92].
The colonization process of the infant gut appears to undergo a series of shifts
during the ﬁrst year [93, 94]. In the Palmer et al. study of 14 infants, the shifts
could not often be correlated to a speciﬁc age or event, apart from a shift towards
an ’adult’ microbiota upon the introduction of solid foods [93]. The Koenig et al.
study had only one infant, albeit with more sampling points, and were largely able
to attribute shifts to changes in diet, illness or antibiotic treatment [94]. This result
does however corroborate with the set of fraternal twins in the Palmer et al. study,
as they displayed a highly similar temporal patterns, indicating that the shifts were
in response to an environmental exposure.
Comparing the composition of the infant gut microbiota revealed that there was
greater variation amongst them, than was present in the adult gut microbiota [87].
The infant gut microbiota was also surprisingly found to not be more similar to their
own parents’ gut microbiota, than to any other parent’s gut microbiota [93]. While
these results may indicate a disorderly infant gut microbiota, colonization does follow
a trend from the initial aerobes, such as Staphylococcus, Streptococcus and Enter-
obacteria, to the strict anaerobes [93]. Many studies have found that Biﬁdobacterium
tend to be a dominant genus in the infant gut microbiota, apart from the Palmer et
al. study [87, 95, 96, 93]. In the Palmer et al. study, Bacteroides dominated early in
some infants, yet was present for the majority of infants by the end of the ﬁrst year
[93].
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3.10 Studying the Human Gut Microbiota
The human gut microbiota has been studied for over a hundred years [97], with
renewed interest upon advances in technology. The earliest studies were cultivation-
based. For example, Tissier and colleagues were the ﬁrst to describe Biﬁdobacterium
when they cultured infant fecal samples, and noted that these ”biﬁdus” bacteria were
dominant and more numerous from infants fed breast milk rather than formula [97, 98].
Research continued in isolating and describing more species from the gut, yet it was
ﬁrst in the 1930s when it was acknowledged that majority of the viable bacteria in
the gut were anaerobic [99].
The next major advances in studying the gut microbiota came with the emergence
of molecular methods and sequencing. These methods provide culture-independent
approaches to study the composition and diversity of the gut microbiota, without the
concern of neglecting the fraction that are not amenable to cultivation.
The initial sequencing studies targeted a speciﬁc gene or set of genes. The target
was primarily the 16S rRNA gene due to its ubiquitous distribution and the phyloge-
netic information it provides [100], but other genes with a more limited distribution
have been targeted to screen for certain functionalities [101]. It may also not even
be the entire gene that is targeted. Some studies have targeted one or more hyper-
variable regions within the 16S rRNA gene to assess the diversity of their samples, yet
still rely on databases of full-length sequences for taxonomic assessment [102]. This
short sequence tag approach made eﬃcient use of the high-throughput, yet relatively
short reads that were produced by next generation sequencing machines. However,
as expected, full 16S rRNA gene sequencing provides higher phylogenetic resolution.
It is important to note that there is often a PCR ampliﬁcation bias which can re-
sult from diﬀering ampliﬁcation eﬃciencies of templates, self-annealing of the most
abundant transcripts in the late ampliﬁcation steps, or from non-linear ampliﬁcation
[103, 104, 105].
Another group of methods for assessing the bacterial community composition and
diversity is based on hybridization of oligonucleotides. Similar to the targeted ampli-
con approach, oligonucleotides are designed to target a speciﬁc region of a gene. How-
ever, here taxonomic classiﬁcation is via the detection of hybridization, and not via
sequence analysis. In ﬂuorescent in situ hybridization (FISH), oligonucleotide probes
are designed to identify certain taxa and are ﬂuorescently labeled. These probes are
added to bacterial samples to hybridize to the DNA of the bacteria, and then the
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bacteria can then be sorted using ﬂow cytometry [106]. FISH studies can provide
spatial resolution by ﬁrst ﬁxating a sample prior to hybridization, and subsequently
visualizing the ﬂuorescent probes [107]. DNA microarrays such as the PhyloChip have
been developed for taxonomic classiﬁcation based on hybridization of ampliﬁed 16S
rRNA genes [108]. These hybridization methods can only detect taxa that have been
targeted by the aﬃxed oligonucleotides. FISH can typically be run for the detection
of 6-8 genus or family level groups [100]. DNA microarrays can detect many more
taxa simultaneously, yet quantiﬁcation of DNA microarrays can be an issue [100].
Lastly, ’ﬁnger print’ types of methods are an inexpensive and relatively simple
way to assess the dominant groups in a microbial community. These methods include
terminal restriction fragment length polymorphism (T-RFLP), denaturing and tem-
perature gradient gel electrophoresis (DGGE and TGGE). In short, these methods
also target a gene, also typically the 16S rRNA gene, followed by subsequent separa-
tion of the variants via gel electrophoresis [102]. Unfortunately, the dynamic range
is not as large as the other methods, and results are often not comparable between
studies [102].
As sequencing technology has improved to generate more reads of longer lengths,
and the cost of sequencing has decreased, the focus has shifted to full metagenomic
studies. In contrast to targeted amplicon sequencing where one or a few speciﬁc
genes are sequenced, all DNA from the microbial community is extracted and se-
quenced. The data can be assembled into a metagenome, a type of environmental
genome. Methods to characterize the metagenome based on composition have been
developed [109, 110, 111, 112], yet challenges remain to correctly ascertain which bac-
teria contained which DNA. However, the leading beneﬁt of metagenomic sequencing
comes from analyzing the function of the genetic content to determine the full capac-
ity of the metagenome [102]. This approach follows the notion that gene-based core
metagenome exists, and it is the function of the metagenome as a whole that is inter-
esting to study. However, assigning gene function can be challenging due to a lack
of close matches in reference databases [73, 101]. On the other hand, metagenomic
reads need not always be assembled, with function subsequently assigned to identi-
ﬁed open reading frames. Alternatively, reads can be mapped to genes or genomes
to determine abundance or absence in sample sets [73, 113, 101].
While many advances have been made to improve our understanding of the gut
microbiota, in both healthy and diseased states, it is still necessary to test the hy-
potheses generated in model systems. To this end, there is renewed interest and need
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for model systems and for further development of culture-based methods, including
improving cultivability of the human gut microbiota.
Germ-free and gnotobiotic mice have been employed as models to study the human
gut microbiota and its relationship to the host. Germ-free mice are born in asceptic
conditions and reared in special facilities where all air, food and water is sterilized.
Gnotobiotic mice are deﬁned as those where the natural microbiota has been replaced
by a deﬁned set of bacteria. In practice, gnotobiotic mice are attained by introducing
a speciﬁc set of bacteria to a germ-free mouse, often through gavaging. The use of
these animals allows for comparisons between germ-free, gnotobiotic and normal gut
microbiota mice. For example, one study found that germ-free mice were less anxious
and more active than the mice with a normal gut microbiota [114]. Other studies
analyzing facultative anaerobes have used mice with a normal gut microbiota that is
treated with streptomycin. Streptomycin-treatment provides an opportunity for the
facultative bacteria of interest, marked with streptomycin resistance, to colonize the
gut while the anaerobic bacteria remain largely intact [115, 116].
Cultivating bacteria isolated from the gut can not only be labourious, but it can
be very technically challenging to establish the correct culture conditions. In fact, this
has led modern sequence-based studies to proclaim that a large fraction of the human
gut may be recalcitrant to culture [72, 117, 118, 119, 120]. This assertion could be due
to a variety of reasons, including the diﬃculties in culturing, such as providing the
correct nutrients and physiological conditions, or lacking symbionts when attempting
to grow in pure cultures [77]. Additionally, disparities in abundances can leave less
abundant species not sampled, while disparities in growth could leave slower growing
organisms less likely to be isolated. Even with these pessimistic views, there have
been a few recent advances in culturing techniques. The new techniques include
the encapsulation of bacteria into microdroplets [121, 122], providing the natural or
closely simulated environment by growing the microorganism in a diﬀusion chamber
allowing for exchange with the environment [123, 124], more eﬀective culture media,
including the use of other solidifying agents instead of agar [125, 126, 127]. Even the
concept of culturomics has been introduced as a high-throughput method combining
new culturing methods with mass spectrometry for detection of newly cultivated
species from the gut microbiota [128]
Even with diﬃculties in culturing bacteria from the human gut microbiota, iso-
lating and culturing gut microbes is an important step towards furthering our under-
standing of the human gut microbiota. Through cultivation-based studies, we can
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assess interactions between bacterial species [129, 130]. Employing full genome se-
quencing on these isolates is less challenging than attempting to discern full genomes
from metagenomic data and this will in turn enhance reference databases. This can
assist in metagenomic studies, or can be mined for new functionalities or to identify
new therapeutic targets [101].
3.11 Lineage Dynamics in the Human Gut Microbiotia
Investigating the human gut microbiota with strain-level of resolution provides insight
into the individual characteristics of the strains and the roles they play in the gut
microbiota. For example, some species present in the gut microbiota may also include
strains that are virulent, such as E. coli. Similarly, only certain strains of Biﬁdobac-
terium can protect the host from enterohaemorrhagic E. coli infection [131]. Fukuda
et al. found that these protective Biﬁdobacterium strains contain an ATP-binding
cassette-type of carbohydrate transporter, which contributes to acetate production
by these strains in the distal colon where glucose has been exhausted [131].
The ability to study the human gut microbiota at the strain-level is also important
to study the population dynamics of this environment. Some studies have taken to
examining lineage turn over in the gut to understand the colonization stability. In the
1950s, Sears and colleagues conducted longitudinal studies examining E. coli strain
composition and persistence in the adult gut, with strains classiﬁed based on their
O-antigen group [132, 133]. Here they termed resident and transient strains as strains
that persist in the gut over long periods of time and strains that maintain a tenure
of only a few days or weeks, respectively [132].
In similar studies, Wold, Adlerberth and colleagues investigated strain turn over
during the colonization of the infant gut for E. coli [134, 135, 136, 137], and for S.
aureus [138]. This work is part of the ALLERGYFLORA study where they enrolled
Swedish infants to study the link between colonization of gut and the onset of allergies
later in life. They quantitatively cultured all major groups of facultative and anaerobic
bacteria from fecal samples and identiﬁed strains via random ampliﬁed polymorphic
DNA (RAPD) typing. In their study with 70 infants, they discovered that there were
2.1 E. coli strains sampled per infant for the year [134], and that the B2 phylogenetic
group had superior capacity to persist in the gut [135]. In the studies regarding S.
aureus, they found that certain combinations of virulence factors, such as the agr
allele I and the spa clonal cluster 630 (spa-CC 630), promoted gut colonization as
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these factors were found in all resident strains [138].
Banﬁeld and colleagues have developed a culture independent approach using time-
series metagenomic samples to gain strain-level resolution. In a sequence of papers,
they employed this approach to investigate the colonization of the infant gut [139,
69, 140]. In general, their approach is based on binning together groups of genomes
with similar abundances and to re-assemble these sequences together, separate from
the rest [69]. The time series abundance proﬁles provide additional information for
grouping contigs correctly into genomes or similar strains. Using this method, they
were able to assemble two near-complete genomes and nine partially complete genomes
for bacteria that comprised as little as 1% and 0.05% of the microbial community
from one infant[69]. They also tracked the relative abundances of three Staphylococcus
epidermis strains and phages distinctly infecting each of them, and related a decline in
one phage to the increase in abundance of the S. epidermis it infected and noted this
strain was the only one that contained an abortive infection bacteriophage system
[69]. In another study, they assembled two distinct Citrobacter strains and linked
strain-level diﬀerences to the dominance of one strain to possible metabolic and host
interaction traits via comparative genomics [139].
Their method to assemble complete- or near-complete genomes from time-series
metagenomic sampled allows for insights into individual strain contributions of the
gut microbiota, while tracking strain abundances over time. Although strain-level
resolution is achieved via their method, it is possible to fail to identify some events
that change the abundance of sequences, such as prophage integration and curing,
acquisition or loss of plasmids, and genomic insertions or deletions. As the method
relies on sequence abundances to group together strain speciﬁc sequences, it is pos-
sible that deﬁciencies in sampling could result in the inability to connect changes in
abundances to a particular strain. With suﬃcient sampling, it could be possible to
detect such events, but great care in interpreting the time-series abundance proﬁles
must be taken to ensure that these events are not missed.
3.12 Horizontal Gene Exchange within the Human Gut
Microbiota
The human gut is regarded as a suitable environment for gene exchange, and is even
considered to serve as a hub. The focus on the role the bacteria in the intestinal tract
play in the dissemination of antibiotic resistance gene is due to many factors. The
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Figure 3.2 | The resistance gene reservoir hypothesis and the role of the human gut
microbiota. Figure adapted from Salyers et al., 2004, Trends Microbiol.
ﬁrst factor is that the gut microbiota has been identiﬁed as a reservoir of antibiotic
resistance genes [55]. A second factor critical to the dissemination of these resistance
genes is that the human gut has the high cell density required to facilitate horizontal
gene transfer via conjugation [12]. And lastly, it may not only be the resident in-
testinal bacteria that is partaking in horizontal gene transfer, but also other bacteria
that are merely transiting through the gut that can be involved in gene exchange [141]
(Fig. 3.2). As many of the commensal bacteria in the gut are opportunistic pathogens,
there is concern that these bacteria may receive virulence factors or antibiotic resis-
tance genes, making them more pathogenic or diﬃcult to treat [141]. Additionally,
concerns exist regarding the potential of non-colonizing bacteria passing through the
gut may disseminate or acquire genes before returning to their normal body sites
[141].
The possibility of the gut serving as an environment for the dissemination of
antibiotic resistance genes was ﬁrst investigated in the late 1960s and 1970s. Quite
a few studies employed experimental setups to assess whether in vivo transfer of ”R
factors” (resistance factors) was possible in the gut [142, 143]. In the studies by Smith
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et al. and Anderson et al., volunteers were orally administered genetically marked E.
coli receiver strains, followed by prospective E. coli donator strains. Fecal samples
collected from the volunteers were cultured to observe if the resistance phenotype
of the receiver strain changed. In the Smith et al. study, they used E. coli strains
isolated from humans and from a variety of animals. While they observed transfer
from both human and animal strains in their one test subject, the animal strains
of E. coli were poorer at colonizing the gut and had to be given to at much higher
numbers than humans would be expected to consume naturally. In the Anderson
et al. study, they were unable to detect transfer of resistance genes in any of their
volunteers without antibiotic treatment. After a course of ampicillin or tetracycline,
transfer of resistance genes to their tagged receiver strain was observed in three out
of the ﬁve volunteers.
Other early studies used epidemiological data to infer that in vivo transfer of re-
sistance genes likely occurred. In a case by Ferrar and colleagues, a probable instance
of interbacterial transfer was recognized during an outbreak of shigellosis in a nurs-
ery caused by Shigella sonnei [144]. The pattern of antibiotic susceptibility of the
isolated S. sonnei was initially the same for all patients; all isolates were resistant
streptomycin, tetracycline, and ampicillin, but sensitive to kanamycin. However, af-
ter therapy with kanamycin, the antibiotic susceptibility proﬁle of S. sonnei changed
in one infant to include kanamycin resistance. Both kanamycin sensitive and resistant
S. sonnei isolates were capable of transmitting antibiotic resistance to E. coli. The
pattern of resistance in the E. coli progeny indicated that there were two distinct
R factors: one carrying streptomycin, tetracycline and ampicillin resistance, and the
other kanamycin resistance. The observation that the determinant for kanamycin re-
sistance was on a separate mobilisable element provided evidence that the S. sonnei
strain acquired kanamycin resistance via horizontal gene transfer in the gut.
Petrocheilou and colleagues reported a possible transfer of a plasmid contain-
ing antibiotic resistance genes between co-existing E. coli O-antigen groups in study
published in 1976 [145]. The main distinction in this study is that their evidence
for transfer is not based on an experimental setup where volunteers were fed marked
strains, nor does it come from epidemiological data, and lastly it is not in conjunction
with antibiotic treatment. However, the proposed transconjugant was only observed
after the suspected transfer occurred. Evidence that a plasmid carrying antibiotic
resistance genes transferred between the diﬀerent E. coli O-antigen groups is based
on molecular methods of the time, namely EcoRI restriction digests separated on gel,
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and phenotypic similarities such as production of F-pili, ﬁ character, similar partial
plasmid incompatibility and resistance phenotype [145]. Still, as this strain with a
similar plasmid was only observed after the suspected transfer occurred, it is not
conclusive whether the transfer occurred in situ of the intestinal tract or if the strain
already harboured such a plasmid.
These early studies mentioned relied to a large extent on selective culturing using
antibiotic resistance phenotypes to detect transfer. This can be problematic when
determining if a particular strain has indeed changed its resistance proﬁle due to
acquisition of antibiotic resistance genes. For the Anderson et al. study, they chro-
mosomally tagged the hosts’ own E. coli strains, and evidence for the transfer of
antibiotic resistance genes was only based on a positive culture of an isolate with a
resistance phenotype that was a union of both the marker and the donator. Although
the receiver strain was isolated from each of the volunteers, there was no mention
of the diversity of E. coli lineages, nor any other phenotypic controls for detecting
transfer. In the Smith et al. study, identiﬁcation of the receiving strain was based on
a chromosomal antibiotic resistance marker, haemolysis, and slide-agglutination tests
with an antiserum prepared against it. In the study by Petrocheilou and colleagues,
they gained a slightly higher level of resolution on the E. coli strain identities of the
microbiota, yet the extent of lineage identiﬁcation was based on O-antigen groups,
some of which varied in their antibiotic resistance proﬁle over the sampling time.
Farrar and co-authors stated that as they were unable to colicin type the S. sonnei
isolates they are likely the same strain. Yet even a study from that time found that
around 40% of the S. sonnei strains were not possible to colicin type [146].
Additionally, for the reports where transfer occurred in an unperturbed gut, where
volunteers or patients hadn’t ingested a donor strain, even discerning whether the re-
sistance genes were located on the same plasmid proved to be challenging. Petrocheilou
and colleagues performed transduction experiments to conclude that the resistance
markers were cotransducible and thus on the same plasmid [145]. Alternatively, Far-
rar and colleagues examined the pattern of the resistance proﬁles of the transconjugant
progeny to discern that there were two plasmids [144].
Current studies have enjoyed the beneﬁt of more advanced methods aﬀording a
higher resolution. For example, in a study by Trobos and colleagues to investigate
whether the sulphonamide resistance gene sul2 could be transferred between E. coli
in the gut, strains were identiﬁed by pulsed-ﬁeld gradient gel electrophoresis (PFGE);
a method of gel electrophoresis that separates long DNA molecules by alternating
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electrical pulses [147, 148]. Although this study intended on observing transfer be-
tween ingested donator and receiver strains, only one case of transfer amongst the
six volunteers was observed. It was infact a native sulphonamide resistant E. coli
strain transferring a plasmid to their receiver strain. Additionally, the sequencing
of sul2 showed that it was identical to that of the native E. coli’s own. The ability
to ’ﬁngerprint’ the strains, combined with sequencing of the resistance determinant
provided compelling evidence for the transfer.
In the Lester et al. study, they examined whether transfer of the vanA vancomycin
resistance gene can occur in the human intestine from animal to human origin isolates
of the gram-positive Enterococcus faecium, in the absence of selective pressure [149].
Transconjugants were observed in three out of the six volunteers, and presence of the
vanA gene was conﬁrmed via PCR. Additionally, a point mutation in the vanX gene
was also conﬁrmed in the donor and transconjugants. PFGE ﬁngerprints of the strains
showed that the resistant in vivo transconjugants had an additional band compared
to non-resistant strain, and that both the in vivo and in vitro transconjugants had
similar proﬁles.
While both of these studies used artiﬁcial experimental setups to determine if
transfer of resistance genes could occur in situ of the gut, they applied more mod-
ern methods to verify and conﬁrm the strains and resistance determinants involved
in transfer. With respect to plasmid identiﬁcation, sequencing segments or even an
entire plasmid has become commonplace. Furthermore, PCR-based assays for deter-
mining the incompatability types of plasmids have been developed based on sequence
information and can be used for plasmid group identiﬁcation [150].
Very few recent reports exist documenting possible transfer in situ of the human
gut, in non-artiﬁcial setups. One such report by Bidet and colleagues, documented the
transfer of a plasmid encoded AAC-1 beta-lactamase gene from a Klebsiella pneumo-
nia strain to an E. coli strain in the gut of an infant [151]. A fecal sample was analysed
before the infant underwent surgery, yielding a cefotaxime-resistant K. pneumonia
strain. The infant later developed a urinary tract infection due to an ampicillin-
resistant E. coli at day 30 and 45 post surgery, and was treated with cefotaxime
and gentamicin both times. At day 45, another fecal sample was analyzed yielding
cefotaxime-resistant resistant K. pneumonia and E. coli strains. The beta-lactamase
gene variants were screened and sequenced, revealing TEM-1 in all isolates, and AAC-
1b in the cefotaxime-resistant K. pneumonia and E. coli isolates. Strain identities
were veriﬁed via PFGE analysis, and plasmid identity was conﬁrmed via restriction
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digest of plasmid DNA separated by gel electrophoresis.
A similar report documenting transfer of resistance genes in the infant gut while
undergoing antibiotic treatment is from Karami and colleagues [152]. The infant
in this report was enrolled in the ALLERGYFLORA study, which set to examine
whether a link exists between the initial colonization of the gut to the onset of al-
lergies later on in life. Two distinct E. coli lineages colonized the gut within the
ﬁrst month of life; one was resistant to ampicillin, and the other one was sensitive to
ampicillin. The E. coli lineage identities were conﬁrmed via random ampliﬁed poly-
morphic DNA (RAPD) typing. The infant developed a urinary tract infection within
the ﬁrst month, and was treated ﬁrst with trimethoprim, then ampicillin, and ﬁnally
amoxicillin. After antibiotic treatment with ampicillin and amoxicillin, both E. coli
lineages were resistant to ampicillin. The beta-lactamase variants were detected via
isoelectric focusing, and a TEM-1 type beta-lactamase that conferred resistance was
conﬁrmed via sequencing. Plasmid identiﬁcation was done through restriction frag-
ment length polymorphism (RFLP) analysis, revealing a plasmid of approximately
40kb, and presence of the TEM-1 type beta-lactamase was conﬁrmed via Southern-
blot hybridization.
These reports by Bidet et al. and Karami et al. demonstrate that transfer of re-
sistance genes in the gut is possible in a non-artiﬁcial experimental set-up. However
in both of the observations, transfer was observed while the infants were undergoing
antibiotic treatment. The other studies by Trobos et al. and Lester et al., demon-
strate that transfer is possible in adult gut without the need for antibiotic pressure.
However, these studies employed artiﬁcial experimental set-ups where volunteers in-
gested high titres of potential donor and/or receiver strains. These conditions do
not accurately represent the natural state of the gut microbiota, and similarly the
amounts of ingested bacteria do not likely correspond to the amount of bacteria in-
gested on food [142]. The question whether transfer occurs in the unperturbed gut
without antibiotic still remains to be answered. Furthermore, follow up analysis to
investigate the fate of the horizontally acquired resistant bacteria in the gut can bring
insight into whether it can remain colonized in the gut, and if any adaptations have
occurred. This potential for the reservoir of resistance genes in the gut to dissemi-
nate and expand within the gut, and for the horizontally acquired resistant bacteria
to survive is crucial in the risk assessment of the gut as a hub of antibiotic resistance
genes exchange.
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4.1 Abstract
The human gut is one of the densest microbial ecosystems and is believed to play
an important role in the exchange of antibiotic resistance genes. We study the dy-
namics of co-existing Escherichia coli lineages in a longitudinally followed infant not
receiving antibiotics. Using whole genome sequencing, we capture the exchange of
multidrug resistance genes and identify a clinically relevant conjugative plasmid medi-
ating the transfer. Quantiﬁcation of the co-existing lineages reveals that the resistant
transconjugant is maintained for months, demonstrating that antibiotic resistance
genes disseminate and remain in the gut microbiome even in absence of antibiotic
selection. Furthermore, we observe large genomic deletions, as well as acquisition of
phages in these lineages during their colonization of the human gut. Our ﬁndings high-
light the dynamic nature of the human gut microbiota and provide the ﬁrst genomic
description of antibiotic resistance gene transfer between bacteria in the unperturbed
human gut.
4.2 Introduction
Resistance to antibiotics is an ever-growing public health concern. Antibiotic re-
sistance in bacteria can either be achieved through mutation in the genome or via
horizontal acquisition of foreign genetic material that confers resistance [1]. While
antibiotic resistance achieved through mutation is of signiﬁcant importance during
long term treatment of chronic infections [2], horizontal gene transfer plays a key role
in the ever-growing problems with multidrug resistant human pathogens [3].
The environment is considered a reservoir of antibiotic resistance genes [4], and in-
direct evidence has shown that antibiotic resistance genes have disseminated between
the soil microbiota to both commensal intestinal microbes and to clinical pathogens
[5, 6]. In addition to the ﬂow of genetic material between environmental and hu-
man resevoirs, antibiotic resistance genes have also been suggested to spread between
bacteria within the human microbiome [7]. In the human intestine, this transfer
would not only be between members of the commensal microbiota, but would also
include non-commensal bacteria transiting through the intestine [8]. While the gut
microbiome has been the subject of numerous metagenomic studies [9, 10, 11], in-
cluding a recent study constructing complete genomes of various species and strains
from metagenomic data [12], the use of metagenomics is not well-suited to detect
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horizontal gene transfer events between species or strains in the human gut.
Transfer of antibiotic resistance genes within the gut microbiota can occur in an-
imals [13], as well as in humans [14, 15]. These studies have directly demonstrated
antibiotic resistance transfer between bacteria in the gut. However, these studies set
up an artiﬁcial scenario where the host is fed a strain that can donate antibiotic resis-
tance genes to the commensal microbiota. A recipient strain or the commensal bac-
teria is subsequently monitored to detect if the antibiotic resistance genes have been
transferred from the donor strain. Despite employing an artiﬁcial experiment set-up,
studies have started to elucidate factors known to inﬂuence transfer between bacteria.
For example, Stecher et al. reported that pathogen-induced gut inﬂammation of lab
mice gives rise to an environment where lineages of various Enterobacteriaceae species
can bloom resulting in unprecedented rates of horizontal gene transfer between these
bacteria [16].
A few instances of natural transfer of antibiotic resistance genes in the unperturbed
human gut microbiota have been published and these reports describe changes in the
antibiotic resistance proﬁles of strains collected from infants undergoing antibiotic
treatment [17, 18]. Additionally, a retrospective study examining a collection of Bac-
teroides collected over a period of 40 years demonstrated that extensive resistance
gene exchange has occurred between species of Bacteroides and other genera in the
human colon [19]. Even though the gut is considered a reservoir of antibiotics resis-
tance genes and considered to serve as hub for horizontal gene exchange, full genomic
data for strains exchanging antibiotic resistance genes in situ of the human gut has
yet to be reported. In this study, we characterize the transfer of antibiotic resistance
between co-existing Escherichia coli lineages in the infant gut at the genomic level
using whole genome sequencing. As this transfer occurred in the absence of antibiotic
treatment and the resistant transconjugant was maintained for months in the gut, we
believe this study provides evidence that resistance genes are stably maintained once
acquired.
4.3 Results
Study Material
Our study material was selected from an infant enrolled in the ALLERGYFLORA
study, which was designed to examine the link between the infant gut microbial
colonization pattern and the development of allergies [20]. Faecal samples from this
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infant were obtained over the course of the ﬁrst year of life at 3 days, 1, 2 and
4 weeks, and 2, 6 and 12 months. The samples were quantitatively cultured for
Enterobacteriaceae selection. Isolates identiﬁed as E. coli by biotyping were initially
assigned to speciﬁc lineages based on random ampliﬁed polymorphic DNA (RAPD)
typing. The sensitivity threshold of the culture method was 102:5 colony-forming
units (CFU) per gram of fecal matter [21], which is several orders of magnitude more
sensitive than current metagenomic sequencing studies [12].
The antibiotic resistance proﬁle was determined for each isolate. Interestingly, a
change in the antibiotic resistance proﬁle was detected in a set of consecutive isolates
from one lineage colonizing one of the infants enrolled in the ALLERGYFLORA
study. The set of E. coli lineages collected from this infant are the subject of this
study, chosen to investigate the genome dynamics involved in the acquisition and
persistence of antibiotic resistance.
E. coli Lineage Sampling
E. coli isolates were obtained from the infant at sampling time points from two weeks
to twelve months after birth (Fig. 4.1). In total, three distinct lineages were iden-
tiﬁed: A, B and C. The sampling at two and four weeks after birth yielded only
isolates belonging to lineage A, which were sensitive to all antibiotics tested (Fig. 4.1,
Supplementary Table 4.1). At the 2-month sampling time, lineage B was observed.
Lineage B was resistant to the antibiotics ampicillin, piperacillin, streptomycin and
sulfamethoxazole (Fig. 4.1). At the two-month sampling time, the antibiotic re-
sistance proﬁle of lineage A changed. Lineage A was now resistant to ampicillin,
piperacillin, streptomycin and sulfamethoxazole. Notably, the change in the resis-
tance proﬁle of lineage A at two months matches that of the incoming lineage B
suggesting a transfer of resistance determinants from lineage B to A. Lineages A and
B were both present at the six months sampling time with no changes in the antibiotic
resistance proﬁle. However, at the 12-month sampling time only lineage B was still
present, with the addition of lineage C, which is only resistant to sulfamethoxazole
(Fig. 4.1).
Genome Sequencing of the Isolates
A total of 13 isolates from lineages A, B and C were genome sequenced. At least one
isolate sequenced per lineage per sampling point when present was selected (Supple-
4.3 Results 51
2w4w 2m 6m 12m
Sampling Times
Lin
ea
ge
s
A
B
C
Resistance
Phenotype
Resistant
Sensitive
Amp
Pip
Str
Sfx
Amp
Pip
Str
Sfx
Amp
Pip
Str
Sfx
Figure 4.1 | Sampling and antibiotic resistance of the E. coli strains. A total of
three E. coli lineages were sampled from the infant’s intestinal microbiota over the
course of the ﬁrst year of life. Stacked squares indicate both the presence of the
lineage at the sampling points, in addition to their antibiotic resistance proﬁle to
ampicillin (Amp), piperacillin (Pip), streptomycin (Str), and sulfamethoxazole (Sfx)
at the time points. Filled coloured squares indicate resistant isolates, and non-ﬁlled
squares indicate sensitive isolates (Supplementary Table 4.1 for MICs).
mentary Table 4.2). Lineage A isolates included two from the 2 week sampling time,
2w1 and 2w2, one from 4 weeks and 2 months, 4w and 2m, respectively, and two from
6 months, 6m1 and 6m2. Lineage B isolates included two isolates form 2 months,
2m1 and 2m2, one from 6 months, 6m, and two from 12 months, 12m1 and 12m2.
Lineage C isolates included two from 12 months, 12m1 and 12m2. Reads from each
isolate were assembled [22] and annotated via RAST [23]. Comparisons between iso-
lates were made based on mapping reads from one isolate to assembled contigs from
another isolate [24] and identifying single nucleotide polymorphisms (SNPs) [25] and
assessing read coverage [26], as well as by aligning contigs [27].
To conﬁrm lineage identities of the isolates, we assessed both the number of SNPs
and the amount of total genomic content shared between lineages. One of the ﬁrst
sampled isolates from each lineage was selected for comparison, speciﬁcally lineage A
2w2, lineage B 2m2, and lineage C 12m2. Both lineages A and C have on the order of
90,000 SNPs when compared to lineage C (Supplementary Table 4.3). Interestingly,
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lineages A and C have an order of magnitude fewer SNPs when compared to each other,
on the order of 7,000 SNPs, than when compared to B. Similarly when comparing
the percentage of the genomic content shared between the lineages, lineages A and C
shared between 79.7% and 82.3% in common with lineage B (Supplementary Table
4.4). Lineage A shared 93.6% of the genomic content from lineage C, and lineage C
shared 95.5% from lineage A. While these results indicate that lineages A and C are
more closely related to each other than to the lineage B, the amount of SNPs and
diﬀerences in genomic content reveal that they are diﬀerent lineages. RAPD-typing
of the isolates was sensitive enough to successfully classify the colonies into the three
distinct lineages.
Evolutionary relationships amongst the isolates within a lineage were established
based on the number of SNPs identiﬁed by aligning reads to one of the ﬁrst sequenced
isolates, where again lineage A 2w2, lineage B 2m2 and lineage C 12m2 was selected
(Supplementary Tables 4.5, 4.6, 4.7 for full list of SNPs with annotations for lineages
A, B and C, respectively). SNPs identiﬁed in isolates from lineages A, B and C
produced consistent phylogenetic trees and show a progression in the acquisition of
SNPs (Fig. 4.2). In the A lineage, one SNP was identiﬁed between the 2m1+2m2
and the 4w isolates, and this SNP was again identiﬁed in all isolates of lineage A
subsequently sampled. Isolates 2m, 6m1 and 6m2 all branched out after this point.
Similarly, lineage B had one SNP propagated to all isolates subsequently obtained
after the initial SNP detection. The 6m isolate branched out after this point, while
the 12m isolates share 4 SNPs in common before branching. One SNP was identiﬁed
between the two lineage C 12m isolates. The consistent phylogenetic tree and the
progression of SNPs indicate that the isolates sampled are representative clones for
both the A and B lineages.
To get further information about the isolated lineages we compared the isolates to
previously sequenced E. coli genomes found in the NCBI reference sequence database,
based on genomic content in common and number of SNPs. Lineage A had 93.2%
genomic content in common with the asymptomatic bacteriuria (ABU) strain, ABU
83972 (NC_017631.1) [28]. ABU 83972 was also the closest previously sequenced
strain to lineage C as well, sharing 91.5% genomic content. The ABU 83972 strain,
which is closely related to the pathogenic CFT073 E. coli strain, has been reported to
show a tendency to evolve toward commensalism from virulence during asymptomatic
colonization of the bladder via the loss of gene function [28]. Lineage B shared 95.4%
genomic content with UMN026 (NC_011751.1), an extra-intestinal pathogenic strain
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Figure 4.2 | Phylogenetic tree of the isolates. Phylogenetic trees based on the
number of SNPs found in each of the isolates of lineages A, B and C. The grey value
next to each branch indicates the number of SNPs between isolates.
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[29]. The UMN026 strain belongs to clonal group A, which is a globally spread
uropathogenic clone that frequently carry multiple antibiotic resistance determinants
[30]. Lineage B was also determined to belong to the clonal group A via gene speciﬁc
PCR [31].
Additionally, we also determined the multi locus sequence types (MLST) and the
phylogenetic groups of the lineages. Surprisingly, lineages A and C belonged to the
same MLST group, ST12, (Supplementary Table 4.8), yet RAPD typing was able to
distinguish between these lineages. Lineage B belonged to ST782. Lineages A and C
belonged to phylogenetic group B2, and lineage B belonged to group D.
Lineage genome dynamics
By examining the genomic changes in the isolates, we observed that the lineages
were highly dynamic. Genome dynamics included acquisition of antibiotic resistance,
major genomic deletions, plasmid loss, and phage integrations (Fig. 4.3).
To identify the genomic changes underlying the acquisition of antibiotic resistance
in lineage A, sequence data collected from the sensitive isolates (2w1, 2w2 and 4w)
were compared to sequence data from the resistant isolates (2m, 6m1 and 6m2). Two
non-conservative genomic mutations in the betaine aldehyde dehydrogenase (betB)
and phosphoenolpyruvate carboxylase (pckA) genes were identiﬁed, however, these
would not be expected to contribute to antibiotic resistance. Instead, additional ge-
netic information totaling 90kb was found in the resistant isolates from lineage A
that were collected at the two and six month sampling points compared to lineage
A isolates from the 2 and 4 week time points (Fig. 4.1). The read coverage of the
newly acquired genetic information had 2 times greater coverage depth compared
to that of the genome, suggesting that a newly acquired low-copy number plasmid
harbored the antibiotic resistance determinants. This putative plasmid contained con-
jugative transfer genes (trb, tra and pil operons). Additionally, the putative plasmid
contained a beta-lactamase (blaTEM 1c), which has been reported to confer resis-
tance to penicillins, including ampicillin [32]. The TEM-1 beta-lactamases are widely
disseminated amongst several diﬀerent pathogens including E. coli, Haemophilus in-
ﬂuenza and Neisseria gonorrhoeae [32]. Furthermore, two genes, aminoglycoside
3’-phosphotransferase (strA) and streptomycin phosphotransferase (strB), known to
mediate resistance to streptomycin and other aminoglycosides, were identiﬁed, the
latter being widely disseminated on a broad host range plasmid [33]. Lastly, a dihy-
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Figure 4.3 | Overview of lineage genome dynamics. The transfer of a multidrug resis-
tance plasmid from lineage B to lineage A occurred before the 2 month sampling time.
The transfer occurred before diversiﬁcation of lineage A. A large genomic deletion oc-
curred in lineage A after 2 months but before the 6 month sampling point, as detected
in the isolates 6m1 and 6m2 isolated at 6 months. At the 6 month sampling point,
both lineages A and B were infected by diﬀerent lambda-like phages. A BcepMu-
like phage infecting lineage B was detected in 6m and 12m2 isolates, identiﬁed in
diﬀerent regions of the chromosome indicating that two distinct phage integrations
occurred. Lineage B contained two plasmids containing a FII replicon in the 2m iso-
lates, whereas isolate 6m contained only the plasmid containing the FII replicon, and
the 12m isolates contained the plasmid with the FII:FIB:FIC replicons. A genomic
deletion was detected in lineage B 12m1 isolate.
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Figure 4.3 continued | No isolates of lineage A were obtained at the ﬁnal sampling
time at 12 months, but a new isolate from lineage C is sampled along with lineage
B. Both lineage C 12m1 and 12m2 isolates contained a plasmid, pNK117-2, that
was 100% identical to a plasmid found in lineage B. This could be due to another
conjugative transfer event, or lineage C could simply have harboured the pNK117-2
on entry in the gut.
dropteroate synthase gene (sul2) was found on the putative plasmid. The sul2 gene
is known to mediate resistance to sulfonamides and is also frequently found in clinical
isolates [34].
Querying sequence databases for similar plasmids yielded the clinically important
conjugative, IncI1-type pHUSEC41-1 plasmid of 91,942bp [35]. Aligning contigs from
the isolates in this study to pHUSEC41-1 resulted in 99.3% coverage of the plasmid
with an average of 99.0% identity. The alignment also showed that there were no
insertions in the transferred plasmid compared to pHUSEC41-1. The pHUSEC41-
1 plasmid was initially identiﬁed in the E. coli serotype O104:H4 strain HUSEC41
isolated from a child in Germany with hemolytic-uremic syndrome (HUS) [35]. The
plasmid has additionally been found in other sequenced E. coli isolates of serotype
O104:H4 isolated from patients in France with sporadic cases of HUS [36]. Here,
the plasmid is found in E. coli strains of serotypes O73: K-:H18 and O179: K12:H-
isolated from a Swedish infant, highlighting the wide dissemination of this multiple
antibiotic resistance plasmid amongst various E. coli strains.
The phenotypic resistance patterns (Fig. 4.1) suggested that the horizontally
acquired resistance was transferred from lineage B to lineage A. To assess this we
analyzed lineage B to see if it contained the acquired genetic information of strain
A. Aligning reads from lineage B to the acquired genetic information of lineage A
resulted in coverage of 100% of the new genetic information with only one identiﬁed
SNP variant (Fig. 4.4). The high-degree of identity between the plasmids and the
change in the antibiotic resistance proﬁle of lineage A to match the proﬁle of lineage
B is consistent with strain B transferring its antibiotic resistance plasmid to lineage
A.
Plasmid content was also found to vary in lineage B, but here plasmid loss was
discovered. We used the PlasmidFinder tool to identify possible plasmid replicons
(Supplementary Table 4.9) [37]. In the 2m1 and 2m2 isolates, multiple IncF plasmid
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Figure 4.4 | Transfer of a plasmid mediating antibiotic resistance. Contigs corre-
sponding to the newly acquired plasmid were identiﬁed by analyzing diﬀerences in the
read alignment coverage before and after the change in the resistance proﬁle. Reads
from lineage B are mapped to the acquired plasmid contigs of A, displaying coverage
depth. High coverage and identity between the strains was observed. The acquired
plasmid contigs of A were aligned to the sequence of pHUSEC41-1.
replicons were identiﬁed, namely two FII, one FIB, and one FIC. The two FII replicons
were distinct and identiﬁed on diﬀerent contigs. In the 6m isolate, only one of the FII
replicons was identiﬁed, while the other FII replicon and the FIB and FIC replicons
were found in the 12m1 and 12m2 isolates. The FII and FIC replicons were identiﬁed
on the same contig for both 12m1 and 12m2 assembled genomes. While we were
unable to close these plasmids, evidence that the FIB replicon is also present on the
FII:FIC plasmid is the pattern of its presence, ie. the FIB is observed in both 12m1
and 12m2 and not in 6m isolates. Typing of these plasmids using the IncF pMLST
typing scheme yielded only a known FIB allele, B:6 [38, 37]. Here, we observe a
reduction in the plasmid content of lineage B of plasmids with similar replicons.
Both FII and FII:FIB:FIB plasmids shared high homology over the 32kb regin
encoding for IncF conjugation machinery. Contigs identiﬁed to be a part of the FII
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Figure 4.5 | Large deletion in the genome of lineage A. Contigs from strain A were
aligned to reference genome CFT073. Dark grey colored contigs represent regions
ﬂanking the excision. Uncoloured contigs represent the region lost due to the deletion.
Arrows indicate the position of the primers designed based on the CFT073 genome
used to conﬁrm the genomic excision.
plasmid from the 2m and 6m isolates totaled 54 kb, and contained genes encoding
for microcin B17 (Supplementary Table 4.10). Contigs identiﬁed to be part of the
FII:FIB:FIC plasmid from the 2m and 12m isolates totaled 110 kb. Genes involved
in iron transport were identiﬁed via RAST (Supplementary Table 4.11) [23]. A 20 kb
region on the contig with the FIB replicon was dedicated to genes encoding for heavy
metal resistance.
Interestingly, a large deletion was detected in lineage A isolates at the six-month
sampling point, i.e. after acquisition of the resistance plasmid. The lost contigs,
totaling 83kb, aligned to a contiguous region in a similar, sequenced strain, E. coli
CFT 073 (Fig. 4.5) (NC_004431). The ABU 83972 strain, which has high homology
to the CFT 073 strain, was not used due to a documented prophage integrated in
this region [28]. Using the alignment information, PCR assays were conducted to
establish that the deletion was an excision (Fig. 4.5, Supplementary Fig. 4.1).
Annotated genes located in the deleted segment included iron scavenging genes,
such as the iroA gene cluster and the hemolysin activator protein, peptide antibiotic
genes microcin H47 and colicin-E1, which target gram-negative bacteria in general and
E. coli speciﬁcally, respectively, and antigen 43, which may have a role in adhesion
[39]. Lastly, genes involved in fatty-acid synthesis, carbohydrate and amino acid
metabolism were also lost as a result of the deletion (Supplementary Table 4.12 for
complete list).
Similarly, a large deletion was also identiﬁed in lineage B, but only in the 12m1
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isolate (Fig 4.3). The contigs associated with this deletion aligned to a contiguous
region in the UMN026 chromosome, spanning a region of 26 kb. This region included
pap genes encoded for P ﬁmbriae (class II), mobile elements and a TonB-dependent
receptor (Supplementary Table 4.13 for complete list). While P ﬁmbriae are a well-
known adhesin involved in the pathogenesis of urinary tract infections [40], they
have also been linked to enhanced persistence of resident E. coli strains in the gut
microbiota in infants [41, 20, 42].
Furthermore, phage content varied in the lineages across sampling time points,
in addition to the several stably integrated phages. At the 6-month sampling time,
a phage bloom had occurred where both lineage A and B were infected by phages
(Fig. 4.3). Lineage A was infected by a 27.1 kilobase (kb) Lambda-like phage, while
lineage B was infected by two phages: a diﬀerent Lambda-like phage of 21.6kb, and
a BcepMu-like phage of 45.4kb. Notably, the BcepMu-like phage infecting lineage B
had very high similarity to an integrated phage in the genome of lineage A (at least
99.9% similarity covering 97.7%), meaning that lineage B had just acquired an extra
40kb of genetic material on par with lineage A. However, the phage likely did not
originate from lineage A due to the diﬀerences in both sequence and structure in one
region. The integration of several phages at this time point comprising more than
90kb highlights how phages play a vital role in horizontal gene transfer. Interestingly,
only the BcepMu-like phage from lineage B was identiﬁed in an isolate again from a
later sampling time, and only in the 12m2 isolate. Aligning the ﬂanking regions of the
phage to the 2m2 isolate revealed that the phage integrated into two diﬀerent regions
in the genome. This suggests that two separate phage integration events occurred
in lineage B. With regards to phylogenetic tree where 12m1 and 12m2 isolates share
4 SNPs in common after branching from the 6m isolate (Fig. 4.2), this also would
appear to be the most likely explanation how both 6m and 12m2 isolates contain the
BcepMu-like prophage.
At the last sampling time at 12 months, lineage C was sampled for the ﬁrst time.
Comparing the genome of lineage C to lineages A and B revealed that it was most
related to lineage A. However, lineage C contained one plasmid and this plasmid
had 100% similarity to a plasmid from lineage B (Fig. 4.3). This 35.8 kb plasmid,
termed pNK117-2, contains the virB conjugation system (Supplementary Table 4.14).
A blastn search revealed that pRPEC180_47 was the most closely related plasmid
with 85% coverage and 98% similarity [43]. The pRPEC180_47 plasmid belongs to
the IncX1 incompatibility group. The PlasmidFinder web service did not identify
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any replicons in lineage C [37] (Supplementary Table 4.9). The grouping for IncX1
plasmids is based on the bis gene encoding an auxiliary replication initiation protein
from the pOLA52 plasmid [37], which the pNK117-2 plasmid was found to only the
ﬁrst 94 bp (20%) of bis. However, the plasmid does bear resemblance to other IncX1
plasmids (Fig 4.6). Typically, IncX plasmids follow the generalized structure of pir-bis-
par-hns-topB-pilX-actX-taxCA [43]. A homologous bis gene was found on an NDM-1
producing plasmid from Raoultella planticola RJA274. Additionally, homologues for
par, hns, topB,pilX (virB), actX, and taxCA from pOLA52 were identiﬁed on pNK117-
2 and in the same order (Fig 4.6).
The presence of pNK117-2 in both lineage B and C with 100% sequence identity
could indicate that another conjugative transfer event occurred in situ of the gut.
However, lineage C was only sampled at 12 months, so we did not sample lineage C
at a previous sampling time without pNK117-2. While the presence of both lineage
B and C harbouring pNK117-2 in the gut may seem like a transfer event is the most
likely reason they both contain pNK117-2, there are examples of sequenced plasmids
with very high identity to other previously sequenced plasmids in diﬀerent genetic
backgrounds (eg. the highly-similar pHUSEC41-1 in this paper, and the pUTI89-like
plasmids [44, 45, 46, 47]).
E. coli lineage population counts in relation to genome dynamics
To investigate whether the various genomic events occurring in the E. coli lineages
possibly aﬀected their ﬁtness in the gut microbiota, we examined the population
counts of lineages A and B at the diﬀerent sampling points (Fig. 4.7). In general,
population numbers of E. coli decrease in the gut of infants over the ﬁrst year of life,
in parallel with the establishment of a microbiota dominated by anaerobic bacteria
[20].
Interestingly, the acquisition of the resistance plasmid in lineage A was associated
with a very steep drop in population counts, from 1010:2CFU per gram of fecal matter
in the 4 week sample to 107:8per gram in the 2 month sample. This could possibly
relate to a ﬁtness cost imposed on lineage A from carrying the resistance plasmid.
This possibility was further supported by pair-wise in vitro growth competition ex-
periments comparing the growth of a lineage A isolate from the 4 week sampling,
before acquisition of the plasmid, and a lineage A isolate from the 2 month sampling,
after acquisition of the plasmid. In these experiments carriage of the plasmid incurred
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Figure 4.6 | Plasmid NK117-2 identiﬁed in both lineage B and C. Here it is compared
to IncX1 plasmids pRPEC180_47 (middle ring, blue) and pOLA52 (outer ring, green).
Open reading frames (ORFs) identiﬁed on pNK117-2 are drawn in the inner most ring
in black, with arrows indicating the reading direction. Annotations for some ORFs
are labeled outside of the rings.
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Figure 4.7 | Population counts of co-existing E. coli lineages. Faecal population
counts of E. coli lineages A, B and C at diﬀerent sampling points during the ﬁrst year
of life of the infant studied. For comparison, the mean population levels and +/- 1
and 2 standard deviations (SD) at the same sampling points for 272 E. coli strains
isolated from 128 infants in the ALLERGYFLORA cohort are indicated in the ﬁgure.
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a cost of -6.3% +/- 1.9% per generation on lineage A. However, despite the ﬁtness
costs the lineage persisted in the gut for at least another 4 months, and even increased
in numbers during this time.
At the 2 month sampling time, when lineage B was ﬁrst sampled, lineages A and B
had roughly the same population counts, 107:8 and 107:7 CFU/g, respectively. At the
6 month sampling time, the population counts of lineage A were several times higher
than the counts of lineage B (108:7 versus 108:0 CFU/g,) and had also increased almost
one log since the 2 month sampling point. The large genomic deletion in the A lineage
was ﬁrst detected at the 6 month sampling point, as well as the phage infections in
both the A and B lineages. Possibly, the large deletion occurring in lineage A between
the 2 and 6 month sampling points reduced the ﬁtness cost imposed on lineage A by
the resistance plasmid. It is also possible that the phage infections diﬀerentially
aﬀected lineage A and B, providing lineage A with a competitive advantage.
4.4 Discussion
The human gut, as a hub for horizontal gene exchange, is expected to play an impor-
tant role in the exchange of antibiotic resistance genes. Yet to our knowledge, there
are no prior reports documenting horizontal gene exchange events at the genomic
level between bacteria in the unperturbed human gut. Here, by genome sequencing
a collection of co-existing E. coli strains, we describe several cases of horizontal gene
transfer mediated by both integrative phages and conjugative plasmids. The substan-
tial genome dynamics captured in this study highlight the highly dynamic nature of
the gut microbiota.
Speciﬁcally, we document at the genomic level transfer of a multiple drug resis-
tance plasmid between co-existing bacterial lineages in the human gut. Notably, the
transfer occurred in the gut of an infant not treated with antibiotics. This provides
compelling evidence to support the idea of the human gut serving as a hotspot for hor-
izontal resistance gene exchange even in absence of selective pressure from antibiotics.
Furthermore, the A lineage persisted in the infant gut for months after acquisition of
the resistance plasmid. The fact that the transconjugant survived and even increased
its population counts highlights that resistance genes might easily disseminate also in
healthy individuals never treated with antibiotics.
We also identify the entire mobile genetic element responsible for this horizontal
gene transfer and discover that it is closely related to the clinically relevant multidrug
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resistance plasmid pHUSEC41-1. This study highlights the advantages of studying
the longitudinal dynamics of co-existing bacterial lineages in the gut microbiota as
a complement to metagenomic sequencing studies. The power of this approach is
expected to increase as cultivation methods for representatively sampling the gut mi-
crobiota further improves and we anticipate that further studies augmenting metage-
nomic sequencing with genomic sequencing will provide a richer and more detailed
view of the highly dynamic nature of strains in the human gut microbiota.
4.5 Materials and Methods
Strain isolation and population counts
Fecal samples were obtained from an infant enrolled in the ALLERGYFLORA study
[20]. A sample of the rectal ﬂora was obtained using a cotton-tipped swab at 3
days after birth. The infant?s parents collected fecal samples at 1, 2, and 4 weeks,
and 2, 6 and 12 months of age. Samples were placed in airtight containers with
an anaerobic sachet (AnaeroGen Compact, Oxoid Ltd, UK) and refrigerated until
brought to the lab, where they were serially diluted and cultivated within 24 hours
on a range of non-selective and selective media, including Drigalski agar plates [48]
for the isolation of Enterobacteriaceae. The detection limit was 102:5 CFU/g fecal
matter. Isolates resembling Enterobacteriaceae were selected from each positive cul-
ture based on diﬀering colony morphological characteristics such as size, shape, color
or mucoid appearance and speciated using API 20E biotyping (API Systems SA,
France). Each morphotype was enumerated separately, and strain identities of the
enumerated morphotypes were conﬁrmed using random ampliﬁed polymorphic DNA
(RAPD) typing [20]. Initial conﬁrmation of the RAPD-typing was conﬁrmed by per-
forming pulsed-ﬁeld gel electrophoresis (PFGE). Isolated strains were subjected to
complete serotyping (O:K:H) (Statens Serum Institute, Denmark). The sample taken
at 3 days and 1 week after birth did not yield any E. coli strains. In samples taken
from 2 weeks to one year after birth, a total of 3 E. coli lineages were isolated from
colonies. From these 5 sampling times positive for E. coli, a total of 13 isolates were
selected and stored for further analysis.
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Antibiotic susceptibility and Minimum Inhibitory Concentration
(MIC) determination
While isolating E. coli strains from fecal samples, isolates were also tested for their
susceptibility to the following antibiotics using the disc diﬀusion method (Oxoid,
Sweden): ampicillin, amoxicillin/clavulanic acid, piperacillin, mecillinam, cefadroxil,
ceftazidime, cefuroxime, cefoxitin, chloramphenicol, gentamicin, tobramycin, strepto-
mycin, nitrofurantoin, nalidixic acid, tetracycline, trimethoprim and sulphonamide.
From the saved isolates, the MIC of the following isolates were determined, such that
there was one isolate selected per lineage per sampling point: lineage A 2w1, 4w, 2m,
6m1 isolates, lineage B 2m1, 6m, 12m1 isolates, and lineage C 12m1 isolate. The
MICs of these 8 isolates were performed in 96 well micro-titer plates using the follow-
ing antibiotics: ampicillin, piperacillin, mecillinam, ceftazidime, cefuroxime, cefoxitin,
chloramphenicol, gentamycin, tobramycin, streptomycin, nalidixic acid, tetracycline,
trimethoprim, sulfamethoxazole (Sigma). Each drug gradient consisted of 11 points
in a two-fold dilution series prepared in Mueller Hinton broth II, cation-adjusted
(MHBII) (Sigma) with a total of 150 l in each well. The MIC plates were inoculated
from diluted over-night cultures grown in MHBII, such that approximately 105 cells
were added per well using a 96-pin replicator. The plates were incubated at 37Cfor
18 - 20 hours and the optical density (OD) at 600 nm was read on a BioTek Epoch
plate reader.
PCR for determination of phylogenetic group identity and clonal
group
Strains were also characterized with respect to phylogenetic group identity (A, B1, B2
or D) by triplex PCR using primers detecting the genes chuA and yjaA and an anony-
mous DNA fragment designated TSPE4.C2 [49]. A PCR recognizing members of the
clonal group A (CGA), which is characteristic of a globally spread, pyelonephritogenic
clone, was applied using previously described conditions [31].
Genome Sequencing
Genomic DNA from each of the 13 isolates was obtained using an UltraClean®
Microbial DNA Isolation Kit (Mobio Laboratories, Inc.). Both single-end (SE) read
libraries and paired-end (PE) read libraries were prepared (Supplementary Table 4.2).
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For SE library preparation, the extracted DNA was sheared into 200bp fragments
using a Covaris E210 and barcoded libraries were constructed for Illumina sequencing
and performed by Partners HealthCare Center for Personalized Genetic Medicine
(Massachusetts, USA). For PE library preparation, the TruSeq Nano DNA kit was
used (Illumina, USA) and MiSeq sequencing was performed at the Novo Nordisk
Foundation Centre for Biosustainability (Denmark).
Sequence Analysis
Reads from each isolate was assembled using Velvet [22]. Single-end and paired-end
reads were assembled with variable k-mer sizes (Supplementary Table 4.2). Contigs
with less than 500 bp were ﬁltered. Contigs were corrected by aligning reads using
Bowtie2 (version 2.1.0) [24], calling single-nucleotide polymorphisms (SNPs) using
SAMtools (version 0.1.19) [25], and edited using custom biopython scripts [50]. Con-
tigs were annotated using the RAST server [23]. Bowtie2 and SAMtools were also
used to determine the number of SNPs between isolates. Identiﬁed variants that had
a Phred quality score less than 50 or with less than 90% of the high-quality reads as
the variant were ﬁltered. SNPs occurring in short homologous regions after genomic
deletions or acquisitions were also ﬁltered. BEDtools [26] was used to calculate read
coverage across genomes and thus identify acquired or deleted genomic information.
MUMmer was used to align sequences [51].
Multi locus sequence typing (MLST)
MLST groups were determined based on the following genes extracted from the as-
sembled contigs: adk, fumC, gyrB, icd, mdh, purA, and recA, using the database
hosted at http://mlst.warwick.ac.uk/mlst/dbs/Ecoli [52].
Phage Identiﬁcation
The PHAST phage search tool server [53] was used to identify possible intact phages
in the contigs. In addition, BLAST was used to identify similar previously described
phages. Phage integration sites were determined by aligning contigs containing the
ﬂanking regions of the phage to an earlier isolate not containing the prophage.
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Plasmid Analysis
The PlasmidFinder web-service (http://cge.cbs.dtu.dk/services/PlasmidFinder) was
used to identify replicons in the assembled contigs and classify plasmids into incom-
patibility groups [37]. Plasmid ring diagrams depicting read coverage were drawn in
R via custom scripts [54], and plasmid ring diagrams were drawn using BLAST Ring
Image Generator (BRIG) [55] with the ?-task megablast? option to BLAST [56]. Ad-
ditionally, contigs belonging to plasmids that have a copy number greater than one
were also identiﬁed based on their relative abundance to the genome. Read depth
was calculated via BEDTools [26]. Plasmid sequence comparisons for pNK117-2 were
made to pOLA52 (NC_010378.1), pRPEC180_47 (NC_019088.1) and NDM-1 pro-
ducing plasmid from RJA274 (KF877335.1). IncF pMLST typing was done using the
web-service (https://cge.cbs.dtu.dk/services/pMLST/) [37].
Genomic Deletion Veriﬁcation
Based on the alignment of contigs to the genome of CFT 073 (NC_004431), primers
were designed to show that the deletion in lineage A was an excision, in addition to
show contiguity prior to the deletion, as well as controls for showing the occurrence
of the deletion only in the lineage A isolate sampled at 6 months.
Competition experiments to assess the ﬁtness costs in vitro of
carriage of the plasmid closely resembling pHUSEC41-1
To assess ﬁtness cost, pair-wise growth competition in Davis minimal medium with
25 mg/mL glucose (DM25) was performed using isolates of lineage A sampled at 2
weeks and 2 months, respectively, the latter which had acquired the plasmid closely
resembling pHUSEC41-1. The experiment was performed as previously described
[57], but in brief, the two isolates were grown overnight in nutrient both, and then
inoculated into DM25 at a dilution of 1:104 and grown for 24 hours. The cultures were
then mixed together in a ratio of 1:1, and then diluted 1:100 into fresh DM25. This
dilution step was continued for 6 days. After initially mixing the two cultures together,
and after each 24 hour period, the cultures were diluted appropriately and 100uL was
added to Iso-Sensitest plates (Oxoid, Sweden) in triplicate, with and without 1000
mg/L of sulfamethoxazole. Colonies were counted after over night incubation at 37C,
and the mean number of colonies on the sulfamethoxazole plates were subtracted
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from the plates without sulfamethoxazole to determine the mean number of colonies
lacking the pHUSEC41-1-like plasmids. Six replicates of this ﬁtness experiment were
conducted.
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4.8 Supplementary Information
Supplementary Table 4.1| MIC values of lineages A, B and C for sampling time
points. One isolate per lineage per sampling time was selected for MIC testing.
Lineage Lineage A Lineage B Lineage C
Sampling Time 2w1 4w 2m 6m1 2m1 6m 12m1 12m1
Antibiotic (ug/mL)
Ampicillin 2 2 512 512 512 512 512 2
Piperacillin 1 1 64 64 32 32 32 0.5
Mecillinam 0.125 0.125 1 1 1 1 0.5 0.125
Ceftazidime 0.25 0.25 0.25 0.25 0.0625 0.125 0.125 0.125
Cefuroxime 8 8 8 8 2 4 2 2
Cefoxitin 2 4 4 4 8 4 8 2
Chloramphenicol 1 1 1 1 1 1 1 1
Gentamycin 0.5 0.5 0.5 0.5 1 1 1 1
Tobramycin 0.25 0.25 0.5 0.125 0.5 0.25 0.5 0.5
Streptomycin 2 2 64 128 128 128 128 4
Nalidixic Acid 1 1 1 1 1 0.5 1 0.5
Tetracycline 0.5 0.5 0.5 0.5 1 1 0.5 1
Trimethoprim 4 4 2 4 0.125 0 0.125 0.125
Sulfamethoxazole 8 16 1024 1024 512 1024 1024 512
Supplementary Table 4.2| Overview of library preparation method and sequencing
technology used for the isolates genome sequenced in this study.
Lineage Sampling Time Library Preparation Sequencing Technology Output
A 2w1 Shear+barcode SE
2w2 TruSeq kit PE
4w Shear+barcode SE
2m Shear+barcode SE
6m1 Shear+barcode SE
6m2 TruSeq kit PE
B 2m1 Shear+barcode SE
2m2 TruSeq kit PE
6m Shear+barcode SE
12m1 Shear+barcode SE
12m2 TruSeq kit PE
C 12m1 Shear+barcode SE
12m2 TruSeq kit PE
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Supplementary Table 4.3| Number of SNPs between the lineages using selected
isolates. The rows of the table indicate the reads that were used aligned to contigs of
the isolate as indicated in the column.
Aligned to contigs from
Lineage A Lineage B Lineage C
2w2 2m2 12m2
Reads from Lineage A 2w2 94346 7324
Lineage B 2m2 95215 94797
Lineage C 12m2 7297 92100
Supplementary Table 4.4| Coverage of the total genomic content between the
lineages using selected isolates. The rows of the table indicate the reads that were
used aligned to contigs of the isolate as indicated in the column.
Aligned to contigs from
Lineage A Lineage B Lineage C
2w2 2m2 12m2
Reads from A 2w2 80.0% 93.60%
B 2m2 82.3% 82.0%
C 12m2 95.5% 79.7%
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Supplementary Table 4.5| Table containing the SNPs from lineage B, including the
annotation and whether the animo acid change was synonymous or nonsynonymous.
Contig
number
Position 2w2 2w1 4w 2m 6m1 6m2 Annotation Change
5 27035 A G G G G
7 282598 G A Formate hydrogenlyase subunit 2 synonymous
32 38337 A C Betaine aldehyde dehydrogenase(EC 1.2.1.8) nonsynonymous
13 108313 C T Phosphoenolpyruvate carboxylase(EC 4.1.1.31) nonsynonymous
12 157912 G A Putative inner membrane protein synonymous
52 28325 C A Protein fdrA nonsynonymous
239 107 T C
93 2581 T C
8 11719 G T type 1 ﬁmbriae anchoring proteinFimD nonsynonymous
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Supplementary Table 4.6| Table containing the SNPs from lineage B, including the
annotation and whether the animo acid change was synonymous or nonsynonymous.
Contig
number
Position 2m2 2m1 6m 12m1 12m2 Annotation Change
12 273551 T A Putative amidohydrolase nonsynonymous
20 13798 T A FIG00639301: hypothetical protein nonsynonymous
590 436 G A Phage major tail tube protein synonymous
91 20935 G A Alcohol dehydrogenase (EC 1.1.1.1) nonsynonymous
709 463 G A
141 121 T C
64 121 T C
237 2376 C G IncF plasmid conjugative transferpilin protein TraA nonsynonymous
37 40257 A G LysR family transcriptional regula-tor lrhA synonymous
389 490 T G Phage capsid scaﬀolding protein nonsynonymous
56 41072 T G Dipeptide transport system perme-ase protein DppB (TC 3.A.1.5.2) nonsynonymous
58 4945 A G
24 63963 A T T T Oligopeptide transport system per-mease protein OppB (TC 3.A.1.5.1) nonsynonymous
28 44283 C T Fe2+-dicitrate sensor, membranecomponent nonsynonymous
35 41468 A T C-terminal domain of CinA type S nonsynonymous
511 121 C T Adenine-speciﬁc methyltransferase(EC 2.1.1.72) nonsynonymous
63 19848 A T
Type III secretion in-
ner membrane protein
(YscU,SpaS,EscU,HrcU,SsaU,
homologous to ﬂagellar export
components)
nonsynonymous
593 514 C T
778 418 G T
36 2740 T A A Chaperone protein DnaK nonsynonymous
37 78302 T A A Putative transporting ATPase nonsynonymous
50 33170 C A Putative vimentin nonsynonymous
80 12348 G A D-Galactonate repressor DgoR nonsynonymous
12 327228 G A
42 91228 G C C
FUSARIC ACID RESISTANCE
PROTEIN FUSB / FUSARIC
ACID RESISTANCE PROTEIN
FUSC
nonsynonymous
18 98805 A T T N-succinyl-L,L-diaminopimelatedesuccinylase (EC 3.5.1.18) nonsynonymous
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104 5105 C T LSU ribosomal protein L22p (L17e) nonsynonymous
8 149794 A T
7 156 T A hypothetical protein synonymous
776 244 T A
7 121 A C hypothetical protein nonsynonymous
80 12641 T G
12 191888 C T NADP-speciﬁc glutamate dehydro-genase (EC 1.4.1.4) synonymous
121 10485 C T
Oligopeptide transport ATP-
binding protein OppD (TC
3.A.1.5.1)
nonsynonymous
Supplementary Table 4.7| Table containing the SNPs from lineage C, including the
annotation and whether the animo acid change was synonymous or nonsynonymous.
Contig
number
Position 12m1 12m2 Annotation Change
35 132 T C
Supplementary Table 4.8| Multi locus sequence typing (MLST) of the lineages.
Lineage adk fumC gyrB icd mdh purA recA Sequence Type
A 13 13 9 13 16 10 9 ST12
B 21 35 27 6 5 5 99 ST782
C 13 13 9 13 16 10 9 ST12
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Supplementary Table 4.9| Replicon type results from PlasmidFinder, presence in
the isolates and the corresponding plasmid. Subvariants of the replicon type from
PlasmidFinder are given in parentheses.
Lineage Isolates Identiﬁed Replicon % Identity Associated Plasmid
A 2m, 6m1;2 B/O/K/Z 100 pHUSEC41-1
B all B/O/K/Z 100 pHUSEC41-1
B 2m1;2,12m1;2 FIB(AP001918) 99.56
B 2m1;2, 6m FII 96.55
B 2m1;2,12m1;2 FII 92.34
B 2m1;2,12m1;2 FIC 96.2
B all Col156 94.81
B all Col8282 89.9
B all ColpVC 88.95
C all none identiﬁed
Supplementary Table 4.10| Annotations of the FII plasmid from the 6m isolate
done by RAST. The FII plasmid was observed in 2m and 6m isolates.
Contig
number
Start Stop Strand Annotation
48 72 359 + FIG00638017: hypothetical protein
48 478 1299 + unnamed protein product
48 1595 2242 - X polypeptide
48 2519 2902 + IncF plasmid conjugative transfer mating signal transduction protein TraM
48 3093 3779 + IncF plasmid conjugative transfer regulator TraJ
48 3918 4100 + IncF plasmid conjugative transfer regulator TraY
48 4134 4493 + IncF plasmid conjugative transfer pilin protein TraA
48 4508 4819 + IncF plasmid conjugative transfer pilus assembly protein TraL
48 4841 5407 + IncF plasmid conjugative transfer pilus assembly protein TraE
48 5394 6122 + IncF plasmid conjugative transfer pilus assembly protein TraK
48 6122 7549 + IncF plasmid conjugative transfer pilus assembly protein TraB
48 7539 8129 + IncF plasmid conjugative transfer protein TraP
48 8116 8436 + IncF plasmid conjugative transfer protein TrbD
48 8429 8680 + IncF plasmid conjugative transfer protein TrbG
48 8677 9192 + IncF plasmid conjugative transfer pilus assembly protein TraV
48 9327 9548 + IncF plasmid conjugative transfer protein TraR
48 9708 12335 + IncF plasmid conjugative transfer pilus assembly protein TraC
48 12332 12718 + IncF plasmid conjugative transfer protein TrbI
48 12715 13347 + IncF plasmid conjugative transfer pilus assembly protein TraW
48 13344 14336 + IncF plasmid conjugative transfer pilus assembly protein TraU
48 14362 14823 + hypothetical protein
48 15054 15305 + hypothetical protein
48 15333 15971 + IncF plasmid conjugative transfer protein TrbC
48 15968 17776 + IncF plasmid conjugative transfer protein TraN
48 17804 18061 + IncF plasmid conjugative transfer protein TrbE
48 18054 18797 + IncF plasmid conjugative transfer pilus assembly protein TraF
48 18813 19160 + IncF plasmid conjugative transfer protein TrbA
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Contig
number
Start Stop Strand Annotation
48 19162 19476 - Protein artA
48 19355 19492 + FIG00640935: hypothetical protein
48 19557 19841 + IncF plasmid conjugative transfer protein TraQ
48 19828 20373 + IncF plasmid conjugative transfer protein TrbB
48 20363 20644 + IncF plasmid conjugative transfer protein TrbJ
48 20631 21011 + IncF plasmid conjugative transfer protein TrbF
48 21011 22384 + IncF plasmid conjugative transfer pilus assembly protein TraH
48 22381 25203 + IncF plasmid conjugative transfer protein TraG
48 25748 26479 + IncF plasmid conjugative transfer surface exclusion protein TraT
48 26731 28884 + IncF plasmid conjugative transfer protein TraD
48 28893 29291 - VapC toxin protein
48 29291 29518 - VapB protein (antitoxin to VapC)
48 29672 34870 + IncF plasmid conjugative transfer DNA-nicking and unwinding protein TraI
48 34890 35636 + IncF plasmid conjugative transfer pilin acetylase TraX
48 35695 36555 + Dienelactone hydrolase and related enzymes
48 36658 37218 + IncF plasmid conjugative transfer fertility inhibition protein FinO
48 37351 37509 + FIG00640597: hypothetical protein
48 37481 37606 + FIG00639321: hypothetical protein
48 37808 38269 + FIG01068181: hypothetical protein
48 38389 38535 - FIG00640641: hypothetical protein
48 38562 39152 + YihA
48 39392 39646 + Replication regulatory protein repA2 (Protein copB)
48 39949 40806 + RepA1
712 1446 2636 - microcin b17 processing protein mcbd, putative
712 2617 3435 - hypothetical protein
712 3437 4291 - Microcin B17-processing protein mcbB
712 4338 4463 - hypothetical protein
712 5004 5300 + COG1266: Predicted metal-dependent membrane protease
712 5345 5797 + Acetyltransferase (EC 2.3.1.-);Ontology_term=KEGG_ENZYME:2.3.1.-
712 6553 7515 - Putative stability/partitioning protein encoded within prophage CP-933T
712 7799 7924 - hypothetical protein
501 761 1426 - Fip
501 1625 1744 + hypothetical protein
340 734 1048 - FIG00641039: hypothetical protein
340 1045 1764 - Plasmid SOS inhibition protein PsiA
340 1761 2159 - PsiB protein
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Supplementary Table 4.11| Annotations of the FII:FIB:FIC plasmid from the
12m1 isolate done by RAST. The FII:FIB:FIC plasmid was observed in 2m and 12m
isolates.
Contig
number
Start Stop Strand Annotation
65 19 819 - Mobile element protein
65 2144 3001 - RepA1
65 3300 3557 - replication protein
65 4382 4645 - FIG00639321: hypothetical protein
65 4780 5340 - IncF plasmid conjugative transfer fertility inhibition protein FinO
65 5395 6135 - IncF plasmid conjugative transfer pilin acetylase TraX
65 6155 11353 - IncF plasmid conjugative transfer DNA-nicking and unwinding protein TraI
65 11425 13605 - IncF plasmid conjugative transfer protein TraD
65 13858 14589 - IncF plasmid conjugative transfer surface exclusion protein TraT
65 14638 14802 - IncF plasmid conjugative transfer surface exclusion protein TraS
65 15139 17982 - IncF plasmid conjugative transfer protein TraG
65 17979 19355 - putative conjugative transfer protein TraH
65 19352 19654 - IncF plasmid conjugative transfer protein TrbJ
65 19644 20189 - IncF plasmid conjugative transfer protein TrbB
65 20176 20460 - IncF plasmid conjugative transfer protein TraQ
65 20579 20926 - IncF plasmid conjugative transfer protein TrbA
65 20942 21685 - IncF plasmid conjugative transfer pilus assembly protein TraF
65 21678 21935 - IncF plasmid conjugative transfer protein TrbE
65 21962 23770 - IncF plasmid conjugative transfer protein TraN
65 23767 24405 - IncF plasmid conjugative transfer protein TrbC
65 24433 24885 - hypothetical protein
65 24915 25376 - hypothetical protein
65 25402 26394 - IncF plasmid conjugative transfer pilus assembly protein TraU
65 26391 27023 - IncF plasmid conjugative transfer pilus assembly protein TraW
65 27020 27406 - IncF plasmid conjugative transfer protein TrbI
65 27403 30030 - IncF plasmid conjugative transfer pilus assembly protein TraC
65 30190 30411 - IncF plasmid conjugative transfer protein TraR
65 30545 31060 - IncF plasmid conjugative transfer pilus assembly protein TraV
65 31057 31308 - IncF plasmid conjugative transfer protein TrbG
65 31305 31622 - IncF plasmid conjugative transfer protein TrbD
65 31619 32191 - IncF plasmid conjugative transfer protein TraP
65 32181 33608 - IncF plasmid conjugative transfer pilus assembly protein TraB
65 33608 34336 - IncF plasmid conjugative transfer pilus assembly protein TraK
65 34323 34889 - IncF plasmid conjugative transfer pilus assembly protein TraE
65 34911 35222 - IncF plasmid conjugative transfer pilus assembly protein TraL
65 35237 35602 - IncF plasmid conjugative transfer pilin protein TraA
65 36831 37214 - IncF plasmid conjugative transfer mating signal transduction protein TraM
65 37582 38139 + X polypeptide
65 38436 39257 - unnamed protein product
65 39376 39663 - FIG00638017: hypothetical protein
90 157 897 + hypothetical protein
90 1056 1193 - hypothetical protein
90 1186 1998 - FIG01047974: hypothetical protein
90 2784 3761 + RepFIB replication protein A
90 3837 3956 - hypothetical protein
90 4040 4780 - Resolvase
90 4901 5026 - hypothetical protein
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Contig
number
Start Stop Strand Annotation
90 5112 5237 - FIG00643146: hypothetical protein
90 5429 5602 - hypothetical protein
90 6392 6826 - probable copper-binding protein
90 6825 6962 + hypothetical protein
90 7044 8444 - Heavy metal sensor histidine kinase
90 8441 9121 - DNA-binding heavy metal response regulator
90 9176 9919 - Copper resistance protein D
90 9998 10123 + hypothetical protein
90 10110 10448 - Copper resistance protein CopC
90 10530 11420 - Copper resistance protein B
90 11426 13243 - Multicopper oxidase
90 13478 13927 + Copper-binding protein PcoE
90 14216 14953 + Cell wall endopeptidase, family M23/M37
90 14987 15184 - FIG00643033: hypothetical protein
90 15225 17030 - Lead, cadmium, zinc and mercury transporting ATPase (EC 3.6.3.3) (EC
3.6.3.5); Copper-translocating P-type ATPase (EC 3.6.3.4);Ontology_term
90 17145 17615 + hypothetical protein
90 17846 18286 - CopG protein
90 18372 21518 - Cobalt-zinc-cadmium resistance protein CzcA; Cation eﬄux system protein
CusA
90 21529 22821 - Cobalt/zinc/cadmium eﬄux RND transporter, membrane fusion protein,
CzcB family
90 22935 23288 - Cation eﬄux system protein CusF precursor
90 23317 24702 - Cation eﬄux system protein CusC precursor
90 24668 24832 + hypothetical protein
90 24892 25572 + Copper-sensing two-component system response regulator CusR
90 25565 27040 + Osmosensitive K+ channel histidine kinase KdpD (EC 2.7.3.-
);Ontology_term
90 27291 27722 + Silver-binding protein
90 28218 29048 - Mobile element protein
90 29075 29338 - Mobile element protein
90 29935 30114 + hypothetical protein
90 30108 30278 - hypothetical protein
90 31003 32025 - Mobile element protein
90 32248 32853 + TnpA transposase
127 141 845 - Mobile element protein
127 836 1342 + putative protein
127 1339 2130 + Resolvase
127 2268 2543 - FIG00641502: hypothetical protein
127 2537 2800 - Plasmid partitioning protein ParA
127 3410 4381 + Putative stability/partitioning protein encoded within prophage CP-933T
127 4386 4778 + stable plasmid inheritance protein
203 213 1040 - UspA-related nucleotide-binding protein
203 1059 2537 - Sulfate permease
203 2925 3509 - DNA-invertase
203 3669 6653 + Mobile element protein
215 318 1721 + S-methylmethionine permease
215 1708 2640 + Homocysteine S-methyltransferase (EC 2.1.1.10);Ontol-
ogy_term=KEGG_ENZYME:2.1.1.10
215 2749 3795 - ABC transporter ATP-binding protein
215 3807 4169 - Iron(III)-transport system permease protein SfuB
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Contig
number
Start Stop Strand Annotation
238 247 3363 - Type I restriction-modiﬁcation system, restriction subunit R (EC
3.1.21.3);Ontology_term=KEGG_ENZYME:3.1.21.3
238 3485 4711 - Type I restriction-modiﬁcation system, speciﬁcity subunit S (EC
3.1.21.3);Ontology_term=KEGG_ENZYME:3.1.21.3
238 4708 6264 - Type I restriction-modiﬁcation systemm DNA-methyltransferase subunit
M (EC 2.1.1.72);Ontology_term=KEGG_ENZYME:2.1.1.72
238 6447 6668 + Prevent host death protein, Phd antitoxin
238 6668 7048 + Death on curing protein, Doc toxin
238 7053 7232 + PdcA
238 7260 7619 + FIG074102: hypothetical protein
240 46 816 + FIG00638373: hypothetical protein
240 893 2005 + Mobile element protein
291 134 2362 - hypothetical protein
291 2359 3540 - FIG00715976: hypothetical protein
291 3677 4537 + COGs COG2378
291 4914 5063 + hypothetical protein
291 5102 7306 - site-speciﬁc recombinase, phage integrase family
291 7296 8303 - possible integrase
362 269 1273 - Mobile element protein
364 289 570 + hypothetical protein
590 55 372 - Type I restriction-modiﬁcation system, restriction subunit R (EC
3.1.21.3);Ontology_term=KEGG_ENZYME:3.1.21.3
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Supplementary Table 4.12| List of Annotated Genes identiﬁed in the deletion of
lineage A.
Category Annotated genes
Fatty Acid Synthesis (3R)-hydroxymyristoyl-[ACP] dehydratase (EC 4.2.1.-)
3-hydroxydecanoyl-[ACP] dehydratase (EC 4.2.1.60)
3-oxoacyl-[ACP] reductase (EC 1.1.1.100)
3-oxoacyl-[ACP] synthase
3-oxoacyl-[ACP] synthase (EC 2.3.1.41) FabV like
Acyl carrier protein
Acyl carrier protein (ACP1)
FIG002571: 4-hydroxybenzoyl-CoA thioesterase domain protein
FIG018329: 1-acyl-sn-glycerol-3-phosphate acyltransferase
FIG143263: Glycosyl transferase / Lysophospholipid acyltrans-
ferase
FIGfam138462: Acyl-CoA synthetase, AMP-(fatty) acid ligase
Carbohydrate and D-galactarate dehydratase (EC 4.2.1.42)
Amino Acid Metabolism D-galactarate dehydratase (EC 4.2.1.42)
Tagatose-6-phosphate kinase AgaZ (EC 2.7.1.144)
Putative O-methyltransferase
Aspartate aminotransferase (EC 2.6.1.1)
2-keto-3-deoxy-D-arabino-heptulosonate-7-phosphate synthase I
alpha (EC 2.5.1.54)
Iron Scavenging Glycosyltransferase IroB
ABC transporter protein IroC
Trilactone hydrolase IroD
Periplasmic esterase IroE
Outer Membrane Siderophore Receptor IroN
Hemolysin activator protein precursor
Putative large exoprotein involved in heme utilization or adhesion
of ShlA/HecA/FhaA family
Bacteriocins and antigen 43 precursor
Virulence Colicin-E1*
mannose-speciﬁc adhesin FimH
Probable microcin H47 secretion/processing ATP-binding protein
mchF (EC 3.4.22.-)
MchC protein Putative F1C and S ﬁmbrial switch Regulatory pro-
tein
type 1 ﬁmbrae adaptor subunit FimF
type 1 ﬁmbriae anchoring protein FimD
type 1 ﬁmbriae major subunit FimA
type 1 ﬁmbriae protein FimI2C unknown function
YeeV toxin protein
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Category Annotated genes
Other Transposase (X4)
Putative Transposase
Mobile element protein
Integrase IS, phage, Tn: Transposon-related functions
Putative metal chaperone, involved in Zn homeostasis, GTPase of COG0523
family
entry exclusion protein 2
membrane: Transport of small molecules: Cations
FIG021862: membrane protein, exporter
FIG027190: Putative transmembrane protein
putative membrane protein (X2)
putative secretion permease
putative regulatory protein
NgrB
RNA-Arg-TCT
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Supplementary Table 4.13| List of Annotated Genes identiﬁed in the deletion of
lineage B.
Category Annotated genes
Virulence putative regulator PapX protein
PapG protein
PapF protein
PapE protein
Fimbrial adapter papK precursor
Periplasmic ﬁmbrial chaperone
Fimbriae usher protein StfC
minor pilin subunit PapH
major pilin subunit PapA
PapI protein
Iron Scavenging TonB-dependent receptor; Outer membrane receptor for ferrienterochelin and
colicins
Other Mobile element protein (X9)
conserved hypothetical protein; putative exported protein
hypothetical protein (X4)
FIG00638040: hypothetical protein
FIG00638658: hypothetical protein
FIG00640659: hypothetical protein
FIG01070050: hypothetical protein
FIG00641173: hypothetical protein
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Supplementary Table 4.14| Annotations of the pNK117-2 plasmid. Annotations
were done via RAST, but modiﬁed to include homologous genes from pOLA52 and
from the Raoultella planticola RJA274 plasmid.
Start Stop Strand Annotation
830 1093 - IncN plasmid KikA protein
1129 1368 - hypothetical protein
1539 3374 - Type IV secretion system protein VirD4
3377 4408 - ATPase provides energy for both assembly of type IV secretion complex
and secretion of T-DNA complex (VirB11)
4410 5615 - Inner membrane protein of type IV secretion of T-DNA complex2C TonB-
like2C VirB10
5612 6541 - Forms the bulk of type IV secretion complex that spans outer membrane
and periplasm (VirB9)
6546 7259 - Inner membrane protein forms channel for type IV secretion of T-DNA
complex (VirB8)
7249 7377 - hypothetical protein
7505 8635 - Integral inner membrane protein of type IV secretion complex (VirB6)
8644 8931 - IncQ plasmid conjugative transfer protein TraG
8932 9690 - Minor pilin of type IV secretion complex (VirB5)
9701 12331 - ATPase provides energy for both assembly of type IV secretion complex
and secretion of T-DNA complex (VirB4)
12476 12772 - Major pilus subunit of type IV secretion complex2C VirB2
12749 13397 - virB1, homologous to pOLA52 pilx1
13572 13934 - hypothetical protein
13571 14090 - actX, homologous to pOLA52
14443 15609 - IncQ plasmid conjugative transfer DNA nicking endonuclease TraR (pTi
VirD2 homolog)
15612 16226 - DNA distortion protein 1
15611 16157 - taxA
16273 16422 - hypothetical protein
16483 16755 - FIG01048616: hypothetical protein
16987 17166 - hypothetical protein
17209 17538 - YagA protein
17631 17846 - FIG01048886: hypothetical protein
17836 18081 - FIG01047979: hypothetical protein
18126 18449 - FIG01047054: hypothetical protein
18595 18876 - RelE/StbE replicon stabilization toxin
18866 19117 - RelB/StbD replicon stabilization protein (antitoxin to RelE/StbE)
19209 19340 + hypothetical protein
19901 20032 - hypothetical protein
20349 21185 + PI protein (pir)
21225 21668 + bis, homologous to RJA274 NDM-1 producing plasmid
21856 22212 + DNA distortion protein 3 (ddp3)
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Start Stop Strand Annotation
22209 23186 - hypothetical protein
23211 23492 - hypothetical protein
23592 24254 - Chromosome partitioning protein ParA (parA)
24635 25603 + Resolvase (res)
25758 25874 + hypothetical protein
25942 26082 - hypothetical protein
26268 26402 - hypothetical protein
26473 26658 - hypothetical protein
26616 26894 - hypothetical protein
26912 27166 - hypothetical protein
27277 28101 - zinc metalloproteinase Mpr protein (mpr)
28104 28337 - hypothetical protein
28393 28569 - hypothetical protein
28547 28954 - hypothetical protein
29010 29474 - DNA-binding protein H-NS (hns)
29490 29696 - Haemolysin expression modulating protein
29693 31846 - DNA topoisomerase III (EC 5.99.1.2);Ontol-
ogy_term=KEGG_ENZYME:5.99.1.2 (topB)
31851 32426 - FIG01045518: hypothetical protein
32430 33692 - Cell division protein FtsH (EC 3.4.24.-
);Ontology_term=KEGG_ENZYME:3.4.24.- (ftsH)
33774 34265 - DNA topoisomerase III (EC 5.99.1.2);Ontol-
ogy_term=KEGG_ENZYME:5.99.1.2
34694 34951 - hypothetical protein
35082 35309 - hypothetical protein
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Positive Control end 1
Positive Control end 2
Deletion end 1
Contiguous end 2 Excision (end 1 + 2)
Contiguous end 1 Deletion end 2
2w1  4w   2m   6m1 2w1  4w   2m   6m1 2w1  4w   2m   6m1 2w1  4w   2m   6m1
2w1  4w   2m   6m1 2w1  4w   2m   6m1 2w1         4w          2m        6m1
1,127,490 bp
end 1
1,241,113 bp
end 2
Supplementary Figure 4.1 | PCR reactions to conﬁrm the deletion in lineage
A isolates from 6 months and show it was an excision. A. Overview of the PCR
primer strategy. Contigs were aligned to CFT073 to identify the order of the contigs
involved in the deletion. PCR primers were designed to conﬁrm that the contigs were
contiguous prior to the deletion (samples 2w1, 4w, and 6m1). PCR primers were also
designed to distinguish isolates without the deletion (samples 2w1, 4w, and 6m1), and
that the deletion identiﬁed in lineage A from 6 months was an excision (demonstrated
here with isolate 6m1). B. PCR products separated via gel electrophoresis to view
PCR results. Contig alignment to CFT073 did order the contigs correctly, as shown in
the ’Contiguous end 1’ and ’Contiguous end 2’ labelled gels, and that the isolates 2w1,
4w, and 6m1 did not have the deletion. Furthermore, the deletion was an excision
that occurred in the lineage A isolates from 6 months, demonstrated here using 6m1.
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5.1 Abstract
The human gut is considered a hub for horizontal gene exchange, and has been shown
to be a reservoir of antibiotic resistance genes. The potential for bacteria in the gut,
many of which are opportunistic pathogens, to acquire resistance genes or virulence
determinants and lead to infections that are more diﬃcult to treat is of high concern.
One of the commensal microbes of the human gut microbiota is Escherichia coli, and
is also a well known pathogen. Here, we follow co-existing E. coli lineages in situ of
the gut through an infants ﬁrst year of life. We identify that it was an E. coli lineage
colonizing the gut that caused a urinary tract infection in the infant and transferred
a conjugative plasmid harbouring a beta-lactamase resistance gene to another co-
existing E. coli lineage in situ of the gut. This uropathogenic E. coli strain was
found to additionally harbor a disseminated plasmid that is implicated in virulence.
While the transconjugant strain was not sampled again after receiving the resistance
plasmid, the uropathogenic strain colonized the gut for the entire year of the study.
Through genome sequencing of these co-existing E. coli we observed genomic events
in these lineages, and catch a glimpse of the dynamics of E. coli lineages in the gut.
5.2 Introduction
The human gut is home to one of the densest microbial ecosystems, the human gut
microbiota, and this microbial community plays an important role in human health
and physiology. Among the commensal residents of the gut microbiota, there are
opportunistic pathogens that can cause infection following perturbation to their host
[1]. Additionally, the gut can serve as a reservoir of bacteria able to cause infection
at other body sites. One such example is Escherichia coli, which is a commensal
microbe of the human gut microbiota, but is also a well known pathogen with strains
causing both intestinal and extra-intestinal infections. It is well established that the
majority of urinary tract infections (UTI) are caused by E. coli strains inhabiting the
gut, although other predisposing factors and transmission routes have been recorded
[2, 3].
The human gut is considered a hub for horizontal gene exchange. It has been
shown to be a reservoir of antibiotic resistance genes [4], and could similarly be a
reservoir of virulence genes [5]. It is not only bacteria colonizing the gut that may
partake in horizontal gene transfer, but also bacteria that are only transiting through
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the gut. Acquisition of antibiotic resistance genes could yield a pathogenic strain
more diﬃcult to treat, while acquisition of virulence determinants could render a
strain pathogenic, or more pathogenic. Transiting bacteria involved in horizontal
gene transfer could leave the gut with new antibiotic resistance or virulence determi-
nants and contaminate the sites they normally colonize and/or infect with the newly
acquired resistance or virulence genes [5].
Investigations into the dynamic nature of the gut microbiota at the level of strain
resolution have included both observations of horizontal gene transfer, as well as strain
abundance and turn over. A few phenotypic reports exist documenting horizontal
gene transfer of antibiotic resistance genes between the constituents of the human
gut microbiota [6, 7]. In these reports, transfer of resistance genes was observed in
connection with antibiotic treatment and detected via a change in the antibiotic resis-
tance susceptibility of the strain. Non-cultivation based methods have been developed
to investigate the abundances of strains during colonization of the gut [8, 9, 10]. In
these studies, time-series metagenomic sampling is processed in a manner that yields
strain resolution, with near-complete and partially-complete genomes assembled for
microbial constituents comprising as little as 1% and 0.05%, respectively [9]. However,
as this method is based on employing strain abundance proﬁles to group sequences
belonging to the same strain, it is not particularly well suited to observe horizontal
gene transfer events.
In this study, we examine co-existing E. coli lineages sampled from an infant over
the ﬁrst year of life. This set of isolates was initially selected to genomically investigate
a reported transfer of a beta-lactamase antibiotic resistance gene between co-existing
E. coli lineages in situ of the gut [7]. As this infant developed a UTI within the ﬁrst
month of life, we additionally wanted to link the uropathogenic strain back to the
lineage dynamics of the source strain in the gut. By full genome sequencing this set
of isolates, we gain insights into the dynamic nature of E. coli strains co-existing in
the gut.
5.3 Results
Study Material
The current study material was obtained from an infant enrolled in the ALLER-
GYFLORA study. The aim of the ALLERGYFLORA study was to investigate the
relationship between intestinal colonization patterns to the development of allergies
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later on in life [11]. Samples from the infants enrolled in this study to investigate
the colonization of the gut microbiota were collected at 2 days after birth via rectal
swab, and 1, 2, and 4 weeks and 2, 6, and 12 months after birth via stool sample.
Escherichia coli was quantitatively cultured on Drigalski agar plates, with various
morphotypes enumerated separately. Lineage identities of the E. coli colonies were
determined via random ampliﬁed polymorphic DNA (RAPD) typing.
E. coli Lineage Sampling
In total, two E. coli lineages were sampled from fecal matter sampled from the infant
over the ﬁrst year of life (Fig. 5.1) [7]. Sampling time points were at 2, 9, 16 and
32 days, and 2, 6 and 12 months of age. E. coli lineage A was recovered at all the
sampling time points. A second E. coli lineage, termed lineage B, was only ﬁrst
sampled at the 9 day sampling point. Lineage B was sampled again at 16 days, and
lastly at 32 days.
Isolates were screened for their antibiotic susceptibility proﬁles using the disc
diﬀusion method (Oxoid, Sollentuna, Sweden). Antibiotics to which an isolate was not
susceptible to were followed up by minimum inhibitory concentration (MIC) testing
[7]. The lineage A isolates were found to be highly resistant to ampicillin (MIC 
256mg/L) (Fig. 5.1). The ﬁrst two lineage B isolates at 9 and 16 days were initially
susceptible to ampicillin. However, the lineage B isolate at 32 days had a change in
its antibiotic susceptibility proﬁle and was discovered to also be highly resistant to
ampicillin (MIC  256 mg/L). Lineage A isolates were also resistant to piperacillin,
but isolates collected from 32 days to 12 months were resistant to a lesser degree [7].
An additional isolate from a urinary tract infection is also included in the study.
At 8 days of age, the infant boy was admitted to hospital due to a suspected urinary
tract infection. He was administered trimethoprim for 5 days. A urinary culture taken
at 11 days of age yielded E. coli at 100 000 colony forming units (CFU) per milliliter.
However, due to enterococci in addition to E. coli in a subsequent urinary sample,
the antibiotic treatment was changed to intravenous ampicillin for 5 days, followed
by amoxicillin perorally for an additional 8 days. Lastly, the infant was administered
trimethoprim prophylactically for the next 7 months.
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Figure 5.1 | Sampling of the co-existing E. coli lineages from the gut microbiota,
and the UTI isolate, and antibiotic treatment of the infant.
Genome Sequencing of the Isolates
E. coli isolates obtained from fecal samples and from the urinary sample were genome
sequenced. One isolate from each lineage for each sampling time was selected, except
for A lineage at 2 and 6 months where two isolates were selected for sequencing. At
least one isolate from each lineage was sequenced using an Illumina MiSeq yielding 150
base-pair (bp) paired-end reads. Speciﬁcally, lineage A isolate from 2 days and 2 and
6 months, labelled 2d, 2m2 and 6m1, respectively, lineage B isolate from 32 days, and
the UTI isolate were selected. Representative genomes for the lineage or isolation site
were assembled from the reads from the A lineage at 2 days, the B lineage at 32 days,
and the UTI isolate. All other isolates were sequenced on an Illumina HiSeq yielding
70bp single-end reads. Comparisons between isolates were conducted to ensure that
the isolates selected as lineage and site representatives were indeed representative of
the lineage and isolation site (see Materials and Methods).
The total genome length, including plasmids, for the lineage A is 4,907,304 bp
(4,750,822 bp without plasmids) from a total of 90 contigs. The N50 of the lineage
A assembly is 141,096 bp. Two conjugative plasmids were identiﬁed in all lineage A
isolates. One plasmid was identiﬁed as an IncX plasmid 42 kb in length, and the
other as a 114 kb plasmid identiﬁed with FIB, FII(29), Col(156) replicons, typed as
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F29:A-:B10 in the IncF pMLST typing scheme [12, 13] (Supplementary Table 5.3).
The total genome length, including plasmids, for lineage B is 5,450,674 bp, from a
total of 239 contigs. The N50 of the lineage B assembly is 123,856 bp. One plasmid of
approximately 88 kb was found in all three lineage B isolates. In silico replicon typing
revealed that this plasmid belonged to the p0111 replicon group, that was named as
such as no RepA protein from a previously assigned Inc group was homologous to
the repA gene from plasmid p0111 [12]. Two other replicon groups identiﬁed via
the PlasmidFinder tool were B/O/K/Z and Col(MG828). With the assembly it was
unfortunately not possible to characterize these plasmids, but the coverage depth data
suggests that the replicons are found on two distinct plasmids, with the B/O/K/Z
plasmid on the order of 110 kb, and the Col(MG828) plasmid on the order of 15 kb.
Genomic Conﬁrmation of Lineage Identities
To conﬁrm the lineage identities of the collected isolates, we ﬁrst conﬁrmed that the
two lineages identiﬁed via RAPD typing were in fact distinct lineages. Using the
single nucleotide polymorphism (SNP) calling pipeline (see Materials and Methods),
there were on the order of 98,000 SNPs between the two representative isolates for
each lineage. Furthermore, when assessing the shared total genetic content, only 77%
and 85% was shared in common between the A and B lineage.
To assess the relationship of the lineage isolates, SNP-based phylogenetic trees
were constructed (Fig. 5.2, Supplementary Table 5.1). For lineage A, no SNPs were
detected between the isolates collected at days 2, 9 and 16, and only one SNP detected
between them and the isolate collected at 32 days. Two isolates were included that
were sampled at 2 months, and these shared 5 SNPs compared to the 32 day isolate,
but then branched with 13 and 14 SNPs from this point, for the 2m1 and 2m2 isolates
respectively. Two isolates were also included that were sampled at 6 months. The 6m1
isolate is located oﬀ the branch from the 2m2 isolate. The 6m2 is distantly related to
both 2m isolates, as seen from the branching oﬀ point only 3 SNPs after the 32 day
isolate. The isolate collected at 12 months is most closely related to the 6m2 with
a total of 158 SNPs between them, or 136 SNPs from the 12 month isolate to their
common ancestor.
There were no SNPs detected in the three isolates from lineage B.
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Figure 5.2 | SNP tree of the E. coli lineage A from the gut microbiota with the UTI
isolate. The numbers beside branches indicate the length of the branch.
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E. coli colonizing the intestine caused the UTI
The E. coli UTI isolate was compared to E. coli isolates from the infant’s stool samples.
Only one SNP was found when compared to the A lineage isolates collected at 2, 9
and 16 days (Fig. 5.2). Given the very high similarity, the A lineage colonizing the
gut microbiota was the likely source of the UTI.
When analyzing the plasmid content of the A lineage, contigs from one of the
plasmids were found to have very high sequence identity to a few plasmids deposited
in NCBI’s Genbank. The SNP calling pipeline was used to compare similarity to this
plasmid, termed pNK29-2 (Table 5.1). In particular, the pUTI89 plasmid was found
to have only 7 SNPs diﬀerence to the pNK29-2 plasmid, and aligning the contigs from
this plasmid showed that there were no additional insertions.
Interestingly, these three highly similar plasmids were all isolated from various
pathogenic E. coli strains. Strain UTI89, harbouring the pUTI89 plasmid, is an
uropathogenic E. coli (UPEC) strain isolated from a patient with an acute bladder
infection [14, 15]. Strain UM146, harbouring the pUM146 plasmid, is an adhesive
invasive E. coli (AIEC) strain isolated from the ileum of a Crohn’s disease patient
[16, 17]. Strain EC14, harbouring the pEC14_144 plasmid, is also an UPEC strain
isolated from a UTI [18].
Genome sequences are available for UTI89 and UM146, but when compared to
lineage A, they did not have very high similarity. Only 88.4% of the 5,065,740 bp
UTI89 genome and 89.5% of the 4,993,012 bp UM146 genome was covered when
aligning reads from lineage A. Additionally, the serotypes of UTI89, EC14 and lineage
A all varied, suggesting that diﬀerent host E. coli strains harboured a very similar
plasmid. Furthermore, the geographical locations where these strains were isolated
varied, from the US, Canada and Sweden, suggesting that these pUTI89-like plasmids
are globally disseminated (Table 5.2).
Wijetunge et al. have recently reported sequencing a plasmid with 99% identity
to pUTI89, isolated from a neonatal meningitis E. coli (NMEC) strain, RS218 [19].
Interestingly, this plasmid shared only 41 - 46% similarity to other previously se-
quenced plasmids from NMEC strains [19]. The sequence of this plasmid, pRS218,
was unfortunately not publicly available yet at the time of writing, but would also be
expected to have high similarity to pNK29-3. However, RS218 has the same serotype
as UTI89, O18:K1:H7, so it will be interesting to see the similarity and diﬀerences of
these two pathogenic strains when the group publishes the genome of RS218.
5.3 Results 101
Table 5.1 | The number of SNPs and INDELs identiﬁed when compared to the
sequences of the plasmid listed below.
Plasmid Name No. SNPs No. INDELs Plasmid Length (bp)
pUTI89 7 0 114,230
pUM146 34 11 114,550
pEC14_144 38 7 114,222
Table 5.2 | Plasmid host name and serotype, type of pathogenic E. coli (UPEC:
uropathogenic E. coli, AIEC: adherent, invasive E. coli, NMEC: neonatal, meningitis
E. coli) and geographical location of isolation.
Plasmid Name Host Name Serotype Pathogen Type Geographical
location
pNK29-2 lineage A O134: K1:H31 UPEC Sweden
pUTI89 UTI89 O18: K1:H7 UPEC USA
pUM146 UM146 not determined AIEC Canada
pEC14_144 EC14 O6:H31 UPEC USA
pRS218 RS218 O18: K1:H7 NMEC USA
When Chen et al. sequenced UTI89 and the pUTI89 plasmid, they identiﬁed
several characteristics in common with the F plasmid [20]. They described a full tra
operon for conjugative transfer and plasmid replication and regulation genes such as
repB, repA6, repA1, ccdA, and ccdB to suggest it is replicated in low copy numbers,
which is in agreement with our coverage depth of the plasmid relative to the genome
[20]. Additionally, several genes on the plasmid are related to pathogenesis, including
the cjrABC operon, which is believed to encode proteins involved in iron uptake,
and cjrB strains sensitive to colicin J, and the senB gene, encoding an enterotoxin
[20, 21, 22]. These four genes are conserved between the virulence plasmid from
the enteroinvasive E. coli (EIEC) O164 strain [20, 21]. Six open reading frames
(ORFs) showed high identity to the UTI89 chromosome, in addition to other sequences
encoding proteins of non-plasmid origin. These results suggest that F-like plasmids,
such as pUTI89, undergo frequent recombination [20].
After Debroy et al. sequenced the pEC14_144 plasmid, apart from noting the
striking sequence similarity to the pUTI89 plasmid, they also found it very similar
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to the p1ESCUM plasmid [18]. When comparing the pEC14_144 plasmid to the
p1ESCUM plasmid from the UMN026 UPEC strain, they found that there were only
46 SNPs between p1ESCUM and pEC14_144, but they identiﬁed three insertions.
The largest of these insertions harboured the tetRACD tetracycline resistance genes.
Out of the 7 SNPs that were identiﬁed in pNK29-2 relative to pUTI89, only two
of these were non-synonymous changes (Supplementary Table 5.2). One of these was
in the rsvB gene, a resolvase, and in the traE gene, a conjugal transfer protein for F
pilus assembly.
Cusumano et al. have studied the role of pUTI89 in urinary tract infections
caused by UTI89 [21]. In an in vitro model, they did not observe any diﬀerences
between UTI89 and a plasmid-cured UTI89 strain when comparing growth, type 1
pilus expression, or bioﬁlm formation. However, in an in vivo mouse model for UTI,
they did observe signiﬁcant diﬀerences in the early aspects of infection for the pUTI89-
cured strain. Speciﬁcally, they observed a decrease in bacterial invasion, a decrease in
the number of bacteria in the bladder, and a decrease in the formation of bioﬁlm-like
intracellular bacterial communities. Similarly, Wijetunge et al. compared RS218 and
plasmid-cured RS218 strains, but found an attenuation of the plasmid-cured strain
for both in vitro invasion potential into human cerebral microvascular endothelial
cells and in vivo with infected rat pups with regards to mortalities, histopathological
lesions in the brain tissue, and bacterial recovery [19]. Apart from knowing that
lineage A had successfully caused a UTI, the exact role of the pNK29-2 plasmid in
causing the infection can only be speculated given the diﬀerent E. coli host.
Genomic Conﬁrmation of Antibiotic Resistance Genes Transfer in
situ of the gut
Karami et al. have previously reported that an observed change in the antibiotic
susceptibility proﬁle of lineage B [7]. When lineage B was sampled at 9 and 16
days, it was susceptible to ampicillin. At 32 days, lineage B was found to be re-
sistant to ampicillin (Fig 5.1). In addition to phenotypic evidence of the antibiotic
susceptibility change, evidence for the transfer included DNA sequencing yielding the
same blaTEM 1b variant. Additionally, a plasmid restriction fragment length poly-
morphism showed similar DNA fragments, from a plasmid approximately 40 kb in
size, termed pNK29.
Here we have determined the sequence of the pNK29 conjugative plasmid of 42.2
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kb. In silico analysis revealed that the plasmid belongs to the IncX1 incompatibility
group [12]. Annotation of the plasmid was initially done by using RAST [23], which
predicted that the plasmid encodes a total of 56 proteins. We compared pNK29 to
pOLA52, a well-annotated IncX1 plasmid [24], and to pRPEC180_47 [25], identiﬁed
via BLAST as the most closely related plasmid based on coverage and identity at
83% and 96%, respectively (Fig. 5.3). Using pOLA52 to identify homologues in
pNK29, we reﬁned the RAST annotation to include an additional plasmid replication
initiator protein, pir, and a replication initiation auxiliary protein, bis. Additionally,
actX and pilx7 were identiﬁed based on homology. Similar to other plasmids of the
IncX compatibility group, this plasmid also followed the generalized structure of pir-
bis-par-hns-topB-pilX-actX-taxCA (Fig. 5.3) [25]. In the genetic load area of IncX1
plasmids, between the par-res genes and the hns-topB genes [25], this plasmid contains
a total of 11 predicted ORFs. The blaTEM 1b gene is located in this region. The full
list of annotations can be found in Supplementary table 5.4.
Karami et al. had documented a change in the resistance phenotype of lineage A
isolates collected from 32 days and onwards. The isolates had a reduced resistance
to piperacillin due to a single nucleotide diﬀerence in the promoter region of the
blaTEM 1b gene on pNK29, converting the weak P3 promoter into a strong Pa/Pb
[7]. This SNP is present on the phylogenetic tree as the single nucleotide diﬀerence
between the 2d, 9d and 16d isolates and the 32d isolate (Fig 5.2).
Lineage A Dynamics
The analysis of the isolates collected from lineage A revealed two diﬀerences in the
genomic content between the isolates. The earlier collected isolates appear to have
an integrated phage, whereas the later collected isolates had a small, cryptic plasmid.
When comparing the isolates to the representative genome of the A lineage, the
6m2 and 12m isolates appeared to be missing approximately 54 kb. Aligning the
contigs conﬁrmed that there was extra genomic content in the isolate from 2 days,
compared to the 6m2 and 12m isolates. Inspection of the annotations in this region led
to the suspicion that the 54 kb region was an integrated phage. Annotated genes in
the regions included multiple phage tail ﬁber, assembly and tail length tape-measure
proteins, DNA transfer proteins, phage terminase, endopeptidase, lysozyme, and in-
tegrase proteins, and an additional 62 hypothetical proteins. Aligning the ﬂanking
sequences of this prophage-associated region and the contigs from the 6m2 and 12m
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Figure 5.3 | Plasmid pNK29 compared to other IncX1 plasmids pRPEC180_47
(middle ring, blue) and pOLA52 (outer ring, green). Open reading frames (ORFs)
identiﬁed on pNK29 are drawn in the inner most ring in black, with arrows indicating
the reading direction. Annotations for some ORFs are labeled outside of the rings,
with the gene name in pOLA52 in brackets.
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isolates revealed a potential 12 bp attR and attL sequence, TCCAGACAGGAC.
To determine if this prophage-associated region could be an intact phage, we used
the PHAST web service [26]. However, PHAST predicted that only the latter 33.4
kb of this 54.2 kb region as an integrated phage, but it did predict this region to
contain an intact, functional prophage. A BLAST search of this suspected phage
region yielded only two hits with greater than 2% coverage. One of the hits was
a recently deposited 288 kb scaﬀold from the FHI99 E. coli strain, yielding 90%
coverage with 94% identity. A second hit was from the complete assembled UMNK88
E. coli genome, yielding 80% coverage with 89% identity. Shepard et al. had in the
analysis of the UMNK88 genome identiﬁed this homologous 55 kb region as prophage-
associated [27]. PHAST analysis of both the scaﬀold from FH199 and the UMNK88
genome identiﬁed the entire homologous region as an intact prophage [26]. All three
prophage regions were determined to be most similar to the 49 kb Salmonella phage
vB_SosS_Oslo, a member of the Siphoviridae family with long non-contractile tails.
In the 6m2 and 12m isolates, a small cryptic plasmid was found, termed pNK29-3.
This 2545 bp plasmid has a low GC content of 33.4% and contains two ORFs both
predicted as hypothetical proteins by RAST annotation. By comparing the coverage
depth of the plasmid to the average coverage depth of the genome, we estimate the
copy number to be around 9 plasmids per cell. In silico typing of pNK29-3 revealed
that it belongs to the ColE1-like group of small plasmids (Supplementary Table 5.3).
The probe for this classiﬁcation was based on the mobility protein sequence from the
pIGMS31 plasmid [12]. The pIGMS31 plasmid was isolated from a pathogenic Kleb-
siella pneumoniae strain and is a narrow host range plasmid that can be maintained
in Gammaproteobacteria [28]. Comparing plasmid pNK29-3 to pIGMS31 yields 63%
coverage by pIGMS31 with 95% identity. The region of homology includes an iden-
tiﬁed oriT site, and a mobilization protein, which Smorawinska et al. have demon-
strated is functional in a wider range of hosts than the replication system (Fig. 5.4)
[28]. The other ORF on pNK29-3 did not share any similarity to the predicted rep
gene in pIGMS31. One highly similar plasmid to pNK29-3 was identiﬁed by BLAST
in NCBI genbank was the pEA1 plasmid isolated from a Pantoa agglomerans strain
(formerly Enterobacter agglomerans). Plasmid pEA1 is the same length as pNK29-3,
covers 100% of pNK29-3 and shares 96% identity. However, this plasmid is neither
annotated nor characterized, so it is not possible to predict how pNK29-3 initiates
replication based on sequence homology.
These two genetic content diﬀerences can be observed in the SNP-based tree (Fig.
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Figure 5.4 | Plasmid pNK29-3 compared to other ColE1-like plasmids pEA1 (middle
ring, blue) and pIMGS31 (outer ring, green). Open reading frames (ORFs) identiﬁed
on pNK29-3 are drawn in the inner most ring in black, with arrows indicating the
reading direction.
5.2). The isolates with the integrated phage, 2d, 9d, 16d, 32d, 2m1, 2m2, 61 and
the UTI isolate, are located together with a maximum of 28 SNPs detected between
them. A long branch after the 32d isolate separates the isolates with the integrated
phage, with the 6m2 and 12m isolates without the phage, but with the small, cryptic
plasmid, pNK29-3. From this branch after the 32d isolate, there are 53 SNPs to the
nearest isolate without the phage, the 6m2 isolate, and 177 SNPs to the 12m isolate.
Based on the phylogenetic tree, it is likely that either the prophage was cleared or
plasmid was acquired at some point between 32 days and 2 months, even though an
isolate without the phage or with pNK29-3 was not sampled at 2 months.
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5.4 Discussion
By genome sequencing this collection of isolates from an infant over the ﬁrst year of
life, we are able to observe complex dynamics of these co-existing E. coli lineages in
situ of the gut.
We have been able to conﬁrm that it was E. coli lineage A that colonized the
gut causing a UTI in this infant. We identiﬁed a 114 kb plasmid that was strikingly
similar to other previously sequenced plasmids from pathogenic E. coli strains. This
plasmid in a host with a diﬀerent genetic background has been shown in a mouse
model to play a role in the initial stages of infection [21], however we can only spec-
ulate as to the role of this plasmid in the lineage A ability to cause a UTI infection.
Nevertheless, observing such a similar virulence-involved plasmid again in a diﬀerent
genetic background and in diﬀerent geographical regions does raise questions how this
plasmid was able to disseminate and be maintained successfully in diﬀerent hosts. As-
sessing the role of this plasmid on the ability of its host to colonize the gut may lead
to evidence explaining why it has been maintained in the various hosts it has been
found in. In this study, lineage A remained colonized in the gut the entire duration
of the study, from 2 days to one year after birth.
We have also been able to conﬁrm via genome sequencing that it was also lineage
A that transferred the pNK29 plasmid to the co-existing lineage B in situ in the
gut. This plasmid conferred resistance to ampicillin and reduced susceptibility to
amoxicillin/clavulanic acid, which would have been beneﬁcial for survival in the gut
while the infant was undergoing treatment [7]. This beneﬁt was also observed in a
dramatic increase in the population counts of lineage B in the microbiota before and
after the transfer [7].
While the isolates collected for the ALLERGYFLORA were originally selected to
serve as a lineage representative for each time point to answer questions regarding
colonization patterns, we have been able to catch a glimpse into the multi-clonal
environment of the human gut. By including only one extra isolate for two time
points, 2 and 6 months, we are able to observe two diﬀerent trajectories of one E.
coli lineage. This intra-lineage diﬀerence is most pronounced with the two isolates
collected at 6 months; 6m1 most related to the 2m2 isolate containing the prophage
whereas the 6m2 isolate branched oﬀ much earlier after 32 days and does not contain
the phage, but instead contains a small cryptic plasmid. While sequencing isolated
single colonies has proven to be very powerful in identifying genomic events, such as
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the loss of the integrated phage or acquisition of plasmids, sequencing more isolates
or further reﬁnement of current time series metagenomic sample processing methods
will lead to a better understanding of the dynamics of the gut microbiota.
5.5 Materials and Methods
E. coli Lineage Sampling and Collecting of Isolates
Samples to investigate the colonization of the gut microbiota of the infants enrolled in
this study were collected at 2 days after birth via rectal swab, and 1, 2, and 4 weeks
and 2, 6, and 12 months after birth via stool sample. Stool samples were collected
by the parents and brought to the lab and processed within 24 hours. Samples were
quantitatively cultured for all major groups of facultative and anaerobic bacteria. E.
coli was quantitatively cultured on Drigalski agar plates, with various morphotypes
enumerated separately. E. coli isolates were speciated via API 20E identiﬁcation
strips (bioMériuex, France). Lineage identities of the E. coli isolates were initially
determined via random ampliﬁed polymorphic DNA (RAPD) typing, and conﬁrmed
via pulsed-ﬁeld gel electrophoresis (PFGE).
Genome Sequencing
Genomic DNA was isolated using an UltraClean®Microbial DNA Isolation Kit (Mo-
Bio Laboratories, Inc., California). Sequencing libraries for Illumina HiSeq single-end
sequencing were prepared by shearing DNA into 200bp fragments using a Covaris
E210 and then constructing barcoded libraries. Illumina HiSeq sequencing was per-
formed by Partners HealthCare Center for Personalized Genetic Medicine (Cambridge,
Massachusetts). Illumina MiSeq paired-end sequencing libraries were prepared by us-
ing the Nextera XT (Illumina, California) for lineage A at 2 days, lineage B at 32
days, and the urinary tract isolate, and by using the TruSeq (Illumina, California) for
lineage A at 2 months and lineage B at 9 days.
Sequence Analysis
Genomes for each sequenced isolate were assembled using Velvet (v1.2.09) [29] and
annotated via RAST [23]. Various tests were conducted to ensure that the selected
isolates were indeed representative for the lineage. First reads from the isolates were
mapped onto the representative genome via Bowtie2 (2.1.0) [30], and single nucleotide
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polymorphisms (SNPs) were enumerated via SAMTools (0.1.19) [31]. Additionally,
to ensure that all isolates from within a lineage consisted of the same genomic con-
tent as the representative isolates, genomic areas lacking mapped read coverage were
identiﬁed using BEDTools (2.17.0) [32]. This included both reads mapped onto the
representative lineage, in addition to reads from the representative lineage mapped
onto genomes assembled from reads of the other isolates. Scripts to assist in the
analysis were written in python using Biopython libraries [33].
Coarse genome sequence comparisons were based on aligning reads from our study
to other genome sequences, and assessing the number of SNPs via the SNP calling
pipeline and/or assessing the coverage of the genome based on BEDTools [32]. This
was done for comparison between lineages A and B, and for comparison of lineage A
to UM146 (NC_017632.1) and UTI89 (NC_007946.1).
The pNK29 plasmid was assembled into a circular plasmid by aligning plasmid
contigs together using MUMMER [34]. Contigs belonging to the plasmid were ﬁrst
identiﬁed in lineage B as the new genetic material of the isolate at 32 days, and then
used to identify the corresponding contigs in lineage A genome. The introduction of
possible errors in plasmid assembly were checked by aligning reads to the plasmid
using Bowtie2 [30] and checking for SNPs and INDELs using SAMTools [31]. The
RAST annotation for this plasmid was reﬁned based on identifying homologous genes
in pOLA52 (NC_010378.1) that were either missing or incorrect in pNK29. Addition-
ally, the descriptions for the two mobile element proteins upstream of the blaTEM1b
gene were added on based on the homologous tnpA and tnpR genes in pRPEC180_47
(NC_019088.1).
Other plasmids were identiﬁed by ﬁrst separating contigs with a copy number
greater than one from the genomic contigs and then by grouping contigs with simi-
lar abundances together. The average coverage of each contig was determined using
BEDTools [32]. Plasmid incompatibility grouping was done using the PlasmidFinder
tool (http://cge.cbs.dtu.dk/services/PlasmidFinder) [12]. Homologous previously se-
quenced plasmids were identiﬁed using BLAST and the NCBI nt database [35]. Plas-
mid diagrams were created using the BLAST ring image generator (BRIG) [36], which
uses BLAST to compare input sequences.
For pNK29-2, blastn searches of these plasmid contigs revealed 3 plasmids with
very high identity: pUTI89 (NC_007941.1), pUM146 (NC_017630.1), pEC14_144
(NC_013175.1). These plasmids were downloaded and the SNP calling pipeline was
used to assess SNP-based similarity. Additionally, the contigs with 2X-genomic cov-
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erage were aligned to the pUTI89 plasmid to determine if the plasmid had any large
insertions.
For pNK29-3, the small cryptic plasmid in the A lineage was identiﬁed based on
the introduction of new genetic content in 6m2 and 12m isolates. Two similar plasmids
identiﬁed via blastn were pIGMS31 (NC_011406.1) and pEA1 (DQ659147.1). Again,
the RAST annotation was reﬁned based on homolog to the pIGMS31 plasmid.
5.6 Acknowledgements
We would like to thank Mari Rodriguez de Evgrafov, Marius Faza and Andreas
Porse for sequence library preparation, and Christian Munck and Lejla Imamovic
for helpful discussions. This work was supported by the Danish Free Research Coun-
cils for Health and Disease, the European Union FP7-HEALTH- 2011-single-stage
grant agreement 282004, EvoTAR, the Medical Faculty of the University of Göte-
borg (ALFGBG138401) and the Swedish Medical Research Council. M.O.A.S further
acknowledges support from the Novo Nordisk Foundation, and the Lundbeck Foun-
dation.
Author Contributions
NK, IA and AW designed the clinical study and isolated the E. coli strains. HG
processed the sequencing data. HG and MS analyzed the sequencing data results and
HG and wrote the manuscript with input from MS.
5.7 References
[1] Sam P Brown, Daniel M Cornforth, and Nicole Mideo. Evolution of virulence in
opportunistic pathogens: generalism, plasticity, and control. Trends in microbi-
ology, 20(7):336–342, July 2012.
[2] Evgeni V Sokurenko, Richard Gomulkiewicz, and Daniel E Dykhuizen. Source-
sink dynamics of virulence evolution. Nature Reviews Microbiology, 4(7):548–555,
July 2006.
[3] PD Brown and B Foxman. Pathogenesis of Urinary Tract Infection: the Role
of Sexual Behavior and Sexual Transmission. Current infectious disease reports,
2(6):513–517, December 2000.
5.7 References 111
[4] M O A Sommer, G Dantas, and G M Church. Functional Characterization of the
Antibiotic Resistance Reservoir in the Human Microﬂora. Science (New York,
N.Y.), 325(5944):1128–1131, August 2009.
[5] Abigail A Salyers, Anamika Gupta, and Yanping Wang. Human intestinal bacte-
ria as reservoirs for antibiotic resistance genes. Trends in microbiology, 12(9):412–
416, September 2004.
[6] P Bidet, B Burghoﬀer, V Gautier, N Brahimi, P Mariani-Kurkdjian, A El-
Ghoneimi, E Bingen, and G Arlet. In Vivo Transfer of Plasmid-Encoded ACC-1
AmpC from Klebsiella pneumoniae to Escherichia coli in an Infant and Selection
of Impermeability to Imipenem in K. pneumoniae. Antimicrobial agents and
chemotherapy, 49(8):3562–3565, July 2005.
[7] N Karami, A Martner, V I Enne, S Swerkersson, I Adlerberth, and A E Wold.
Transfer of an ampicillin resistance gene between two Escherichia coli strains in
the bowel microbiota of an infant treated with antibiotics. Journal of Antimicro-
bial Chemotherapy, 60(5):1142–1145, September 2007.
[8] Michael J Morowitz, Vincent J Denef, Elizabeth K Costello, Brian C Thomas,
Valeriy Poroyko, David A Relman, and Jillian F Banﬁeld. Strain-resolved com-
munity genomic analysis of gut microbial colonization in a premature infant.
Proceedings of the National Academy of Sciences, 108(3):1128–1133, January
2011.
[9] I Sharon, M J Morowitz, B C Thomas, E K Costello, D A Relman, and J F
Banﬁeld. Time series community genomics analysis reveals rapid shifts in bacte-
rial species, strains, and phage during infant gut colonization. Genome Research,
23(1):111–120, January 2013.
[10] Christopher T Brown, Itai Sharon, Brian C Thomas, Cindy J Castelle, Michael J
Morowitz, and Jillian F Banﬁeld. Genome resolved analysis of a premature
infant gut microbial community reveals a Varibaculum cambriense genome and
a shift towards fermentation-based metabolism during the third week of life.
Microbiome, 1(1):30, 2013.
[11] Forough Nowrouzian, Bill Hesselmar, Robert Saalman, Inga-Lisa Strannegård,
Nils Åberg, Agnes E Wold, and Ingegerd Adlerberth. Escherichia coli in Infants’
112
5 Pathogenic and commensal Escherichia coli lineage dynamics in situ of the gut
during antibiotic treatment
Intestinal Microﬂora: Colonization Rate, Strain Turnover, and Virulence Gene
Carriage. Pediatric Research, 54(1):8–14, July 2003.
[12] A Carattoli, E Zankari, A Garcia-Fernandez, M Voldby Larsen, O Lund, L Villa,
F Moller Aarestrup, and H Hasman. In Silico Detection and Typing of Plasmids
using PlasmidFinder and Plasmid Multilocus Sequence Typing. Antimicrobial
agents and chemotherapy, 58(7):3895–3903, June 2014.
[13] L Villa, A Garcia-Fernandez, D Fortini, and A Carattoli. Replicon sequence
typing of IncF plasmids carrying virulence and resistance determinants. Journal
of Antimicrobial Chemotherapy, 65(12):2518–2529, November 2010.
[14] M A Mulvey, J D Schilling, and S J Hultgren. Establishment of a persistent
Escherichia coli reservoir during the acute phase of a bladder infection. Infection
and immunity, 69(7):4572–4579, July 2001.
[15] J D Schilling, M A Mulvey, C D Vincent, R G Lorenz, and S J Hultgren.
Bacterial Invasion Augments Epithelial Cytokine Responses to Escherichia coli
Through a Lipopolysaccharide-Dependent Mechanism. The Journal of Immunol-
ogy, 166(2):1148–1155, January 2001.
[16] R Kotlowski, C N Bernstein, S Sepehri, and D O Krause. High prevalence
of Escherichia coli belonging to the B2+D phylogenetic group in inﬂammatory
bowel disease. Gut, 56(5):669–675, May 2007.
[17] D O Krause, A C Little, S E Dowd, and C N Bernstein. Complete Genome
Sequence of Adherent Invasive Escherichia coli UM146 Isolated from Ileal Crohn’s
Disease Biopsy Tissue. Journal of bacteriology, 193(2):583–583, December 2010.
[18] Chitrita Debroy, Mandeep S Sidhu, Upal Sarker, Bhushan M Jayarao, Adam L
Stell, Nathan P Bell, and Timothy J Johnson. Complete sequence of pEC14_114,
a highly conserved IncFIB/FIIA plasmid associated with uropathogenic Es-
cherichia coli cystitis strains. Plasmid, 63(1):53–60, January 2010.
[19] Dona Wijetunge, Kurundu Karunathilake, Atul Chaudhari, Robab Katani, Ed-
ward G Dudley, Vivek Kapur, Chitrita Debroy, and Subhashinie Kariyawasam.
Complete nucleotide sequence of pRS218, a large virulence plasmid that
augments pathogenic potential of meningitis-associated. BMC Microbiology,
14(1):203, August 2014.
5.7 References 113
[20] Swaine L Chen, Chia-Seui Hung, Jian Xu, Christopher S Reigstad, Vincent Ma-
grini, Aniko Sabo, Darin Blasiar, Tamberlyn Bieri, Rekha R Meyer, and Philip
Ozersky. Identiﬁcation of genes subject to positive selection in uropathogenic
strains of Escherichia coli: a comparative genomics approach. Proceedings of the
National Academy of Sciences of the United States of America, 103(15):5977–
5982, 2006.
[21] C K Cusumano, C S Hung, S L Chen, and S J Hultgren. Virulence Plasmid
Harbored by Uropathogenic Escherichia coli Functions in Acute Stages of Patho-
genesis. Infection and immunity, 78(4):1457–1467, March 2010.
[22] D Smajs and G M Weinstock. The Iron- and Temperature-Regulated cjrBC
Genes of Shigella and Enteroinvasive Escherichia coli Strains Code for Colicin Js
Uptake. Journal of bacteriology, 183(13):3958–3966, July 2001.
[23] Ramy K Aziz, Daniela Bartels, Aaron A Best, Matthew DeJongh, Terrence
Disz, Robert A Edwards, Kevin Formsma, Svetlana Gerdes, Elizabeth M Glass,
Michael Kubal, Folker Meyer, Gary J Olsen, Robert Olson, Andrei L Oster-
man, Ross A Overbeek, Leslie K McNeil, Daniel Paarmann, Tobias Paczian,
Bruce Parrello, Gordon D Pusch, Claudia Reich, Rick Stevens, Olga Vassieva,
Veronika Vonstein, Andreas Wilke, and Olga Zagnitko. The RAST Server: Rapid
Annotations using Subsystems Technology. BMC genomics, 9(1):75, 2008.
[24] Anders Norman, Lars Hestbjerg Hansen, Qunxin She, and Søren Johannes
Sørensen. Nucleotide sequence of pOLA52: A conjugative IncX1 plasmid from
Escherichia coli which enables bioﬁlm formation and multidrug eﬄux. Plasmid,
60(1):59–74, July 2008.
[25] Timothy J Johnson, Eliza M Bielak, Daniela Fortini, Lars Hestbjerg Hansen,
Henrik Hasman, Chitrita Debroy, Lisa K Nolan, and Alessandra Carattoli. Ex-
pansion of the IncX plasmid family for improved identiﬁcation and typing of
novel plasmids in drug-resistant Enterobacteriaceae. Plasmid, 68(1):43–50, July
2012.
[26] Y Zhou, Y Liang, K H Lynch, J J Dennis, and D S Wishart. PHAST: A Fast
Phage Search Tool. Nucleic Acids Research, 39(suppl):W347–W352, June 2011.
[27] S M Shepard, J L Danzeisen, R E Isaacson, T Seemann, M Achtman, and T J
Johnson. Genome Sequences and Phylogenetic Analysis of K88- and F18-Positive
114
5 Pathogenic and commensal Escherichia coli lineage dynamics in situ of the gut
during antibiotic treatment
Porcine Enterotoxigenic Escherichia coli. Journal of bacteriology, 194(2):395–405,
December 2011.
[28] Maria Smorawinska, Magdalena Szuplewska, Piotr Zaleski, Paweł Wawrzyniak,
Anna Maj, Andrzej Plucienniczak, and Dariusz Bartosik. Mobilizable narrow
host range plasmids as natural suicide vectors enabling horizontal gene transfer
among distantly related bacterial species. FEMS Microbiology Letters, 326(1):76–
82, November 2011.
[29] D R Zerbino and E Birney. Velvet: Algorithms for de novo short read assembly
using de Bruijn graphs. Genome Research, 18(5):821–829, February 2008.
[30] Ben Langmead and Steven L Salzberg. Fast gapped-read alignment with Bowtie
2. Nature methods, 9(4):357–359, April 2012.
[31] H Li, B Handsaker, A Wysoker, T Fennell, J Ruan, N Homer, G Marth, G Abeca-
sis, R Durbin, and 1000 Genome Project Data Processing Subgroup. The Se-
quence Alignment/Map format and SAMtools. Bioinformatics, 25(16):2078–
2079, August 2009.
[32] A R Quinlan and I M Hall. BEDTools: a ﬂexible suite of utilities for comparing
genomic features. Bioinformatics, 26(6):841–842, March 2010.
[33] P J A Cock, T Antao, J T Chang, B A Chapman, C J Cox, A Dalke, I Friedberg,
T Hamelryck, F Kauﬀ, B Wilczynski, and M J L de Hoon. Biopython: freely
available Python tools for computational molecular biology and bioinformatics.
Bioinformatics, 25(11):1422–1423, May 2009.
[34] Stefan Kurtz, Adam Phillippy, Arthur L Delcher, Michael Smoot, Martin
Shumway, Corina Antonescu, and Steven L Salzberg. Versatile and open software
for comparing large genomes. Genome Biology, 5(2):R12, 2004.
[35] S F Altschul, W Gish, W Miller, E W Myers, and D J Lipman. Basic local
alignment search tool. Journal of molecular biology, 215(3):403–410, October
1990.
[36] Nabil-Fareed Alikhan, Nicola K Petty, Nouri L Ben Zakour, and Scott A Beatson.
BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons.
BMC genomics, 12(1):402, August 2011.
5.8 Supplementary Information 115
5.8 Supplementary Information
Supplementary Table 5.1| Overview of library preparation method and sequencing
technology used for the isolates genome sequenced in this study.
Lineage Sampling Time Library Preparation Sequencing Technology Output
Lineage A 2d Nextera kit PE
9d Shear+barcode SE
16d Shear+barcode SE
32d Shear+barcode SE
2m1 Shear+barcode SE
2m2 TruSeq kit PE
6m1 Shear+barcode SE
6m2 TruSeq kit PE
12m Shear+barcode SE
UTI Nextera kit PE
Lineage B 9d Shear+barcode SE
16d Shear+barcode SE
32d Nextera kit PE
Supplementary Table 5.2| Table containing the SNPs from lineage B, includ-
ing the annotation and whether the animo acid change was synonymous or non-
synonymous. The isolates from days 2, 9 and 16 are left out as they did not have any
SNP diﬀerences from the representative genome for the lineage (isolate taken at 2d).
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Contig
number
Position 2d UTI 32d 2m1 2m2 6m1 6m2 12m Annotation Change
61 61701 A G 6-phosphogluconate dehydrogenase,decarboxylating (EC 1.1.1.44) nonsynonymous
56 6755 G A A A A A A
5 176310 G A A A A A Dihydrofolate reductase (EC1.5.1.3) synonymous
93 189 G A A A
42 18614 G A A Primosomal protein I nonsynonymous
93 95 G A A
93 104 G A A
93 105 G A A
93 171 G A A
15 137066 G A
Radical SAM family enzyme, sim-
ilar to coproporphyrinogen III
oxidase, oxygen-independent,
clustered with nucleoside-
triphosphatase RdgB
synonymous
24 77511 G A Transcriptional activator of maltoseregulon, MalT nonsynonymous
49 14209 G A FIG00613320: hypothetical protein synonymous
4 85958 G A 3-oxoacyl-[acyl-carrier protein] re-ductase (EC 1.1.1.100) synonymous
62 46358 G A
5 175792 T C C C C C Dihydrofolate reductase (EC1.5.1.3) nonsynonymous
20 275987 T C C Glutamate synthase [NADPH] largechain (EC 1.4.1.13) nonsynonymous
20 297334 T C
FUSARIC ACID RESISTANCE
PROTEIN FUSB / FUSARIC
ACID RESISTANCE PROTEIN
FUSC
nonsynonymous
21 19073 T C IS, phage, Tn nonsynonymous
24 25690 T C Nitrite reductase [NAD(P)H] smallsubunit (EC 1.7.1.4) nonsynonymous
34 44455 A G LSU ribosomal protein L19p synonymous
70 8108 A G Putative Ton-B dependent heminereceptor nonsynonymous
62 60490 C T T T T T Alpha-2-macroglobulin synonymous
93 150 C T T
10 126386 C T Ferredoxin-type protein NapG(periplasmic nitrate reductase) nonsynonymous
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Contig
number
pos 2d UTI 32d 2m1 2m2 6m1 6m2 12m annotation change
14 3707 C T Putative GTP-binding protein nonsynonymous
20 214976 C T LppC putative lipoprotein nonsynonymous
23 43422 C T Putative phosphatase YieH nonsynonymous
16 43695 G A Inner membrane protein YiaA nonsynonymous
20 74596 G A Hexuronate utilization operon tran-scriptional repressor ExuR nonsynonymous
42 9944 G A putative tail protein nonsynonymous
46 5067 G A
Putative stability/partitioning pro-
tein encoded within prophage CP-
933T
synonymous
5 123037 G A Cell division protein FtsQ nonsynonymous
17 98463 T C Holliday junction DNA helicaseRuvB synonymous
24 60742 T C Transcription elongation factorGreB nonsynonymous
30 120639 G C expressed protein nonsynonymous
10 92885 A G Putative membrane protein nonsynonymous
26 193630 A G Putative inner membrane protein synonymous
26 218585 A G
30 97163 A G
Glutamate Aspartate transport
ATP-binding protein GltL (TC
3.A.1.3.4)
nonsynonymous
83 6188 A G FIG01045219: hypothetical protein synonymous
26 171451 G A Inner membrane ABC transporterpermease protein YcjP stop
3 137385 T C FIG138056: a glutathione-dependent thiol reductase synonymous
27 15149 C T IncF plasmid conjugative transferpilus assembly protein TraU nonsynonymous
51 40378 C T Chitinase (EC 3.2.1.14) synonymous
10 196403 C A A DedA family inner membrane pro-tein YohD nonsynonymous
15 10933 G A A Protease III precursor (EC3.4.24.55) synonymous
16 34911 G A A Outer membrane protein A precur-sor nonsynonymous
20 182830 G A A Inner membrane protein synonymous
23 37891 G A A 6-phospho-beta-glucosidase (EC3.2.1.86) nonsynonymous
25 57550 G A A ATP-dependent hsl protease ATP-binding subunit HslU nonsynonymous
35 4250 G A A O-antigen ligase synonymous
39 14389 G A A Ubiquinone biosynthesis monooxy-genase UbiB nonsynonymous
3 26626 G A A
Enoyl-CoA hydratase (EC
4.2.1.17) / 3-hydroxyacyl-CoA
dehydrogenase (EC 1.1.1.35) /
3-hydroxybutyryl-CoA epimerase
(EC 5.1.2.3)
nonsynonymous
4 39270 G A A Arginine/ornithine antiporter ArcD nonsynonymous
4 66817 G A A Uncharacterized protein YtfN stop
5 5863 G A A Prolyl-tRNA synthetase (EC6.1.1.15), bacterial type nonsynonymous
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Contig
number
Position 2d UTI 32d 2m1 2m2 6m1 6m2 12m Annotation Change
10 145962 G A Putative ABC transporter ATP-binding protein nonsynonymous
15 147808 G A Ornithine decarboxylase (EC4.1.1.17) nonsynonymous
17 309028 T A FIG00638170: hypothetical protein nonsynonymous
18 136370 G A Hydroxylamine reductase (EC 1.7.-.-) synonymous
19 96733 G A Per-activated serine protease auto-transporter enterotoxin EspC nonsynonymous
1 53133 G A PTS system, sorbose-speciﬁc IICcomponent (EC 2.7.1.69) nonsynonymous
4 95471 G A
53 22400 G A Single-stranded DNA-binding pro-tein synonymous
5 191026 G A Carnitine operon protein CaiE nonsynonymous
147 554 T C C hypothetical protein nonsynonymous
20 183063 T C C Inner membrane protein nonsynonymous
3 70340 T C C
3 122654 T C C NADP-dependent malic enzyme(EC 1.1.1.40) synonymous
43 100362 T C C Flagellar hook-associated proteinFlgK nonsynonymous
49 16016 T C C LysR family transcriptional regula-tor YafC nonsynonymous
5 120353 T C C Cell division protein FtsZ (EC3.4.24.-) nonsynonymous
5 170421 T C C
Outer membrane protein Imp, re-
quired for envelope biogenesis / Or-
ganic solvent tolerance protein pre-
cursor
nonsynonymous
62 31047 T C C Uncharacterized protein YphG,TPR-domain containing nonsynonymous
94 267 T C C
13 17707 T C Phage head-to-tail joining protein nonsynonymous
25 1495 T C Outer membrane vitamin B12 re-ceptor BtuB synonymous
53 13735 T C Holin-like protein CidA synonymous
10 178934 A G G GTP cyclohydrolase I (EC 3.5.4.16)type 1 nonsynonymous
21 56232 A G G
adherence and invasion outermem-
brane protein (Inv,enhances Peyer’s
patches colonization)
nonsynonymous
83 198 A G G
35 2808 A G
43 106731 A G Ribosomal large subunit pseudouri-dine synthase C (EC 4.2.1.70) nonsynonymous
5 62832 A G glutamyl-Q-tRNA synthetase synonymous
77 4289 A G hypothetical protein nonsynonymous
147 436 C T T
17 79481 C T T Flagellar biosynthesis protein FlhA synonymous
17 216927 C T T PTS system, chitobiose-speciﬁc IICcomponent (EC 2.7.1.69) nonsynonymous
17 299242 C T T
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number
Position 2d UTI 32d 2m1 2m2 6m1 6m2 12m Annotation Change
30 65147 C T T Ribonuclease I precursor (EC
3.1.27.6)
nonsynonymous
43 39245 C T T
17 232929 C T Threonyl-tRNA synthetase (EC
6.1.1.3)
synonymous
26 200370 C T
3 94889 C T Sulfate and thiosulfate import ATP-
binding protein CysA (EC 3.6.3.25)
synonymous
43 29182 C T
5 225896 C T Aspartokinase (EC 2.7.2.4) /
Homoserine dehydrogenase (EC
1.1.1.3)
synonymous
7 65266 C T ATP-dependent Clp protease prote-
olytic subunit (EC 3.4.21.92)
synonymous
10 14792 G A Phosphate acetyltransferase (EC
2.3.1.8)
synonymous
122 2192 G A Pyruvate formate-lyase (EC
2.3.1.54)
nonsynonymous
15 104208 G A Protein involved in stability of MscS
mechanosensitive channel
nonsynonymous
15 115558 G A PTS system, mannitol-speciﬁc IIB
component (EC 2.7.1.69) / PTS sys-
tem, mannitol-speciﬁc IIC compo-
nent (EC 2.7.1.69)
nonsynonymous
17 296387 G A Purine nucleotide synthesis repres-
sor
synonymous
18 176760 G A Dipeptide transport system perme-
ase protein DppC (TC 3.A.1.5.2)
nonsynonymous
18 200735 T A Glutamate transport membrane-
spanning protein
nonsynonymous
19 113564 G A Flagellar biosynthesis protein FlhA synonymous
20 29027 G A Malate synthase G (EC 2.3.3.9) synonymous
21 38804 G A iron aquisition yersiniabactin syn-
thesis enzyme (Irp2)
nonsynonymous
23 7535 G A Ribose ABC transport system,
ATP-binding protein RbsA (TC
3.A.1.2.1)
synonymous
23 14472 G A
23 135025 G A 3-deoxy-D-manno-octulosonic-acid
transferase (EC 2.-.-.-)
nonsynonymous
24 31001 G A FIG006427: Putative transport sys-
tem permease protein
synonymous
25 1435 G A Outer membrane vitamin B12 re-
ceptor BtuB
synonymous
26 254547 T A hypothetical protein nonsynonymous
26 254550 T A hypothetical protein nonsynonymous
30 39378 G A Enterobactin synthetase compo-
nent F, serine activating enzyme
(EC 2.7.7.-)
nonsynonymous
32 23323 G A
32 70369 G A PhnJ protein synonymous
42 3849 G A 12 nonsynonymous
51 23078 G A LSU ribosomal protein L4p (L1e) synonymous
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number
Position 2d UTI 32d 2m1 2m2 6m1 6m2 12m Annotation Change
53 1415 G A Glutamate-aspartate carrier pro-tein synonymous
53 6083 G A NrfC protein synonymous
5 25753 G A
Intramembrane protease RasP/Y-
luC, implicated in cell division
based on FtsL cleavage
nonsynonymous
5 103289 G A VgrG protein nonsynonymous
5 296526 G A Putative inner membrane protein synonymous
7 15002 G A Glucokinase, ROK family (EC2.7.1.2) synonymous
7 35837 G A Nucleoside-speciﬁc channel-formingprotein Tsx precursor synonymous
10 41534 T C FIG00638014: hypothetical protein synonymous
10 155429 T C
Putative metal chaperone, involved
in Zn homeostasis, GTPase of
COG0523 family
nonsynonymous
15 25680 T C Lysophospholipid transporter LplT nonsynonymous
15 59616 T C Predicted oxidoreductase, Fe-S sub-unit nonsynonymous
15 91830 T C
2-octaprenyl-3-methyl-6-methoxy-
1,4-benzoquinol hydroxylase (EC
1.14.13.-)
synonymous
15 102370 T C
17 149347 T C FIG00639292: hypothetical protein nonsynonymous
17 257077 T C Acyl-CoA dehydrogenase (EC1.3.99.3) nonsynonymous
19 125833 T C FIG00641604: hypothetical protein synonymous
20 29055 T C Malate synthase G (EC 2.3.3.9) nonsynonymous
20 166907 T C Integral membrane protein TerC synonymous
20 260128 T C Uncharacterized ABC transporter,ATP-binding protein YrbF nonsynonymous
21 13870 T C hypothetical protein synonymous
24 56129 T C FIG00638818: hypothetical protein nonsynonymous
24 106762 T C Aspartate-semialdehyde dehydroge-nase (EC 1.2.1.11) nonsynonymous
26 131738 T C DNA topoisomerase I (EC 5.99.1.2) nonsynonymous
27 43829 T C
30 47089 T C Isochorismate synthase (EC 5.4.4.2)of siderophore biosynthesis nonsynonymous
31 39231 T C
Branched-chain amino acid ABC
transporter, amino acid-binding
protein (TC 3.A.1.4.1)
nonsynonymous
32 37751 T C Lysyl-tRNA synthetase (class II)(EC 6.1.1.6) synonymous
39 73336 T C Arylsulfatase (EC 3.1.6.1) nonsynonymous
39 109139 T C Protein yifE synonymous
4 23661 T C FIG000988: Predicted permease nonsynonymous
56 21039 T C
ATPase provides energy for both as-
sembly of type IV secretion com-
plex and secretion of T-DNA com-
plex (VirB11)
nonsynonymous
5 61314 T C Sugar/maltose fermentation stimu-lation protein homolog synonymous
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Position 2d UTI 32d 2m1 2m2 6m1 6m2 12m Annotation Change
5 85250 T C Blue copper oxidase CueO precur-sor synonymous
5 127065 T C Cell division protein FtsW nonsynonymous
5 278788 T C
TRAP dicarboxylate transporter,
DctM subunit, unknown substrate
8
nonsynonymous
5 324641 T C
Phosphoenolpyruvate-
dihydroxyacetone phosphotrans-
ferase (EC 2.7.1.121), subunit
DhaM
nonsynonymous
61 31544 T C Propanediol dehydratase reactiva-tion factor large subunit nonsynonymous
61 51403 T C
7 53127 T C FIG01057005: hypothetical protein nonsynonymous
10 106855 A G Sensory histidine kinase AtoS nonsynonymous
11 4616 A G Single-stranded DNA-binding pro-tein nonsynonymous
14 17663 A G GTP-binding protein TypA/BipA nonsynonymous
15 15860 A G FIG004819: Prepilin peptidase de-pendent protein B precursor nonsynonymous
15 34683 A G
16 65330 A G L-xylulose/3-keto-L-gulonate ki-nase (EC 2.7.1.-) nonsynonymous
17 102945 A G Cell wall endopeptidase, familyM23/M37 nonsynonymous
17 117869 A G Putative amidohydrolase synonymous
17 143930 A G Rtn protein synonymous
17 164143 A G Putative uncharacterized proteinYeaK nonsynonymous
17 240500 A G Vitamin B12 ABC transporter, per-mease component BtuC synonymous
18 227304 A G Putative membrane protein synonymous
19 74778 A G oxidoreductase, aldo/keto reduc-tase family nonsynonymous
20 82805 A G Putative cell division protein pre-cursor synonymous
20 161873 A G Putative cytoplasmic protein synonymous
24 48644 A G
Multimodular transpeptidase-
transglycosylase (EC 2.4.1.129)
(EC 3.4.-.-)
synonymous
26 254549 A G hypothetical protein synonymous
28 32170 A G BarA sensory histidine kinase (VarS GacS) nonsynonymous
28 53920 A G Putative electron transfer ﬂavopro-tein subunit YgcQ synonymous
28 87481 A G Formate hydrogenlyase transcrip-tional activator nonsynonymous
30 59369 A G LysR-family transcriptional regula-tor YbeF nonsynonymous
30 134664 A G SeqA protein, negative modulatorof initiation of replication nonsynonymous
31 21929 A G
Nickel ABC transporter, periplas-
mic nickel-binding protein NikA
(TC 3.A.1.5.3)
nonsynonymous
122
5 Pathogenic and commensal Escherichia coli lineage dynamics in situ of the gut
during antibiotic treatment
Contig
number
Position 2d UTI 32d 2m1 2m2 6m1 6m2 12m Annotation Change
32 75262 A G FIG00638130: hypothetical protein nonsynonymous
37 18162 A G Protein yhjK nonsynonymous
39 100861 A G Threonine dehydratase biosynthetic(EC 4.3.1.19) nonsynonymous
3 158670 A G Exopolyphosphatase (EC 3.6.1.11) nonsynonymous
43 66383 A G Major curlin subunit precursorCsgA synonymous
4 86155 A G 3-oxoacyl-[acyl-carrier protein] re-ductase (EC 1.1.1.100) nonsynonymous
55 5078 A G Respiratory nitrate reductase betachain (EC 1.7.99.4) nonsynonymous
5 230361 A G Inner membrane protein CreD nonsynonymous
62 46866 A G Iron-sulfur cluster regulator IscR synonymous
62 59308 A G Alpha-2-macroglobulin synonymous
7 2996 A G putative lipoprotein nonsynonymous
7 55881 A G Cytochrome O ubiquinol oxidasesubunit IV (EC 1.10.3.-) nonsynonymous
9 29805 A G Protein ydgH precursor synonymous
9 31986 A G NAD(P) transhydrogenase alphasubunit (EC 1.6.1.2) synonymous
9 37980 C G Permeases of the major facilitatorsuperfamily nonsynonymous
10 192408 C T tRNA-dihydrouridine synthase C(EC 1.-.-.-) nonsynonymous
10 228596 C T Scaﬀold protein for [4Fe-4S] clusterassembly ApbC, MRP-like synonymous
10 232712 C T Fimbriae usher protein StcC nonsynonymous
10 300700 C T
Mannose-1-phosphate guanylyl-
transferase (GDP) (EC 2.7.7.22)
/ Mannose-6-phosphate isomerase
(EC 5.3.1.8)
nonsynonymous
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Supplementary Table 5.2| Table containing the SNPs from the A lineage, in-
cluding the annotation and whether the animo acid change was synonymous or non-
synonymous. The isolates from days 2, 9 and 16 are left out as they did not have any
SNP diﬀerences from the representative genome for the lineage (isolate taken at 2d).
Position pUTI89 lineage A Original amino acid Amino acid change Annotation
17995 A G G hypothetical protein
51718 G T D Y rsvB
53060 C T
68939 G A Q hypothetical protein
69562 C T Q hypothetical protein
80619 G A G D traE
91269 T G L trbC
Supplementary Table 5.3| Replicon type results from PlasmidFinder, presence in
the isolates and the corresponding plasmid. Subvariants of the replicon type from
PlasmidFinder are given in parentheses.
Lineage Isolates Identiﬁed Replicon % Identity Associated Plasmid
A all Col156 98.70 pNK29-2
A all FII(29) 99.61 pNK29-2
A all FIB(AP001918) 96.63 pNK29-2
A all X1 98.66 pNK29
A 6m2, 12m Col(IMGS31) 100.00 pNK29-3
B 32d X1 98.66 pNK29
B all p0111 98.87 not characterized
B all B/O/K/Z 93.29 not characterized
B all Col(MG828) 91.92 not characterized
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Supplementary Table 5.4| Annotations for pNK29. Annotations were done using
the RAST server, but modiﬁed to include homologous genes from pOLA52. Gene
names in square brackets indicate the name of the homologue in pOLA52.
ORF No. Start Stop Strand Annotation
1 105 650 + DNA distortion protein 1 [taxA]
2 653 1819 + IncQ plasmid conjugative transfer DNA nicking endonuclease TraR (pTi
VirD2 homolog) [taxC]
3 2172 2690 + actX, homologous to actX on pOLA52
4 2620 2832 + hypothetical protein
5 2865 3512 + Peptidoglycan hydrolase VirB1, involved in T-DNA transfer [pilx1]
6 3490 3786 + Major pilus subunit of type IV secretion complex, VirB2 [pilx2]
7 3808 6561 + ATPase provides energy for both assembly of type IV secretion complex
and secretion of T-DNA complex (VirB4) [pilx3-4]
8 6572 7330 + Minor pilin of type IV secretion complex (VirB5) [pilx5]
9 7331 7618 + IncQ plasmid conjugative transfer protein TraG
10 7627 8757 + Integral inner membrane protein of type IV secretion complex (VirB6)
[pilx6]
11 8885 9013 + pilx7, homologous to pilx7 on pOLA52
12 9003 9716 + Inner membrane protein forms channel for type IV secretion of T-DNA
complex, VirB8 [pilx8]
13 9721 10650 + Forms the bulk of type IV secretion complex that spans outer membrane
and periplasm (VirB9) [pilx9]
14 10647 11852 + Inner membrane protein of type IV secretion of T-DNA complex, TonB-like,
VirB10 [pilx10]
15 11854 12885 + ATPase provides energy for both assembly of type IV secretion complex
and secretion of T-DNA complex (VirB11) [pilx11]
16 12888 14723 + Type IV secretion system protein VirD4 [taxB]
17 14720 15133 + hypothetical lipoprotein, homologous to pOLA52
18 15130 15432 + IncN plasmid KikA protein
19 15533 16858 + Phage tail ﬁber protein
20 16887 17114 + hypothetical protein
21 17194 17712 + putative nuclease
22 17794 19056 + Cell division protein FtsH (EC 3.4.24.-
);Ontology_term=KEGG_ENZYME:3.4.24.-
23 19060 19626 + FIG01045518: hypothetical protein
24 19640 21793 + DNA topoisomerase III (EC 5.99.1.2);Ontol-
ogy_term=KEGG_ENZYME:5.99.1.2 (topB)
25 21790 21996 + Haemolysin expression modulating protein
26 22012 22473 + DNA-binding protein H-NS [hns]
27 22524 22787 + hypothetical protein
28 22898 25699 - Mobile element protein, homologous to tnpA of Tn3 pRPEC180_47
29 25670 25921 + hypothetical protein
30 26067 26624 + Mobile element protein, homologous to tnpR of pRPEC180_47 (transposon
Tn3 resolvase)
31 26807 27667 + Beta-lactamase (EC 3.5.2.6);Ontology_term=KEGG_ENZYME:3.5.2.6
32 27814 27948 - hypothetical protein
33 28012 28128 + hypothetical protein
34 28432 30354 - L. lactis predicted coding region ORF00041
35 30398 30754 + DNA distortion protein 3
36 30751 31728 - hypothetical protein
37 31753 32034 - hypothetical protein
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38 32132 32794 - Chromosome partitioning protein ParA [par]
39 33175 33819 + Resolvase [res]
40 33935 34114 - hypothetical protein
41 34145 34264 + hypothetical protein
42 34687 34803 - hypothetical protein
43 35175 35429 + hypothetical protein
44 36056 36724 + L. lactis predicted coding region ORF00041
45 36758 37204 - bis, homologous to pOLA52 (FIG01048616: hypothetical protein)
46 37244 38080 - pir, homologous to pOLA52
47 37673 38002 - YagA protein
48 38095 38310 - FIG01048886: hypothetical protein
49 38300 38545 - FIG01047979: hypothetical protein
50 38590 38913 - FIG01047054: hypothetical protein
51 39059 39340 - RelE/StbE replicon stabilization toxin
52 39330 39581 - RelB/StbD replicon stabilization protein (antitoxin to RelE/StbE)
53 39578 39751 - hypothetical protein
54 40368 40499 - hypothetical protein
55 40816 41652 + PI protein
56 41692 42138 + FIG01047678: hypothetical protein
Supplementary Table 5.5| Annotations for pNK29-3. Annotations were done using
the RAST server, but modiﬁed to include homologous genes from pIGMS31.
ORF No. Start Stop Strand Annotation
1 324 923 + hypothetical protein
2 972 2144 - MOB mobilization protein, homologous to pIGMS31
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6 Cultivation-based multiplex phenotyping of the human gut microbiota allows
targeted recovery of previously uncultured bacteria
6.1 Abstract
The human gut microbiota is linked to a variety of human health issues and impli-
cated in antibiotic resistance gene dissemination. Most of these associations rely on
culture-independent methods since it is commonly believed that gut microbiota can-
not be easily or suﬃciently cultured. Here we show that carefully designed conditions
enable cultivation of a representative proportion of human gut bacteria, enabling
rapid multiplex phenotypic proﬁling. We use this approach to determine the phyloge-
netic distribution of antibiotic tolerance phenotypes for 16 antibiotics in the human
gut microbiota. Based on the phenotypic mapping, we tailor antibiotic combinations
to speciﬁcally select for previously uncultivated bacteria. Utilizing this method we
cultivate and sequence the genomes of 4 isolates, one of which apparently belongs to
the genus Oscillibacter; uncultivated Oscillibacter strains have been previously found
to be anti-correlated with Crohn’s disease.
6.2 Introduction
The human gut microbiota is a diverse microbial environment consisting of mostly
anaerobic bacteria containing up to 1012 cells per gram of fecal matter [1]. The links
with human disease [2, 3, 4] and other health concerns such as obesity [5, 6] have made
it an important area for research. Increasing concerns about antibiotic resistance have
also led to further study in the human gut as it is an ideal environment for acquisition
and transfer of resistance genes to occur [7, 8, 9, 10]. New advances in culture-
independent methodologies to study microbial communities have revolutionized how
we study the human microbiome [1, 11], but in the process use of culture-based
approaches has declined. While culture-independent methods can address a range
of complex questions [12, 13] these approaches cannot make the deﬁnitive links to
bacterial physiology that culturing does. Consequently, there is an increasing interest
in improving culturing techniques for studying the gut microbiota.
Advances in culturing techniques include encapsulation of bacteria into micro-
droplets [14, 15], diﬀusion chambers simulating the natural environment of the sam-
ples [16, 17], microfabricated cultivation chips [18], and design of more eﬀective culture
media [19, 20, 21] with high-throughput identiﬁcation of the cultured bacteria [22].
Furthermore, there have been several studies looking at the eﬀect of using alternative
solidifying agents to agar [20, 21]. The use of combinations of media has also allowed
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sampling of a more diverse collection of bacteria. Indeed, a recent study utilizing
212 diﬀerent culturing conditions retrieved 340 bacterial species from 3 human stool
samples [23].
In spite of recent advances it remains widely believed that our ability to culture the
human gut microbiota is far from comprehensive and relies on complicated techniques
that cannot be readily implemented in most laboratories. Consequently, there remains
a need for relatively simple procedures to cultivate and characterize the human gut
bacterial community.
Here we combine novel cultivation conditions with high-throughput sequencing to
identify conditions that allow representative cultivation and multiplex phenotypic pro-
ﬁling of the gut microbiota, allowing cultivation of important previously uncultivated
species.
6.3 Results
Anaerobic cultivation retrieves a substantial part of live cells
To identify optimal anaerobic cultivation conditions for cultivating the human gut
microbiota we tested the growth of bacteria from fecal samples on 10 diﬀerent solid
media. These media were chosen to represent a range of nutrient concentrations and
several had previously been shown to have good potential for recovery of gut bacteria
[22, 24, 25]. The goal was to try to more closely represent the conditions in the
gut so a careful consideration of media components was undertaken (Supplementary
Discussion). The growth was monitored over 7 days and it was observed that the
colony count leveled out by day 3 for the majority of media (Supplementary Fig. 6.1).
One of the lower nutrient media had pronounced growth between days 5-7, suggesting
continued growth with increased incubation times. The lower nutrient media (GM1
and GM2 (M9 agar and gellan)), GM3 (GMM agar), and GM4 (GMM gellan) media
(see Supplementary Methods for complete media descriptions) also tended to have
overall lower plate counts. About half of the tested media had roughly the same
(1010) ﬁnal colony counts, although the growth patterns varied by medium. The
GM7 (modiﬁed GAM agar) medium had the highest overall plate counts. Notably,
a diﬀerence in solidifying agent (agar vs. gellan) aﬀected the growth on all media
(Supplementary Fig. 6.1).
It is commonly believed that only a minor part of the gut microbiota can be culti-
vated using any speciﬁc cultivation condition [26, 27]. To assess the extent to which
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the colony counts correlated with the number of live cells present in our samples we
determined the fraction of live cells by microscopy (Methods) in parallel to cultivation
using three independent samplings of two unrelated human adult volunteers. By de-
termining the viable cells counts over time we hoped to establish that similar counts
could be repeated in the same individual and determine if there was a large variability
between individuals. Notably, the percentage of culturable cells (plate counts/viable
cell counts) had a modest variability over time and varied between 30-40% for the two
volunteers (Fig. 6.1a). This demonstrates that a substantial fraction of the viable
bacteria in the gut microbiota can form colonies under these conditions. In contrast,
the viable cells and culturable cells only represented 44% and up to 17% of the total
cells, indicating the presence of dead or non-viable cells in the sample.
Cultivation allows representative sampling of gut microbiota
To assess the diversity of microorganisms capable of growing under our diﬀerent
cultivation conditions relative to those identiﬁed using culture-independent methods
we determined the phylogenetic diversity of bacteria grown on each of our diﬀerent
cultivation media. We ﬁrst combined multiple dilutions from each media in equal pro-
portions to better sample the microbes capable of growing on each media (Methods).
Our goal was to identify bacteria that were culturable at some point during the 7-day
growth period. We are conﬁdent that most colonies did not grow as co-cultures as vi-
sual observation showed most colonies did not appear to touch (Methods), so we don’t
anticipate that they represented a substantial proportion of the population. Colonies
were resuspended from solid media and DNA was extracted. Previous work from
Goodman et al. [22] indicated that inoculum from non-viable or non-growing cells
does not represent more than 2% of sequences recovered from scraping plates (sample
diluted 10,000-fold). Most cells we recovered were from samples diluted 100,000 to
1,000,000-fold, further decreasing the likelihood of DNA persisting through the incu-
bation period from non-growing cells. The V6 region of the 16S rRNA was ampliﬁed
and sequenced to yield phylogenetic proﬁles for each of the growth conditions. To re-
move the noise from errors in sequencing we applied a ﬁltering step during the initial
sequence processing as previously suggested for Illumina data [28] (Methods). After
ﬁltering, each unique sequence (100% similarity) was considered a phylogenetic tag
and subsequent analyses are based on these tags.
A graph of the taxonomic classiﬁcations (order level) and tag counts of each of
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Figure 6.1 | Eﬀectiveness of culturing conditions for recovery of human gut bacterial
community. (a) The percentage of viable cells that we were able to culture. It was
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Figure 6.1 continued | determined by dividing the GM7 plate counts by the trypan
blue viable cell counts. The viable cells cultured were calculated for fecal samples
obtained from two human subjects over 3 time points to show reproducibility across
time and subjects. (b) An order-level taxonomic comparison of all tested media and
the culture-independent (Cult-Ind.) sample based on tag abundance (Sample D1-T1).
The order of the taxa is by abundance of the culture-independent sample. Bacterial
taxa represented by less than 5 sequences for all samples are not displayed. (c) An
assessment of each culture media’s eﬀectiveness for the recovery of the human gut
bacterial community. The smaller the Morisita-Horn dissimilarity index (range from
0 to 1) and the larger the percentage of recovered viable cells the better the culture
media represented the culture-independent community. The x-axis represents the
Morisita-Horn index and the y-axis indicates the percentage of viable cells cultured
on each media (Sample D1-T1).
the media and culture-independent sample highlights the diﬀerences in taxonomic
representation between the samples. It was observed that 66-81% of order-level and
50-71% of family-level taxonomic groups from the total fecal sample were recovered
on the tested media (Fig. 6.1b). If all media were combined a total of 95% of order-
level and 88% of family-level taxonomic groups were recovered. It was also observed
that changing a solidifying agent increased selection (relative sequence abundance) for
certain taxa (Supplementary Fig. 6.2a). Lactobacillaceae increased in GM4 (gellan)
compared to GM3 (agar) (Supplementary Fig. 6.2b) as opposed to an increase of
Enterococcaceae in GM3 (agar) compared to GM4 (gellan) (Supplementary Fig. 6.2c).
In other cases, the nutritional components (media composition) caused a selection
as observed for Actinobacteria and Enterococcaceae, which are enriched in the GM9
(diluted modiﬁed GAM agar) and GM10 (diluted modiﬁed GAM gellan) as compared
to most other media (Supplementary Fig. 6.2d).
Ninety-three of the tags (54.4% of unique tags) from the culture-independent
sample were not represented in any culture media (Supplementary Data 1). However,
these tags made up only a minority of the total sequences (15.8%) indicating many
were of low abundance. None of these low abundance tags represented more than 2%
of the uncultivated community. As total bacterial cells in the gut are known to reach
1012 CFU/g, dead cells that would be unable to be cultured likely represent some of
the discrepancy between the methods. However, since distinct bacterial populations
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are unlikely to be composed of a single cell we would expect that most bacteria have
viable representatives within the sample. While the observance of tags unable to be
recovered by culturing was anticipated, we were able to recover tags that represented
84% of sequences (Supplementary Data 2) in the gut microbiota (uncultivated sam-
ple). Notably, these tags represented 86% of sequences in the uncultivated sample.
Recovery from individual media ranged from 68-78% (sequences). We also observed
the recovery of 113 tags in culture that were not found in the culture-independent
sample (Supplementary Data 3). The identity of these tags varied between media
and originated from a variety of taxonomic groups. Many of these tags were selected
for by multiple media and could be found in varying abundances. Not all of them
appeared to be of very low abundance. Indeed, a number of Clostridia/Clostridium
tags were among the culture-only isolates. Clostridia are well-known endospore form-
ers that can be diﬃcult to lyse in spore form [29]. These endospores may form during
passage from the body, but sporulate into vegetative cells due to more favorable cul-
ture conditions making their recovery more likely. Other taxa poorly recovered in the
total fecal sample include Staphylococcaceae and Enterococcaceae, whose thick gram-
positive cell walls can also present a barrier to extraction [30, 31]. We cannot rule
out the possibility that some variation arose due to variation in technical replicates
and because slightly diﬀerent extraction methods were used for the fecal samples vs.
the cultured samples. The results highlight that while both culture-dependent and
independent methods can broadly capture the same bacterial constituents, they also
select for distinct subsets of the gut microbiota.
We then quantiﬁed the similarity between the tags obtained from diﬀerent culti-
vation media to the community as determined using a culture-independent approach
using the Morisita-Horn index, which measures the dissimilarity in community struc-
ture. We chose this comparative index because we are not only interested in maximiz-
ing the recovery of tags shared with the uncultivated sample, but also in preserving
overall community structure. A similar community structure could indicate that
growth conditions more closely represent what is found in the gut, better represent-
ing the microbiota’s natural environment. We found that media GM5 (GAM agar),
GM6 (GAM gellan), GM7 (modiﬁed GAM agar), and GM8 (modiﬁed GAM gellan)
had average Morisita-Horn indices of 0.18 (Morisita-Horn index can range from 0 to
1), which demonstrates that the overall community architecture is well represented
in these media. This is supported by biological replicates of the culture-independent
sample showing Morisita-Horn indices of 0.12, while technical replicates had Morisita-
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Horn indices of less than 0.04 indicating homology in PCR replicates. An optimal
media would have a low Morisita-Horn index relative to the cultivation-independent
community and a high percentage recovery of live cells. Notably, media GM5, GM6,
GM7, GM8, and GM10 closely clustered to show good recovery while the remaining
media were scattered along the graph highlighting the factors causing their divergence
from the culture-independent sample (Fig. 6.1c, Supplementary Fig. 6.3). The GM4
media was clearly the worst media while several nutritionally similar media (GM5,
GM6, GM7, and GM8) were the best. The GM7 had a slightly higher recovery of
viable cells compared to the other similarly composed media (GM5, GM6, and GM8)
while maintaining a high community structure similarity to the culture-independent
sample. Further discussion on the cultivation and media is available in the Supple-
mentary Discussion.
Since human gut microbiomes across individuals and geography are highly variable
[32], the same eﬀectiveness of these media may not be reﬂected across all samples
tested. We suggest an application of this methodology to determine media appropriate
to speciﬁc studies. To show that similar recovery could be repeated across several
samples, we applied our GM7 media to compare culture-dependent and independent
samples (Supplementary Fig. 6.4). Our results demonstrate that the recovery of
taxonomic groups was repeatable both over time in the same subject and between
multiple subjects.
Cultivation-based multiplex antibiotic tolerance phenotyping
Using high-throughput sequencing of the cultured community we were able to demon-
strate that a good representation of the human gut microbiota can be cultivated on
several of our media. The use of cultivation to survey a bacterial community provides
us with the advantage of being able to link phenotypic characteristics to particular
taxa which cannot be as deﬁnitively characterized by culture-independent methods.
This method of phenotyping via culturing can be easily multiplexed to simultane-
ously look at speciﬁc phenotypic characteristics within a range of taxa within a given
microbial community, which we term cultivation-based multiplex phenotyping.
To demonstrate this, we mapped the antibiotic tolerance phenotypes of the human
gut microbiota, which demonstrates functionality (phenotypic tolerance) rather than
only observed genotypes [33]. A fecal sample from a healthy volunteer that had been
antibiotic free for the preceding year was tested against 16 diﬀerent antibiotics (Sup-
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plementary Table 1). The antibiotic concentrations targeted 2x the MICs (average) of
commensal gut bacteria (mostly Bacteroidetes, Enterococcaceae, Enterobacteriaceae,
and Lactobacillus) based on Eucast data (http://mic.eucast.org/Eucast2/). These
antibiotic concentrations are not necessarily clinically relevant, but demonstrate how
multiplex culture-based phenotyping can be applied to study microbial phenotypes.
Without antibiotic selection we recovered 1.7x1010 cfu/g, while the presence of an-
tibiotics reduced the recovery to 5.1x107- 1.5x1010 cfu/g, except for the chlorampheni-
col plates, which did not support growth (Supplementary Fig. 6.5). The antibiotics
clindamycin and metronidazole had the lowest prevalence of tolerance phenotypes
in the sampled gut microbiota varying between 0.3% and 1.1%. This is consistent
with their common use to target anaerobic bacterial infections [34]. In contrast, gen-
tamycin had the highest prevalence of tolerance phenotypes (91.4%), which is con-
sistent with previous reports highlighting its reduced capability to inhibit growth of
anaerobic and facultative anaerobic bacteria under anaerobic conditions [35, 36]. In
general tolerance phenotypes towards beta-lactams (ampicillin, cefepime, cefotaxime,
cephalexin, cefuroxime, dicloxacillin, and piperacillin) were high; on average 33% of
the recovered taxa (tags) were able to grow in the presence of various beta-lactam an-
tibiotics (calculated by determining (average counts on beta-lactam plates)/(control
plate counts)).
To assess which tags were retrieved under diﬀerent antibiotic selective pressures,
the two dilutions above the countable plate (2 replicates per dilution) were collected
and sequenced after 5 days of incubation at 37°C (see Methods). The tags were
taxonomically classiﬁed (Supplementary Data 4) and a heat map was created in R
to visualize the data (Fig. 6.2a). These mapped tags represent those that were also
recovered on control plates (bacteria making up the majority of the gut community).
This data provides a representative view of how antibiotic tolerance phenotypes are
distributed across taxonomic groups in the microbiota (Fig. 6.2b-e). A mapping of all
tags recovered as adjusted by plate count recovery (Supplementary Fig. 6.6) allows a
more accurately proportional representation of the tags recovered on each antibiotic.
The distribution of the number of tolerance phenotypes linked to a speciﬁc tag
varied widely. However, there were a large number of highly tolerant bacteria present.
Indeed 31% of the tags were linked to tolerance phenotypes towards all tested antibi-
otics (Fig. 6.2b). The recoveries of tags broadly resistant to antibiotics are most likely
associated with highly abundant tags that could comprise several bacterial species.
The taxonomic classiﬁcation of the most tolerant tags highlighted that Porphyromon-
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adaceae, Bacteroidaceae, Enterobacteriaceae, and Enterococcaceae were the most
tolerant taxa. Overall the Lachnospiraceae and Ruminococcaceae carried the least
tolerance along with a number of unclassiﬁed Firmicutes and unknown Bacteria.
This phylogenetic mapping of the antibiotic tolerance phenotypes allows a bet-
ter understanding of the tolerance levels of speciﬁc taxonomic groups in the gut
microbiota. For instance many of our tolerant tags were classiﬁed as Bacteroides
(Bacteroidetes) (Fig. 6.2c). Bacteria belonging to the phylum Bacteroidetes are
among the most abundant in the human gut making up 20-30% of the total bacteria
[9]. While there are some clinically relevant Bacteroides species (e.g. Bacteroides
fragilis) they are generally considered commensals or mutualists [37]. Interestingly,
Bacteroides have previously been associated with antibiotic resistance transfer events
[9, 38]. In this study we ﬁnd that 39% of the tags belonging to Bacteroidetes are
associated with pan-tolerance phenotypes, highlighting their potential as a reservoir
of antibiotic resistance.
Bacteria belonging to the phylum Proteobacteria, mostly Enterobacteriaceae, were
also identiﬁed as highly tolerant in our sample. Enterobacteriaceae are of lower abun-
dance in the gut, but the number of human pathogens and reports of resistance across
classes of antibiotics associated with this group make it an important target of char-
acterization [39, 40]. Consistent with these reports [8], we show that these tags are
linked to tolerance towards most antibiotics tested (Fig. 6.2d).
We also recovered many tags on the antibiotic selection plates that were not found
on the control plates (Supplementary Fig. 6.7 and 8). These likely represent bacterial
community members of lower abundance (representing minorities of the community)
that may have been missed by insuﬃcient sequencing depth or sampling. However, an-
tibiotics capable of reducing or suppressing growth of abundant strains could select for
these less abundant populations provided they could grow in the presence of the antibi-
otics. Among those drugs that recovered more rare tags were those that reduced the
growth of highly abundant Bacteroidaceae (Bacteroides) and/or Enterobacteriaceae
populations (erythromycin, sulfamethoxazole, and ciproﬂoxacin) (Supplementary Fig.
6.7 and 9). These types of antibiotics could potentially be used to enrich cultivation
for certain lower abundance populations of interest, as the medium itself was not the
limiting factor in culturing these organisms. Indeed a previous study looking at the
eﬀect of ciproﬂoxacin treatment on human gut bacteria showed less perturbation in
Lachnospiraceae and Clostridiales with treatment [41], supporting our enrichment for
these groups on ciproﬂoxacin plates.
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It should be noted that this technique is not able to distinguish between bacteria
with intrinsic tolerance traits and transferable elements. Also, the association of a
single tag with 15 tolerances doesn’t mean that all bacteria with the same sequence
carry all 15 tolerances. There are likely subpopulations of cells that only carry a
fraction of the tolerance traits, but when looking at the total population of that
particular tag at least one cell has tolerance to each of the antibiotics where tolerance
was observed. Population-based resistance mechanisms, as demonstrated in E. coli
communities [42], could also provide bacteria with protection from antibiotics without
themselves carrying any tolerance traits.
Recovery of uncultivated bacteria using phenotypic mapping
To demonstrate the ability to enrich for subpopulations and recover speciﬁcally tar-
geted taxa containing previously uncultured bacteria, a frozen sample of mixed bac-
teria preserved from antibiotic phenotyping plates (ciproﬂoxacin, sulfamethoxazole,
and erythromycin) and a fresh sample from the same human subject were anaerobi-
cally cultured on antibiotic selective media (Methods). Using the Human Microbiome
Project’s (HMP) Most Wanted List http : //hmpdacc:org/most_wanted/ as a guide
we tailored a combination of antibiotics based on the phenotyping data (Supplemen-
tary Fig. 6.9) to select for those taxa listed, speciﬁcally targeting Odoribacter, Oscil-
libacter, Ruminococcus, and Faecalibacterium (Fig. 6.3a). One hundred ninety-two
individual colonies were screened via 16S Sanger sequencing to determine their iden-
tity. A total of 106 sequences were retrieved with 26 unique isolates identiﬁed. Five of
those isolates had 95% or less identity to previously cultured isolates (Supplementary
Data 5).
Genomic sequencing was performed on 4 of the 26 recovered isolates (2 of those
with identities of less than 95% to a cultured isolate) and MIC testing was done to
conﬁrm the previously collected phenotyping data (Fig. 6.3b-e). The eﬀectiveness of
combining antibiotics to selectively culture isolates of interest can be clearly demon-
strated with the increased recovery of the targeted genera (Eubacterium and Blautia)
(Fig. 6.3c+d) or strains (P1C2 and P2C1) (Fig. 6.3b+e) when antibiotic combina-
tions are used vs. single drugs. Genomic sequencing conﬁrmed that two of these
genomes had 16S rRNA identities of less than 95% to previously cultured bacteria
suggesting they are likely to be new species. Isolates P1C2 and P1G4 had a high sim-
ilarity (>99%) to previously cultured isolates Intestinimonas butyriciproducens and
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Figure 6.3 continued | Human Microbiome Project’s (HMP) Most Wanted List).
Particular antibiotics (e.g. Ciproﬂoxacin (Cip), Erythromycin (Ery), Sulfamethoxa-
zole (Sulfa)) preferentially select for bacterial taxa that have few cultured isolates
as compared with non-selection (Control). Combining antibiotics helps to further
narrow the recoverable bacteria by exclusion of strains susceptible to both antibiotics.
Therefore, particular combinations of drugs (e.g. Cip and Ery) are able to increase
the recovery of strains that belong to poorly cultured taxa (such as HMP’s Most
Wanted List). (b-e) The 4 bacteria cultivated and genome sequenced based on mul-
tiplex phenotyping. The isolate name, genome size, and closest similarity (16S) to
a previously cultured bacterium are indicated. A graph of the percentage of bacte-
ria from either a speciﬁc isolate (b+e) or the genera Eubacterium (c) and Blautia
(d) recovered on culture plates with a single antibiotic vs. a combination of antibi-
otics demonstrates successful targeted recovery based on phenotyping data. The MIC
data on ciproﬂoxacin, erythromycin, and sulfamethoxazole tolerance for each of the
4 sequenced isolates is also reported. (f-g) The four genomes mapped to publically
available MetaHIT metagenome data to determine their percentage genome coverage
and abundance. For the box plots, the whisker bars span the minimum to maximum
values while the box deﬁnes the 1st quartile, the median, and the 3rd quartile. The
blue diamond denotes the mean. (f) The genome coverage represents the percent-
age of each of the 4 genomes that is covered by at least one read among MetaHIT
metagenomes. (g) The abundance represents the total percentage of the metagenomes
represented by each of the 4 sequenced genomes.
Blautia producta. Our novel isolates were most closely related to species Eubacterium
contortum (94.8% similarity) (P1C11) and Oscillibacter ruminantium (93% similar-
ity) (P2C1). The abundance of these isolates in the uncultivated library was very low
or undetected (Supplementary Table 2). RAST [43] annotations indicated that all
bacteria carried multiple antibiotic resistance genes conferring resistance to aminogly-
cosides, streptothricin, vancomycin, tetracycline, beta-lactams, ﬂuoroquinolones, and
multidrug eﬄux pumps.
To assess the abundance of these new isolates in gut metagenomes we mapped
the reads from the publicly available MetaHIT [44] data to the sequenced genomes.
We ﬁrst determined what percentage of each of our genomes was covered in the
MetaHIT samples and then quantiﬁed the overall abundance of the four genomes
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within the MetaHIT metagenomes (Fig. 6.3f+g). Isolates P1C2, P1C11, and P1G4
had low genome coverage and abundance among the MetaHIT data which might
suggest they are of low abundance or these particular isolates are not ubiquitous to
the human microbiome. However our Oscillibacter-like isolate had a high percentage
of coverage across the MetaHIT samples (43% average) and abundances of up to 1.36%
in some metagenomes. Metagenomic data has suggested the existence of 19 species of
Oscillibacter without a reference genome [45]. Genome comparisons in RAST of our
Oscillibacter-like isolate (P2C1) to Oscillibacter ruminatium GH1, our Intestinimonas
butyriciproducens isolate (P1C2), an unrelated gut microbe Biﬁdobacterium animalis
subsp. lactis AD011, and a non-gut organism Geobacillus thermodenitriﬁcans NG80-2
were undertaken to determine if there were any regions of high sequence homology
between isolates (Supplementary Figure 10). Surprisingly the I. butyriciproducens
isolate had more regions of high homology than the O. ruminantium GH1 genome, but
we are unable to speculate on functional similarities as they were mainly hypothetical
proteins. Uncultured Oscillibacter have been previously associated as responders to
dietary change and as depleted in patients suﬀering from Crohn’s disease [46, 47].
The ability to cultivate such organisms and study their physiology will contribute to
our understanding of gastrointestinal disorders and devising treatment strategies.
6.4 Discussion
It is commonly believed that cultivation-based approaches are only able to capture
a small part of organisms within the gut microbiota. Yet, our study has identiﬁed
factors that can successfully help recover a representative fraction of the bacterial
communities found in the human gut using techniques that can be readily imple-
mented in most labs. Optimized cultivation procedures allow for multiplex mapping
of phenotypes by directly coupling selective culture conditions with phylogenetic tag
sequencing. In this way we surveyed the prevalence of antibiotic phenotypes in the
human gut microbiota. The tolerances can be directly linked to speciﬁc taxa and
provide useful phenotypic information that cannot readily be derived from culture-
independent studies. We sampled a substantial proportion of the cells (1010) in the
human gut microbiota and were able to identify both common and rare tolerances.
In this way we were able to detect a variety of taxonomic groups and assess the
phylogenetic distribution of antibiotic tolerance phenotypes.
Cultivation-based multiplex phenotyping is a quick and easy way to screen for
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antibiotic tolerance and look for tolerance patterns in human gut bacteria and should
be a useful approach for studying the response to antibiotic treatment of the gut
microbiome as well as illuminate possible risk factors predisposing individuals for
antibiotic-associated diarrhea and other diseases.
Antibiotic tolerance phenotyping constitutes one useful application of cultivation-
based multiplex phenotyping; however, this approach also has the potential to be
used to identify substrate-speciﬁc utilization phenotypes as well as other tolerance
phenotypes, including tolerance towards bile salts or high/low pH. This methodology
could also be modiﬁed and applied to other environments such as soil or water to
characterize phenotypic traits of interest. Notably, direct phenotyping can identify
phenotypic characteristics, which cannot be as deﬁnitively characterized on a genetic
basis and linked to speciﬁc bacteria using culture-independent methods.
Finally, mapping the antibiotic tolerance proﬁles among bacteria in the gut allowed
us to target the recovery of speciﬁc taxa with previously uncultured isolates. As a
proof of concept we identiﬁed 4 isolates, 2 of them novel species. One of these isolates
appears to be a novel species of Oscillibacter; uncultivated strains belonging to this
genus are signiﬁcantly reduced in patients suﬀering from Crohn’s disease. The ability
to cultivate novel species with potential health beneﬁts could be of interest to the
probiotics industry and facilitate the development of novel probiotic supplements.
6.5 Methods
Sample Collection
All fecal samples were collected from 2 healthy adult human donors that had not
taken antibiotics in the past year. One donor (D1) supplied three samples (T1, T2,
T3), while the other donor (D2) supplied four samples over time (T1, T2, T3, T4).
Sample D1-T1 was utilized for the initial media culture comparison, samples D1-T2
and all D2 samples were used to conﬁrm reproducibility of culturing results, sample
D1-T2 was used for the antibiotic tolerance phenotyping, and samples D1-T2 (frozen
cultivated sample) and D1-T3 for directed recovery of bacteria. Consent was gained
from all participants and proper ethical guidelines (Hvidovre Hospital) were followed
throughout the study. Samples were transported to an anaerobic chamber within 5
minutes of collection. Five grams was separated out for culturing and 2.5 grams was
collected for total DNA extractions. The remaining sample was stored at -80°C.
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Media
The complete compositions of all media are listed in the Supplementary Methods.
Cultivation, Viable Cell Counts, and DNA Extraction All manipulations were per-
formed in a Type B Vinyl Anaerobic Chamber (Coy Lab Products) ﬁlled with an
atmosphere of 95% nitrogen and 5% hydrogen.
Five grams of fecal sample was homogenously resuspended in 50 mL of 1X PBS
that had been pre-reduced with resazurin (0.1 mg/mL). Ten-fold serial dilutions were
performed to 10-9. Fifty µL of the 10-3, 10-4, and 10-5 dilutions were combined in
equal proportion with 0.4% trypan blue. The countable dilution was identiﬁed and
a hemocytometer and light microscope were used to perform a viable cell count in
the anaerobic chamber. Viable cells counts were done in triplicate for each sample
(per time point), and viable counts were performed three separate times for the same
individual to make sure that recovery counts were consistent over time. The samples
utilized for the viable cell counts included D1-T1, D1-T2, D1-T3, D2-T1, D2-T2, and
D2-T3. Total cell counts were also performed on two samples from D1 to determine
the fraction of cells that were not viable and/or culturable. We never observed the
culturable cells as a higher number than the viable or total cells.
One hundred microliters of the serial dilutions were plated in 5 replicates on each
of the 10 media (Supplementary Methods) to be tested. Seven to twelve sterile glass
beads were used to spread the liquid on the plates through even shaking. Plates were
anaerobically incubated at 37°C for 7 days. Plate counts were conducted each day to
track the growth over time. On day 7, 3 dilutions, consisting of the countable dilution
(between 25-250 colonies) and the dilutions above and below it, were chosen to select
for a variety of plate crowding conditions (exceptions occurred for the Minimal and
GMM media, where 4 dilutions were collected to accommodate lower overall plate
counts). None of the plate dilutions utilized represented a situation where a lawn
was formed or the plate would not be able to be counted. While it is not possible
to conﬁrm that all colonies scraped oﬀ the plates grew as individual colonies rather
than co-cultures, the visual observations of the plates indicated that most colonies
did not appear to touch. Further evidence to support this observation is that 95% of
individual colonies picked into 96-well plates (see below) from dilution plates resulted
in the identiﬁcation of a single species. These dilutions were manually scraped oﬀ the
media surface following a rinse with 5 mL 1x PBS and collected into 10 mL tubes.
The collected tubes were centrifuged at 5000 x g for 30 minutes and remnants of solid
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media were carefully removed from the pelleted samples. The pelleted samples were
then extracted as individual dilutions (except Minimal and some GMM dilutions)
using the MoBio UltraClean Microbial DNA Isolation kit.
The uncultivated total fecal sample was extracted using 2.5 grams of sample and
the MoBio PowerMax Mega Soil DNA Isolation kit.
PCR and Sequencing
Extracted DNA was diluted to 5 ng/µL for all samples in order to keep quantities con-
stant for the ampliﬁcation step. PCR was performed using 1x Phusion High-Fidelity
PCR Master Mix and tagged Illumina primers (10 µM concentration) in 30 µL reac-
tions targeting the hypervariable V6 region (positions 969-1046) (primer and barcode
sequences listed in Supplementary Data 6). Illumina overhangs (100 µM concentra-
tion) were attached in a second PCR reaction by combining barcoded samples in
equal amounts as template for amplifying multiple 30 µL reactions. Thermocycling
conditions for both PCR steps were as follows: initial denaturation 98°C for 1 min,
followed by 30 cycles of 98°C for 10 sec, 65°C for 30 sec, and 72°C for 30 sec, and a
ﬁnal elongation at 72°C for 5 min. PCR product sizes were conﬁrmed at each step
and the ﬁnal PCR product was gel puriﬁed using the Qiaex II Gel Extraction Kit
(Qiagen). The samples were sequenced on an Illumina MiSeq.
Sequence Quality Control and Processing
Sequence quality control, processing, and analysis was performed using a modiﬁed
version of the sequence quality control and analysis protocol [48] recommended for
mothur (version 1.30.2) [49]. To pass the initial quality control, the sequence needed
to (i) perfectly match the barcode, forward primer, and last 15 bases of the reverse
primer, (ii) have a rolling window quality of 30 (rolling window size of 25); the se-
quences were truncated where they fell below quality window (iii) contain no ambigu-
ous bases, (iv) have homopolymers of no more than 8 bases, and (v) have a minimal
length of 60 bp [28, 48, 50]. Sequences that did not align along the same region
(full V6) based on the Silva alignment were removed from the analysis. Sequences
only occurring a single time (more than 50% of the unique sequences) were removed
following the alignment step to denoise and reduce the dataset for further processing.
The reverse primer and all but 4 bases of the forward primer were removed from the
sequences. The 4 bases of the forward primer were kept as a reference to conﬁrm
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correct alignment throughout the analysis. A pre-clustering step in mothur (1 bp
diﬀerence) was performed as recommended to reduce tag number inﬂation due to
sequence errors [51]. Samples were checked for chimeras using UCHIME [52] and
sequences identiﬁed as non-bacterial or unknown (80% cutoﬀ) were removed from
further analysis. Sequences were then compared at a 0% diﬀerence (unique) cutoﬀ,
giving each unique sequence its own taxonomic signature, which we refer to as a ”tag”.
Sequences from multiple dilutions recovered from each media type were combined in
equal proportions to better represent recovery from each media (e.g. For example,
the sequences from the 3 GM5 dilutions (D5, D6, D7) were combined in equal propor-
tion to represent the GM5 media). For each group of samples analyzed together, the
sequences were sub-sampled (36040 for media comparison and 15450 for antibiotic
phenotyping) to equalize the number of sequences per sample and rare sequence re-
moval cutoﬀ was established at 0.0166% abundance (abundance of 5 or less for 30000
sequences). Total tags and Morisita-Horn indices were calculated in mothur. BIOM
ﬁles created in mothur were exported to MEGAN [53] to visualize taxonomic classiﬁ-
cations on a family level and taxonomic classiﬁcation and abundances as deﬁned in
mothur were used to construct further taxonomic graphs. Sequence abundance data
and taxonomic classiﬁcations were used to create heat maps in R.
Culturing of Antibiotic Tolerant Bacterial Community
One hundred microliters of the serial dilutions were plated in 2 replicates on GM7
agar containing one of 16 antibiotics. The GM7 medium was chosen for the antibiotic
tolerance testing because cultivation of samples on this medium showed good similar-
ity to the uncultivated sample and because gellan-containing media has not yet been
shown eﬀective for antibiotic susceptibility testing. The selected antibiotic concen-
trations were based on Eucast data (http://mic.eucast.org/Eucast2/) of commensal
gut bacteria, (mostly Bacteroidetes, Enterococcaceae, Enterobacteriaceae, and Lacto-
bacillus), and were aimed for 2x higher than MICs (Supplementary Fig. 6.5). Seven
to twelve glass beads were used to spread the liquid on the plates through even shak-
ing. Plates were anaerobically incubated at 37°C for 5 days. These dilutions were
manually scraped oﬀ the media surface following a rinse with 5 mL 1x PBS and col-
lected into 10 mL tubes. One mL of the collected sample was centrifuged at 5000 x g
for 30 minutes and remnants of solid media were carefully removed from the pelleted
samples. DNA was then extracted from pelleted samples using the MoBio Ultra-
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Clean Microbial DNA Isolation kit. The remaining 9 mL of the collected colonies was
preserved at -80°C in 10% glycerol stocks.
Anaerobic Cultivation of New Bacterial Isolates
Frozen stocks of bacterial colonies (100 ’l) previously scraped oﬀ ciproﬂoxacin, sul-
famethoxazole, and erythromycin plates were plated in duplicate serial dilutions on
GM7 media containing either erythromycin or sulfamethoxazole (concentrations as
above). A fresh fecal sample from the same subject was used to make serial dilu-
tions in duplicate on erythromycin and control (no antibiotics) plates. Plates were
incubated anaerobically at 37°C for 5 days.
Ninety-six colonies from the frozen samples and 96 colonies from the fresh sample
were freshly isolated on new media. Colony PCR was performed on the 16S rRNA re-
gion for the two 96-well plates using primers 8F (5’-AGAGTTTGATCCTGGCTCAG-
3’) and 1391R (5’-GACGGGCGGTGTGTRCA-3’) and Sanger sequenced using the
forward primer. The sequences were quality control processed in CLC Main Work-
bench, and BLAST [54] and EzBioCloud [55] were used to identify the sequences.
A total of 26 unique sequences were identiﬁed and the closest match to a cultured
reference sequence was determined (Supplementary Data 5).
Genome Sequencing, Processing, and Analysis
Bacteria to be genome sequenced were anaerobically grown up in GAM broth for
1-3 days at 37°C. DNA from these bacteria was isolated using the MoBio UltraClean
Microbial DNA Isolation Kit, genome sequence libraries were constructed using the
Nextera DNA Sample Preparation Kit, and sequencing was performed on an Illumina
MiSeq (150 bp paired-end reads). Genome assembly was done using Velvet (v1.09)
[56], and contigs that were less than 500bp or with less than 3X coverage were ﬁltered.
The range of kmer values used were 93-125, and the assembly providing the best
N50 score was used. Annotation of the assembled genomes was done using RAST
[43]. RAST was also used to generate genome sequence comparisons between several
isolates and publically available genomes.
Additionally, the high quality reads from the MetaHIT project [44] were aligned
to each of the assembled genomes. Read alignment was done using Bowtie2 (v2.1.0)
[57], with processing of the alignment ﬁles was done using SAMTools (v0.1.19) [58].
Coverage and sequencing depth of the aligned reads was assessed using BEDTools
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(v2.17.0) [59]. The abundance of each assembled genome in the MetaHIT samples
was calculated as the number of reads that aligned to the genome divided by the total
number of reads.
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6.8 Supplementary Discussion
Choosing an eﬀective media for human gut bacteria
To choose cultivation media for this study, we utilized previous research to determine
which media could eﬀectively recover anaerobic human gut communities. These media
represented diﬀerent nutritional conditions and made use of multiple solidifying agents.
Space is often a limitation in anaerobic studies, so high-throughput (short incubation
times) potential was also considered, as it can be a key factor in determining the
depth and breadth of studies.
Variations in the recovery of bacteria was observed across both diﬀerent nutritional
components and solidifying agents. While no single media recovered all the observed
diversity, particular media better represented the bacterial community recovered from
the uncultivated fecal sample.
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Minimal Media (GM1 and 2)
In this study, the use of M9 minimal media (GM1 and 2) served as a baseline media
with an expected low recovery as it is composed of only the essential components for
the growth of bacteria with simple nutritional requirements. To try and encourage
growth of slightly more fastidious organisms it was supplemented with additional vita-
mins and minerals, some of which would normally be available in the gut environment.
As expected, lower plate counts and greater dissimilarity to the uncultivated sample
was observed in this study.
GMM Media (GM3 and 4)
GMM (Gut Microbiota Medium) (GM3 and 4) is a recently devised media [1] that is
a diluted form of tryptone-glucose-yeast supplemented (TGYS) media with modiﬁca-
tions. It is a complex media containing multiple energy sources, including carboxylic/-
fatty acids, vitamins, minerals, and supplements such as hematin and is formulated
for the growth of gut microbes. Overall the GMM was not best performer in this
study, particularly the gellan, as it vastly diverged in similarity to the uncultivated
sample. The lower plate counts and domination by Lactobacillaceae suggested that
gellan might have reacted with a media component to make it more selective. In
the original study [1], GMM agar applied to human fecal samples in vitro recovered
70% of the genera found in an uncultivated sample. While the diﬀerences in recov-
ery observed between that study and ours might be partially due to diﬀerences in
the sample participants’ microbial communities, we believe that much of the varia-
tion originates from how the sequences were clustered in the analysis. We utilized
a ’tag’ level clustering which required that the sequences have the same nucleotide
sequence (100% similarity) to be considered present in compared samples, while in
the Goodman et al. paper [1] they clustered at 97% and evaluated their recovery
based on the sequences belonging to the same taxonomic classiﬁcation (e.g. genera,
family, ect.). We also evaluated our recovery based on more than a presence/absence
measure by taking into account the structure of the recovered communities. Using
their comparative methods, we observed that we could recover 81% of order-level and
71% of family-level taxonomic groups using GMM agar, which is more similar to their
results.
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GAM and MGAM Media (GM5, 6, 7, 8)
Gifu and modiﬁed Gifu anaerobe media (GAM and MGAM) (GM5, 6, 7, 8) are
commercially available media principally used in anaerobic clinical and antibiotic
susceptibility testing [2, 3]. The modiﬁed version contains diluted components and
extra amino acids, vitamin K, and hemin, but both are complex media with a variety
of energy sources. They have been used in a small number of studies [4, 5] and recently
applied to recover novel bacteria from human fecal samples [6, 7, 8]. A large-scale
study of their eﬀectiveness had not been previously undertaken. In this study these
media recovered the highest plate counts and had the best maintenance of community
structure, suggesting its usefulness in cultivation of human fecal samples.
Diluted GAM Media (GM9 and 10)
Diluting media has been shown to select for previously uncultivated bacteria [9, 10] as
it is thought that high nutrient media may exclude cultivation of many slower growing
organisms [11]. Diluted versions of modiﬁed GAM (DMGAM) (GM9 and 10) with
1/10 the concentration of all nutrients was created to test this idea. Although the
diluted version of the agar (GM9) showed less similarity to the uncultivated sample
than the other GAM media, the DMGAM did recover more unique tags than the
undiluted version (MGAM), supporting that lower nutrient media can help recovered
greater diversity.
Solidifying Agents
While agar remains the standard solidifying agent for culture media, there has been
increasing interest in alternatives such as gellan. Studies have shown that some bac-
teria recovered on gellan cannot be grown on agar even if the media’s nutritional
composition is the same [12, 13]. It has also been observed that gellan sometimes has
the eﬀect of accelerating colony formation [12]. However, we saw a more gradual in-
crease in colony counts over time for gellan-containing media. A previous bacterial soil
study found that gellan recovered higher numbers of viable cells, but did not change
diversity [14]. We did not observe the same eﬀect in our study in the human gut;
rather we observed that the eﬀect of gellan was media-dependent. Gellan-containing
media in this study did not capture a greater number of tags overall, but they did
tend to capture a diﬀerent subset of tags than found in in agar-containing media. It
is not yet completely understood why gellan can change bacterial recovery, but our
158
6 Cultivation-based multiplex phenotyping of the human gut microbiota allows
targeted recovery of previously uncultured bacteria
observations along with previous studies [12] suggest a media and/or environmental-
dependent growth modulation. Gellan had not been previously utilized for human
gut culturing, but this study has shown its eﬀectiveness in this untested environment.
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6.10 Supplementary Methods
Media Recipes
Minimal Media (Supplemented) (1 L)
Disodium phosphate 6.78 g
Monopotassium phosphate 3 g
Sodium chloride 0.5 g
Ammonium chloride 1 g
ATCC Vitamin Mix 4 mL
ATCC Mineral Mix 4 mL
Sugar Mix (50 mM stock) 4 mL
-Arabinose L(+)
-Galactose D(+)
-Glucose D(+)
-Maltose D(+)
Vitamin K (1 mg/mL) 400 L
Casamino Acids (20% stock) 4 mL (Final Concentration 0.1%)
Agar/Gellan 12 g
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Gut Microbiota Media (adjust pH to ±7.0 before autoclaving) (1 L) (Goodman et al.,
2011)
Component Amount/L Concentration Comments
Tryptone Peptone 2 g 0.20%
Yeast Extract 1 g 0.10%
D-glucose 0.4 g 2.2 mM
L-cysteine 0.5 g 3.2 mM
Cellobiose 1 g 2.9 mM
Maltose 1 g 2.8 mM
Fructose 1 g 2.2 mM
Meat Extract 5 g 0.50%
KH2PO4 100 mL 100 mM 1M stock solution pH 7.2
MgSO4-7H20 0.002 g 0.008 mM
NaHCO3 0.4 g 4.8 mM
NaCl2 0.08 g 1.37 mM
CaCl2 1 mL 0.80% 0.8g/100mL stock
Vitamin K (menadione) 1 mL 5.8 mM 1 mg/mL stock solution
FeSO4 1 mL 1.44 mM 0.4 mg FeSO4/mL stock solution
Histidine Hematin Solution 1 mL 0.10% 1.2 mg hematin/mL in 0.2M histidine
Tween 80 2 mL 0.05% 25% stock solution
ATCC Vitamin Mix 10 mL 1%
ATCC Trace Mineral Mix 10 mL 1%
Acetic acid 1.7 mL 30 mM
Isovaleric acid 0.1 mL 1 mM
Propionic acid 2 mL 8 mM
Butyric acid 2 mL 4 mM
Resazurin 4 mL 4 mM 0.25 mg/mL stock solution
Noble Agar/Gellan 12 g 1.20%
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GAM (Final pH ±7.1) (1 L)
Peptone 10.0 g
Soya Peptone 3.0 g
Proteose Peptone 10.0 g
Digested Serum 13.5 g
Yeast Extract 5.0 g
Meat Extract 2.2 g
Liver Extract 1.2 g
Dextrose 3.0 g
Potassium Dihydrogen Phosphate 2.5 g
Sodium Chloride 3.0 g
Soluble Starch 5.0 g
L-Cysteine Hydrochloride 0.3 g
Sodium Thioglycollate 0.3 g
Agar/Gellan 15 g
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Modiﬁed GAM (Final pH ±7.3) (1 L)
Peptone 5.0 g
Soya Peptone 3.0 g
Proteose Peptone 5.0 g
Digested Serum 10.0 g
Yeast Extract 2.5 g
Meat Extract 2.2 g
Liver Extract 1.2 g
Dextrose 0.5 g
Soluble Starch 5.0 g
L-Tryptophan 0.2 g
L-Cysteine Hydrochloride 0.3 g
Sodium Thioglycollate 0.3 g
L-Arginine 1.0 g
Vitamin K1 5 mg
Hemin 10 mg
Potassium Dihydrogen Phosphate 2.5 g
Sodium Chloride 3.0 g
Agar/Gellan 15g
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Diluted Modiﬁed GAM (Final pH ±7.3) (1 L)
Peptone 0.5 g
Soya Peptone 0.3 g
Proteose Peptone 0.5 g
Digested Serum 1.0 g
Yeast Extract 0.25 g
Meat Extract 0.22 g
Liver Extract 0.12 g
Dextrose 0.05 g
Soluble Starch 0.5 g
L-Tryptophan 0.02 g
L-Cysteine Hydrochloride 0.03 g
Sodium Thioglycollate 0.03 g
L-Arginine 0.1 g
Vitamin K1 0.5 mg
Hemin 1 mg
Potassium Dihydrogen Phosphate 0.25 g
Sodium Chloride 0.3 g
Agar/Gellan 15g
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Wolfe’s Mineral Solution (ATCC)
Add nitrilotriacetic acid to approximately 500 ml of water and adjust to pH 6.5 with
KOH to dissolve the compound. Bring volume to 1.0 L with remaining water and
add remaining compounds one at a time.
Nitrilotriacetic acid 1.5 g
MgSO4 . 7H2O 3.0 g
MnSO4 . H2O 0.5 g
NaCl 1.0 g
FeSO4 . 7H2O 0.1 g
CoCl2 . 6H2O 0.1 g
CaCl2 0.1 g
ZnSO4 . 7H2O 0.1 g
CuSO4 . 5H2O 0.01 g
AlK(SO4)2 . 12H2O 0.01 g
H3BO3 0.01 g
Na2MoO4 . 2H2O .0.01 g
Distilled water 1.0 L
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6.11 Supplementary Information
Supplementary Table 6.1 | A list of the antibiotics used in this study and their
drug classes
Antibiotic Drug Class
Ampicillin (Amp) Penicillin (Broad-spectrum)(Beta-lactamase)
Cefepime (Cefe) Cephalosporin (4th Gen.) (Beta-lactamase)
Cefotaxime (Cefo) Cephalosporin (3rd Gen.) (Beta-lactamase)
Cephalexin (Ceph) Cephalosporin (1st Gen.) (Beta-lactamase)
Cefuroxime (Cefu) Cephalosporin (2nd Gen.) (Beta-lactamase)
Chloramphenicol (Clm) None (Bacteriostatic, Broad-spectrum)
Ciproﬂoxacin (Cip) Fluoroquinolone
Clindamycin (Clinda) Lincosamide
Dicloxacillin (Diclox) Penicillin (Narrow-spectrum) (Beta-lactamase)
Erythromycin (Ery) Macrolide
Gentamycin (Genta) Aminoglycoside
Metronidazole (Metro) Nitromidazole
Piperacillin (Pip) Penicillin (Extended-spectrum)(Beta-lactamase)
Sulfamethoxazole (Sulfa) Sulfonamide
Tetracycline (Tet) Tetracycline
Vancomycin (Vanc) Glycopeptide
Supplementary Table 6.2 | The percentage of the total library that each of the 4
sequenced genomes represented in the uncultivated samples that they were isolated
from
Sequenced Genome Isolate Represented % in the Uncultivated Libraries
P1C2 0.01%
P1C11 0.08%
P1G4 Not Detected
P2C1 0.17%
6.11 Supplementary Information 167
Supplementary Figure 6.1 | Plate counts of bacteria on various media. Plate
counts of 10 tested media collected daily over 7 days of anaerobic growth at 37°C
(These counts represent a single subject and sample (D1-T1)). The lines are the
average of 5 replicates with standard error of mean (s.e.m.). Some points have no
discernable error bars due to low replicate variability. Circles represent agar as a
solidifying agent while squares indicate gellan as a solidifying agent.
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Supplementary Figure 6.2 | Taxonomic identity and relative abundance of re-
covered bacteria. (a) The heat map shows a family-level taxonomic comparison of
the media based on relative sequence abundance and the culture-independent sample
(Cult-Ind) (from Sample D1-T1). Bacteria unclassiﬁed at a family level or repre-
sented by less than 10 sequences are not shown. The order of the taxa is by total
abundance of the taxonomic group over all samples. The abundance is shown on a
square root scale. (b-d) Examples of taxonomic groups that were enriched for by
a solidifying agent (b) Lactobacilliaceae (GM4 (gellan)), (c) Enterococcaceae (GM3
(agar)) or by media nutritional composition (d) Actinobacteria and Enterococcaceae
(GM9 and GM10).
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Supplementary Figure 6.3 | Nonmetric Multidimensional Scaling of Morita-Horn
Indices. A Nonmetric Multidimensional Scaling (NMDS) graph calculated in mothur
comparing the relatedness of all the tested culture media (Sample D1-T1 (GM1-
10)) and the culture-independent sample (Cult-Ind). A replicate of the culture-
independent sample (Cult-Ind2) reﬂects the variability in independent extractions
(biological replicate) from the same sample. The R-squared for the conﬁguration
was 0.96 and the stress was 0.10 for 2 dimensions. Unﬁlled circles represent media
containing agar while squares represent gellan-containing media.
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Supplementary Figure 6.4 | Repeatability of Culture Media Recovery. An order-
level taxonomic comparison showing the relatedness of several samples cultured on
GM7 media and their corresponding culture-independent samples (D indicates the
donor, C or U indicates cultured or uncultivated, and T indicates sample number)
based on relative tag abundance. Bacterial taxa represented by less than 5 sequences
for all samples are not represented on the graph.
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Supplementary Figure 6.5 | Antibiotic tolerance phenotyping plate counts. The
total number of bacteria recovered on each of the antibiotic plates and the control
plates. These values are the average of 2 replicate plates. The concentration of most
antibiotics in the media was determined by using Eucast to determine MIC concentra-
tions for bacteria recovered from the human gut. A concentration was chosen which
had a 2x minimum inhibitory concentration (MIC) for the majority of commensal
organisms (excluding high intrinsically resistant organisms).
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Supplementary Figure 6.6 | Total antibiotic tolerance phenotyping heat map as
adjusted by plate count recovery. Heat map of the tags recovered from GM7 contain-
ing antibiotics and plates with no antibiotics (control). The heat map is sorted by
taxonomic classiﬁcations and increasing number of tags is indicated by darker shades
of gray. The highest level of classiﬁcation was reported. Tag abundances were ad-
justed based on the recovery of bacteria from plate counts to more accurately reﬂect
the comparable diversity from each antibiotic. Antibiotic abbreviations are available
in Supplementary Table 6.1.
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Supplementary Figure 6.7 | Antibiotic tolerance distributions in minority gut
bacterial populations. Heat map of the tags making up the minority of cells within
the gut community (tags not found in control). The heat map is sorted by taxonomic
classiﬁcations and increasing number of tags is indicated by darker shades of gray.
The highest level of classiﬁcation was reported. Tag abundances were calculated by
proportion of sequences recovered by each antibiotic or control sample. Antibiotic
abbreviations are available in Supplementary Table 6.1.
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Supplementary Figure 6.8 | Recovered tags in the minority gut bacterial commu-
nity. The numbers of tags recovered for each antibiotic in the minority gut bacterial
communities (those not recovered on control plates). Antibiotic abbreviations are
available in Supplementary Table 6.1.
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Supplementary Figure 6.9 | Total antibiotic tolerance phenotyping heat map.
Heat map of the tags recovered from GM7 containing antibiotics and plates with
no antibiotics (control). The heat map is sorted by taxonomic classiﬁcations and
increasing number of tags is indicated by darker shades of gray. The highest level
of classiﬁcation was reported. Tag abundances were calculated by proportion of se-
quences recovered by each antibiotic or control sample. Antibiotic abbreviations are
available in Supplementary Table 6.1.
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Supplementary Figure 6.10 | Genome Similarity Comparisons. A comparison of
the similarity of 4 publically available genomes to the sequenced genome of our P2C1
(Oscillibacter-like) isolate. The similarity calculations and mappings were generated
in RAST.
CHAPTER 7
Conclusion and
Perspectives
In this thesis, the genome dynamics of co-existing Eschericia coli lineages in situ of
the infant gut were investigated. In the ﬁrst set of isolates, where the infant was not
exposed to antibiotics, we discovered that a conjugative plasmid harbouring antibiotic
resistance genes was transferred from one E. coli lineage to another E. coli lineage.
The transconjugant remained in the gut for months. This is, to the best of our knowl-
edge, the ﬁrst documented case of antibiotic resistance genes transferred in situ of
the gut in a non-artiﬁcal experimental set-up and without antibiotic pressure. While
the gut has been considered a hub for horizontal gene exchange, this is one of the
ﬁrst pieces of evidence that demonstrates that antibiotic resistance genes are trans-
ferred in the gut naturally without antibiotic pressure. In the second set of isolates,
where the infant was undergoing antibiotic treatment, we genomically conﬁrmed that
transfer of an antibiotic resistance plasmid occurred between two co-existing E. coli
lineages and we went further on to characterize the plasmid. Both of these reports
highlight the role of the gut as a hub for horizontal gene exchange.
Via full genome sequencing, we identiﬁed that the lineages in the gut are highly
dynamic. By comparing the E. coli isolates collected over the ﬁrst year of the two
infants’ lives, we observed multiple phage infections, phage curing, large genomic
deletions and plasmid acquisition and loss. Future in vivo studies will relate these
identiﬁed genomic events to gut colonization ﬁtness. For example, in the lineage
that received the antibiotic resistance plasmid in absence of antibiotic treatment, are
the isolates with the pHUSEC41-1-like plasmid better at colonizing the gut than
without the plasmid? Additionally, are the isolates with the plasmid better or poorer
colonizers of the gut after the large genomic deletion? By addressing these questions,
we will gain a better understanding of the ability of the transconjugant to remain and
to adapt in the gut.
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In each of these studies, plasmids were identiﬁed with strikingly high sequence
similarity to previously sequenced clinically relevant plasmids. In the sets of isolates
from Chapter 4, it was the pHUSEC41-1-like plasmid carrying antibiotic resistance
genes that was transferred between lineages that shared high sequence similarity to
previously sequenced plasmids. The plasmid was identiﬁed in E. coli isolates from two
geographically separated patients with hemolytic-uremic syndrome (HUS) [1, 2]. Both
of these clinical E. coli isolates were of the serotype O104:H4, while in our study it was
found in E. coli isolates with serotypes O73: K-:18 and O179: K12:H-. In the set of
isolates from Chapter 5, where the infant was treated with antibiotics due to a urinary
tract infection (UTI), we identiﬁed a pUTI89-like plasmid in the uropathogenic E. coli
(UPEC) strain. This plasmid has been shown to play a role in the early stages of UTI
[3]. This plasmid has been identiﬁed in a variety of diﬀerent hosts, including those of
the serotypes O18:H31 and O6:H31 [4, 5, 6]. Furthermore, this plasmid has not only
been found in UPEC isolates, but also in an adherent-invasive E. coli strain isolated
from the ileum of a Crohn’s disease patient [7], and from a neonatal meningitis E.
coli isolate [5]. Both the pHUSEC41-1-like and pUTI89-like plasmids identiﬁed in
these studies highlight how clinically relevant plasmids can disseminate both with
respect to host and to geographical location. In future in vivo studies, we would like
to examine the inﬂuence of the pUTI89-like plasmid on the host’s ability to colonize
the gut. As this plasmid has primarily been identiﬁed in UPEC strains, and as the
gut microbiota is the source of most UTIs [8], we hypothesize that this plasmid must
also provide a beneﬁt for the host to colonize the gut. Linking ﬁtness beneﬁts of
gut colonization to this virulence-implicated plasmid may give insight as to why this
plasmid is globally disseminated.
Lastly, work in this thesis also highlights that a large fraction of the gut microbiota
are indeed cultivable. We demonstrated this by ﬁrst assessing the antibiotic tolerance
proﬁle of the gut microbiota via V6 region 16S rRNA sequencing, and then tailoring
antibiotic combinations to target previously unsequenced bacteria. One of the isolates
that we cultivated and genome sequenced belonged to the genus Oscillibactor. Un-
cultivated Oscillibactor strains have been negatively correlated with Crohn’s disease
[9, 10], so the ability to cultivate these strains will provide physiological insight into
these strains and will contribute to our understanding of gastrointestinal disorders
and devising treatment strategies. This work also opens up possibilities to cultivate
novel species that could have various health beneﬁts and probiotic applications.
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